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Summary 
Thesis title: Retinal thickness in adults with Down’s syndrome: Relationship with age, 
cognition and dementia. 
Applicant: Ms Madeleine Jane Walpert 
People with Down’s syndrome (DS) are known to experience premature ageing and have a 
high propensity for clinical diagnosis of dementia due to Alzheimer’s disease (AD). In DS 
there is a unique and natural model of over-expression of amyloid-beta (Aβ) protein, the 
accumulation of which is proposed to be the central early event in the pathogenesis of AD. In 
DS, AD neuropathology is universally seen in the brain from the fourth decade. Identifying 
biomarkers are essential to the evaluation of future treatment trials. The retina has been shown 
to experience changes in patients with AD, such as retinal thinning, compared to age-matched 
controls. As an extension of the brain, the retina can be quickly and non-invasively imaged and 
may provide a proxy measure of brain changes in AD.  
Using optical coherence tomography (OCT), cross-sectional retinal examinations were 
completed in 50 people with DS aged 18 years and over. Comparisons between retinal 
thickness of the DS and control groups were examined, as well as the effect of age on thickness 
in both groups. For the DS group, further investigations were made into the relationships 
between retinal thickness and (i) cognitive performance, (ii) diagnosis of dementia, (iii) cortical 
thickness and, (iv) presence of Aβ binding in the brain. 
Contrary to expectations, people with DS had thicker retina compared to age-matched controls. 
In addition, normal age-related retinal thinning was not seen in the DS group. People with DS 
have a life-long overproduction of Aβ, deposits of which have been previously imaged in the 
retina. Aβ may be responsible both directly, through physical mass, and indirectly through 
inflammation as a response to Aβ, for increased retinal thickness in people with DS. 
Consequently, retinal thickness in DS may be a proxy measure of Aβ deposition in the retina. 
As part of a collaborative study, brain Aβ binding was measured using positron emission 
tomography neuroimaging in a subset of the DS group. Individuals with positive Pittsburgh 
compound [11C]-PIB (PIB) binding to Aβ displayed a trend towards having thinner retina than 
those with negative PIB binding. These results indicate that a shift towards thinning retina in 
people DS may reflect changes in brain pathology. Future studies are discussed which aim to 
investigate Aβ and Aβ driven pathology in the retina. 
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Chapter One:  
Introduction 
1.1 Objective 
The aim of this study is to investigate retinal thickness in adults with Down’s syndrome 
(DS) in relation to ageing and the onset of Alzheimer’s disease (AD) using optical coherence 
tomography (OCT). People with DS have a very high prevalence of early-onset dementia of 
the Alzheimer’s type, which manifests with the typical neuropathological features seen in 
typically developing AD, including amyloid-beta (Aβ) plaques, neurofibrillary tangles and 
neuronal death. DS is proposed as a unique and natural model through which AD pathology 
and mechanisms can be studied (Teipel & Hampel, 2006). Research in sporadic AD in the 
general population has found that retinal thickness measures can be used to successfully 
distinguish between patients with AD and age-matched controls, and that subtle changes in 
the retina could provide early markers of AD. In this study, retinal thickness was examined 
in adults with DS and compared to typically developing age-matched controls and an older 
comparison group. Thickness measures were evaluated in association with age, cognitive 
performance and dementia status. This cross-sectional study is the first to investigate retinal 
thickness in an adult population of DS and has examined the possibility that the retina could 
become a marker of AD in people with DS. Early identification of AD related change in the 
form of robust biomarkers is essential to the development of effective treatments that are 
aimed to slow or stop the progression of the disease. Retinal changes not only have the 
potential to be markers of early AD, but the retina could become a site to be used for 
measuring and monitoring the efficacy of future treatment trials.  
 
1.2 Down’s syndrome 
1.2.1 Trisomy of chromosome 21 
Down’s syndrome (DS) was first described by John Langdon Down in 1866 (Down, 1866) 
as a set of characteristics identified in many of his patients with intellectual disabilities (ID). 
For almost 100 years the cause of the syndrome was unknown, until in 1959, Lejeune 
identified the trisomy of chromosome 21 (Lejeune 1959). Full trisomy of chromosome 21 
accounts for approximately 95% of cases of people with DS, the remaining 5% include 
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mosaicism and partial trisomy caused by Robertsonian translocation (Hunter, 2010; Mutton, 
Alberman, & Hook, 1996). People with DS display particular phenotypical characteristics 
due to dysregulated expression of multiple genes (see section 1.2.2). In individuals with 
mosaicism and translocation the DS phenotype is almost always less pronounced. Although 
genes are significant in the manifestation of DS, abnormalities seen in patients are 
multifactorial and the result of combined genetic and environmental influences (Reeves, 
Baxter, & Richtsmeier, 2001). DS is the most common cause of ID worldwide, accounting 
for 10 in 10,000 and 14 in 10,000 live births in Europe and the United States respectively 
(Loane et al., 2013; Parker et al., 2010). Improved antenatal screening has increased the 
termination rate of DS pregnancies, leading to a 1% reduction in live births. Without 
antenatal screening it is predicted that DS births would have risen substantially in 
accordance with rising maternal age (Morris & Alberman, 2009). It is estimated that in 
England and Wales there are approximately 38,000 people with DS (Wu & Morris, 2013). 
The median life expectancy of a person with DS has increased dramatically in recent 
decades, from 12 years in the 1940s, to 60 years in 2002 within developed countries (Bittles 
& Glasson, 2004; Bittles, Bower, Hussain, & Glasson, 2007). Longer life expectancy is 
attributed to both improvements in health and social care and general awareness of DS.  
Increased longevity has raised awareness of the issue of dementia in people DS. However, 
a lifespan of approximately 60 years falls drastically short of what is expected in developing 
countries for those without DS, and is most likely due to the high prevalence of early-onset 
AD (Holland, Hon, Huppert, Stevens, & Watson, 1998). Dementia research in people with 
DS is not only important for the DS population but also for AD in general. The similarities 
in the presentation of the disease, along with the over-expression of Aβ in DS mean that 
people with DS will likely be the first population for whom treatment trials show positive 
results, from which they would hopefully be generalised into sporadic AD.  
 
1.2.2 Phenotype 
People with DS share certain physical characteristics as a result of the dysregulated 
expression of some genes, these include; short stature, flat nasal bridge, small head, broad 
hands, small ears and mouth, and upward slanting eyes with epicanthic folds. These features 
are characteristic of DS, but are not homogeneous within the syndrome (Roizen & Patterson, 
2003). From a cognitive perspective, all individuals with DS present with some level of ID, 
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again this varies significantly. Characteristically people with DS have slow development 
and cognitive impairment is seen in the following areas; phonological disorder in speech 
(Dodd & Thompson, 2001), verbal working memory (Baddeley & Jarrold, 2007) and short 
attention span (Dierssen, 2012; Lott & Dierssen, 2010). Individuals with DS present with a 
limited capacity short-term memory span (Purser & Jarrold, 2010) and deficits on long term 
memory tasks (Pennington et al., 2015). Typical IQ range is between 20 and 80 points 
(Nadel, 2003). There are many health conditions associated with the DS phenotype, most 
common are; congenital heart defects, hearing and vision impairments, thyroid dysfunction, 
childhood leukaemia, skin and dental abnormalities, seizures later in life, obesity and early-
onset dementia (Freeman et al., 2008; Krinsky-McHale, Jenkins, Zigman, & Silverman, 
2012; Roizen & Patterson, 2003). Research in adults with DS is relatively scarce in 
comparison to research conducted in infants and children, partly due to the relatively recent 
improvement in lifespan.  
 
1.2.3 Accelerated ageing 
People with DS appear to exhibit changes that are typically associated with old age much 
earlier in life (Oliver & Holland, 1986; Zigman, 2013). Signs of physical ageing such as skin 
thinning and wrinkling, greying and loss of hair is seen in individuals between the ages of 
30 and 70 (Brugge, Grove, Clopton, Grove, & Piacquadio, 1993), and the autoimmune 
condition alopecia areata has been reported as commonly emerging in the third or fourth 
decade of life (Carter & Jegasothy, 1976). Motor skills in people with DS decline early in 
life, reaction time, grip strength and gait speed have all been found to correlate with age and 
begin to deteriorate from middle age (Smith, Stergiou, & Ulrich, 2005; Smith & Ulrich, 
2008). Levels of physical activity in people with DS are reduced in comparison to those 
without DS, both typically developing controls and individuals with non-DS ID. Studies 
have shown found that no children or adults with DS met the recommended daily physical 
activity recommendations, and engaged in more sedentary behaviour than those without ID. 
Activity levels were found to further reduce alongside increasing age (Phillips & Holland, 
2011). Lower levels of exercise may increase the risk of people with DS developing diseases 
associated with physical inactivity. People with DS are diagnosed with osteoporosis, 
hypothyroidism and vision and hearing complaints earlier in life, and women experience 
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early menopause (Baptista, Varela, & Sardinha, 2005; Carr & Hollins, 1995; Covelli, Raggi, 
Meucci, Paganelli, & Leonardi, 2016; Milberger et al., 2002; Zigman, 2013).  
The most striking age-related change in people with DS is undoubtedly the early onset of 
dementia. Dementia manifests in clinical symptoms at around the age of 80 years in the 
typically developing population, in people with DS, age of dementia diagnosis is closer to 
50 years. Pathological changes occur in the brain many years before clinical onset. AD 
neuropathology has been reported in the brains of virtually all people with DS over the age 
of 30 years (Wisniewski, Dalton, Mclachlan, Wen, & Wisniewski, 1985), including Aβ 
senile plaques, neurofibrillary tangles, brain atrophy and volume reduction, found in 
individuals from the age of 40 years onwards, regardless of a diagnosis of dementia or any 
sign of clinical symptoms (Annus et al., 2016; Beacher et al., 2010; Mann & Esiri, 1989; 
Nelson et al., 2011; Wisniewski et al., 1985). Brain changes in people with DS are similar 
to those seen in the brains of non-DS patients with sporadic, or late-onset AD, only much 
earlier in life (Jack et al., 2014). 
 
1.2.4 Ocular disorders 
The eyes of people with DS have particular characteristics, they are typically small, upward 
slanting and have epicanthic folds (Dykens, Hodapp, & Finucane, 2000; Scherbenske, 
Benson, Rotchford, & James, 1990). Ocular and orbital abnormalities are reported in people 
with DS, with varying frequencies. There is increased prevalence of nystagmus, strabismus, 
keratoconus, amblyopia, refractive error, astigmatism, hyperopia and cataracts in this 
population, most often reported in children (Da Cunha & Moreira, 1996; Kim, Hwang, Kim, 
& Yu, 2002; Merrick & Koslowe, 2001; Weiss, Kelly, & Phillips, 2016). In adults with DS, 
research is more scarce, however, adult population studies have also shown an increased 
prevalence of the ocular disorders seen in children (Evenhuis, Theunissen, Denkers, 
Verschuure, & Kemme, 2001; Krinsky-McHale et al., 2012). In adults, research has 
indicated an age-related increase in ocular disorders. Krinsky-McHale et al., (2012) reported 
a large increase from a 5.1% prevalence of an opthalmic disorder in the thirties, to 41.3% 
prevalance in those in their forties. Evenhuis, Theunissen, Denkers, Verschuure, & Kemme, 
(2001) reported a smaller change from 4% in individuals under 50 years to 7.5% in the over 
fifties, although much higher prevalences (51% and 53% respectively) were seen in 
individuals with severe/profound ID compared to those with mild/moderate ID.  
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Incidence rates of ophthalmic diseases commonly associated with old age have been 
identified in younger people with DS, particularly cataracts, which are often assessed for at 
birth and seen in children (Cunha & Moreira, 1996). In adults, cataract severity was 
generally reported to be mild and corrective surgery was rare. In older individuals the highest 
cataract prevalence reported was 42%, with the average age of diagnosis being 48 years 
(Krinsky-McHale et al., 2012). Glaucoma is another age-related ocular disorder, however 
this is not so frequently reported in people with DS. In children, rates of primary childhood 
glaucoma are lower (<1%) than in typically developing children (2.29%; Aponte, Diehl, & 
Mohney, 2010; Fimiani et al., 2007; Stephen, Dickson, Kindley, Scott, & Charleton, 2007;  
Wong & Ho, 1997), whilst for adults reports are more varied, 2% in an age range of 30-83 
years (Caputo, Wagner, Reynolds, Guo, & Goel, 1989) and 5% in an age range of 3.5 months 
to 26 years (Krinsky-McHale et al., 2012). In the typically developing population glaucoma 
prevalence is 3.54% between the ages of 40 and 80 years (Tham et al., 2014). Yokoyama 
found significantly higher rates of glaucoma in people with DS (11.5%) compared to age-
matched controls (1.1%), in this study, glaucoma diagnosis was based on optic disc 
abnormalities, and it was noted that there was no difference in the intraocular pressure 
between glaucomatous and non-glaucomatous eyes in the DS group. It has been suggested 
that glaucoma could be over-diagnosed in people with DS, perhaps due to the similarities 
between glaucoma presentation and amyloid-related retinal pathology presentation (see 
Figure 1.6, section 1.4.3), and one of the crucial differences being that increased intraocular 
pressure is only seen in glaucoma.  
 
1.3 Alzheimer’s disease in people with Down’s syndrome 
1.3.1 Introduction 
Alzheimer’s disease is a degenerative neurological disorder and the most common cause of 
dementia, affecting an estimated 46.8 million people in the year 2015. This number is 
expected to double every 20 years with the ageing population, potentially reaching 131.5 
million by 2050 (Mahajan & Votruba, 2017). The hallmarks of familial, or sporadic AD are 
chiefly; senile plaques containing Aβ peptide, neurofibrillary tangles consisting of 
hyperphosphorylated tau protein, and, neuronal death (Hardy & Selkoe, 2002). Expression 
of AD in people with DS is very similar to that of the typically developing population, the 
main difference being the age at which the pathology manifests. In the typically developing 
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population, dementia is usually diagnosed after the age of 80 years, although it is understood 
that AD pathology is present in the brain for many years, even decades prior to clinical 
presentation (Bateman et al., 2012). In children with DS, instances of neuritic Aβ plaques 
have been seen as young as eight years (Olson & Shaw, 1969), and are frequently seen in 
adults with DS from the age of 35 years (Burger & Vogel, 1973; Hof et al., 1995; Leverenz 
& Raskind, 1998; Wisniewski et al., 1985). After the age of 40, virtually all people with DS 
will express Aβ in the brain (Annus et al., 2016; Beacher et al., 2010; Mann & Esiri, 1989; 
Nelson et al., 2011; Wisniewski et al., 1985), and typical age of dementia onset is 50 years 
(Holland, Hon, Huppert, Stevens, & Watson, 1998; Oliver, Crayton, Holland, Hall, & 
Bradbury, 1998).  
 
1.3.2 Prevalence 
Despite that all individuals with DS present with AD pathology, not all develop the clinical 
presentation of dementia, as was thought to be the case until as recently as the 1980s. 
Prevalence rates of dementia in people with DS are varied, likely due to difficulties in the 
assessment of dementia in people with DS, (discussed in more detail in section 1.3.3), 
however, it is certain that the incidence of age-related cognitive decline and onset of 
dementia is considerably higher and occurs at a much younger age in people with DS 
compared to the typically developing population. 
Variation in reported dementia prevalence in people with DS is vast (see Figure 1.1); Coppus 
et al., (2006) found that incidence rates doubled every five years from 49 years (8.9%) to 59 
years (32.1%). Holland, Hon, Huppert, Stevens, & Watson, (1998) looked at a wider age 
range, finding relatively low prevalence in the thirties (3.4%), increasing to 10.3% in the 
forties and up to 40% in the 50+ age group. Tyrrell et al., (2001) found fewer incidences of 
dementia in people with DS than other research studies, with a prevalence rates of 5.7% in 
the 40-50 category and 30.4% in the 50-60 age group. In older individuals with DS 
prevalence records are even more diverse, from 25.6% in those in their 60s (Coppus et al., 
2006), to 100% diagnosis in those over 70 years (Visser, Aldenkamp, Van Huffelen, & 
Kuilman, 1997). Lower prevalence rates are likely to be influenced by increased mortality 
rates in this age group, and it could be argued that those surviving past the age of 70 could 
be protected from AD.  
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Figure 1.1 Graphical representation of the reported variation in age–specific prevalence 
of dementia in adults with DS across prevalence studies. Figure reproduced 
from Wilson, Annus, Zaman, & Holland, (2014). 
 
1.3.3 Presentation and assessment 
Early clinical presentation of dementia is different in people with DS than in typically 
developing patients (Holland, 2000; Holland et al., 1998). Rather than the classic symptoms 
of memory loss and forgetfulness, Holland and colleagues have found that changes in 
personality and behaviour, including social withdrawal, apathy, and stubbornness are among 
the first dementia-related changes that are seen in people with DS (Ball et al., 2006; Holland, 
Hon, Huppert, & Stevens, 2000; Holland et al., 1998). Ball et al., (2006) found that 
individuals identified as having personality and behaviour changes were more likely to have 
developed AD by a re-assessment five years later than those with changes in other areas of 
functioning. Behavioural and personality changes are commonly more related to the 
presentation of “dementia of the frontal type” (DFT), however progression of dementia in 
people with DS results in an eventual diagnosis of AD rather than DFT. Personality and 
behaviour are functionally associated with the frontal lobes which are developmentally 
smaller in people with DS (Pinter, Eliez, Schmitt, Capone, & Reiss, 2001) and may be 
compromised earlier in the AD pathway.   
Diagnosing AD in people with DS is completed using the same pathway and diagnostic 
criteria as in the typically developing population, as is described in the fifth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, 
2013) and the tenth edition of the International Classification of Diseases (World Health 
Organisation, 1992). Whilst it is desirable to have consistency in the classification of AD, it 
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should be recognised that there are additional complexities when assessing dementia in a 
person with DS. The primary challenge is to determine the extent to which cognitive and 
functional limitations are a result of deterioration due to dementia, rather than relating to 
pre-existing ID, or due to effects of ageing (Holland and Walpert, 2016). Dementia 
assessments are usually undertaken when a friend, family member or carer of the individual 
with DS becomes concerned about their changing behaviour; however, this is not the optimal 
baseline assessment. Ideally, baseline assessments should be completed before there are any 
signs of change and routinely followed up over several years to establish a “cognitive 
profile” of the individual. Another difficulty in the diagnosis of AD in people with DS is the 
complexity of pseudo-dementia. Pseudo-dementia is a term for a condition that can present 
with similarities to dementia, but that is not a progressive disorder of the brain. The 
conditions include: severe depression, hypothyroidism, vitamin B12 and folate deficiencies, 
and brain tumours. Most commonly there is a misdiagnosis of AD in those with severe 
depression. This problem is not exclusive to people with DS, in fact, in DS it is argued that 
the pseudo-dementias are easier to eliminate because of the high incidence of early-onset 
AD – however this thought process may also lead to an over diagnosis of AD.  
 
1.3.4 Mechanisms of Alzheimer’s disease 
 The amyloid-beta cascade hypothesis  
Central to the theory of AD in people with DS is the trisomy of chromosome 21, which 
includes triplication of the amyloid precursor protein (APP) gene. APP is a precursor 
molecule whose proteolysis generates Aβ. Fibrillar Aβ is found in senile plaques in the 
brains of people with AD and is considered one of the driving forces and potentially the 
most influential pathology of AD, particularly in people with DS. 
The amyloid cascade hypothesis, proposed by Hardy and Higgins in 1992, proposes that 
excessive build-up of Aβ protein in the brain is the main causative agent of the subsequent 
neuropathology of AD, including neurofibrillary tangles, vascular damage, inflammatory 
responses and cell death (Selkoe, 1994). Aβ is generated by the sequential proteolytic 
processing of the APP gene, resulting in the formation of peptides 40 to 42 amino acids in 
length. These soluble peptides spontaneously aggregate to form Aβ oligomers and fibrils 
that are subsequently deposited within the brain to form diffuse and dense amyloid plaques. 
The APP gene generates transcripts for coding for the production of Aβ, the central 
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component of neuritic plaques that is generated from APP by cleavage by the β- and 
γ-secretases. The amyloid cascade hypothesis states that Aβ or APP cleavage products which 
contain Aβ are neurotoxic and lead to tangle formation and cell death. Some research has 
indicated that Aβ itself is not neurotoxic, but that its presence causes weakening of the 
neurons, making them more sensitive to excitotoxic damage (Mattson et al., 1992). It is not 
immediately clear how Aβ causes neuronal loss and tangle formation, however, the peptide 
is known to disrupt intracellular calcium stability and increase calcium concentrations within 
the neuron. This could explain how tangles are formed as they are largely composed of 
hyperphosphorylated tau, which is controlled by the intracellular calcium (Hardy & Higgins, 
1992; Mattson, 2004). It is suggested that abnormal deposition or clearance of Aβ, identified 
by CSF Aβ42 or PET imaging, could be the earliest marker of AD (see Figure 1.2, Jack et 
al., 2010). 
In people with DS, the amyloid cascade hypothesis is arguably more important than in any 
other AD population, as the APP gene is located on chromosome 21, and is therefore 
inherited in triplicate in people with DS. In cases of DS where there is a partial triplication 
of chromosome 21, one that does not include an additional copy of the APP gene, there are 
reduced incidences of AD (Korbel et al., 2009; Prasher et al., 1998). When there is presence 
of an extra copy of the APP gene, it is likely that this leads to a lifelong overproduction of 
Aβ protein (Hyman, 2002). This has provided much support for the amyloid theory and has 
been instrumental in determining research efforts (Korczyn, 2008).  
 
Figure 1.2  A model of the earliest biomarker changes seen in AD. Figure reproduced 
from Jack et al., 2010, p.122. 
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AD is a multi-factorial disease with many contributors, and many influencing factors, as 
shown in Figure 1.3. Evidence to date has shown that although it is necessary, the presence 
of amyloid alone is not sufficient to result in AD (Kim et al., 2013), therefore other factors 
must be considered. Nevertheless, the connection between AD and Aβ is robust, and the 
amyloid theory will remain a prominent factor in the consideration of the pathophysiology 
of AD and particularly so in AD in people with DS.  
 
 Apolipoprotein E allele inheritance  
The apolipoprotein E (ApoE) gene is influential in the risk of AD, allele type ε4 increases 
the risk of disease (Hyman, 2002; Patel et al., 2011), whilst inheriting the ε2 allele is 
considered protective against development of AD (Royston, et al., 1994). In people with DS, 
the majority of studies have found no discernible differences between the rates of ApoE 
inherited genes than is found in the typically developing population, particularly noting that 
the allele ε4 is not more frequently inherited in DS (van Gool, Evenhuis, & van Duijn, 1995; 
Wisniewski, Morelli, Wegiel, Wisniewski, & Frangione, 1995). However, Sekijima et al., 
(1998) found higher prevalence of the allele ε4 in patients with DS who developed AD 
before the age of 50 years (28.6%). This study concluded that the ApoE ε4 is likely to further 
increase the risk factor of AD in people with DS.  
 
 Inflammatory responses 
Neuroinflammation has an important role in AD and accelerates the pathological process 
(Lott & Head, 2005). Inflammatory responses are evident in many brain diseases besides 
AD, however, in AD there is a unique association between chronic inflammation and 
disease, with a strong indication that inflammation serves as an additional cause of AD 
(Herrup, 2010), rather than being protective against further deterioration. Long-term use of 
anti-inflammatory drugs have been found to lower the risk of AD (McGeer, Schulzer, & 
McGeer, 1996). Inflammation is arguably even more important in the DS model, certain 
genes that are responsible for regulating inflammatory processes are located on chromosome 
21 (Wiseman et al., 2015) and impact cognitive impairment and neurodegeneration 
(Wilcock, 2012). The inflammation argument has been expanded to propose that AD 
requires three steps; (1) injury that initiates changes distinct from normal ageing, (2) 
establishment of a chronic inflammatory state and, (3) shift in cellular physiology, a tipping 
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point which marks the beginning of the degenerative process, leading to synaptic 
dysfunction and neuronal death (Herrup, 2010).  
Specifically microglial mediated inflammation is known to contribute to the progression of 
AD (Mandrekar-Colucci & Landreth, 2010). Microglial cells form the primary immune 
system of the brain and are the integral component of maintaining brain homeostasis and 
protecting the brain from infections. Microglia are present at the sites of Aβ plaques and 
increase in number and size in relation to the deposits (Sasaki et al., 2002; Wegiel et al., 
2001). Whilst initially microglia exert a neuroprotective role, working to clear soluble Aβ, 
research has shown that they are unable to phagocytose Aβ plaques (Frackowiak et al., 
1992). The role of microglia in AD is disputed and some suggest that microglial activation 
contributes to excessive degeneration. Researchers have suggested that AD represents a 
failure of neuronal cell cycle control (Arendt, Brückner, Mosch, & Lösche, 2010; Yang, 
Mufson, & Herrup, 2003), and there is a strong case for the central role in this failure being 
neuroinflammation (Cameron & Landreth, 2010; Heneka & O’Banion, 2007; Krstic & 
Knuesel, 2012; McGeer, Schulzer, & McGeer, 1996; Mosher & Wyss-Coray, 2014). As with 
many mechanisms in AD, it is unclear whether inflammation is a cause, contributor or a by-
product in the disorder (Wyss-Coray et al., 2012). 
 
 Tau protein hyperphosphorylation and aggregation 
Tau protein are abundant in the neurons of the central nervous system (CNS) and provide 
structure to assist in the clearance of unwanted and toxic proteins. Excessive or abnormal 
phosphorylation of tau results in neurofibrillary tangles and allows toxic proteins, including 
Aβ, to accumulate inside the neurons and exert toxic effects on the cell, ultimately leading 
to cell death (Lonskaya, Hebron, Chen, Schachter, & Moussa, 2014).  Hyperphosphorylated 
forms of tau are the main constituent of neurofibrillary tangles. Tau protein is most profusely 
expressed in the axons in the CNS neurons (Šimić et al., 2016) and there is a strong 
correlation between the anatomical location of tangles and the greatest cell loss in AD 
(Herrup, 2010). Studies have shown that AD mouse models carrying human tau mutations 
develop late-onset neurodegenerative disease, including high levels of neuronal loss 
(Andorfer et al., 2005; Ramsden et al., 2005). The role of tau in AD is complex, mutations 
in the tau gene have not been identified in familial forms of AD, but have in other late-onset 
forms of dementia (Hutton et al., 1998; Poorkaj et al., 1998). Herrup (2010) proposed that 
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the role of tau in AD occurs in the later stages, and that the phosphorylation of tau is a 
mechanistic part of programmed cell death. This theory is contradicted by the early 
appearance of tau tangles in the AD process; consequently, it is likely that tau holds several 
roles in the progression of AD.  
 
Figure 1.3  Venn diagram showing the degenerative events which ultimately lead to AD. 
Figure reproduced from Herrup, (2015), page 798.  
 
1.3.5 Therapeutic targets  
Biomarkers are defined as being, “characteristics that are objectively measured and 
evaluated as indicators of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention” (Atkinson et al., 2001). As with all 
degenerative diseases, biomarkers are critically important for improving the possibilities of 
the identification, diagnosis and prevention of AD. Due to the similarities between the 
progression of AD in people with DS and those without, it is likely that any biomarkers 
identified in the DS population will also be relevant for the typically developing population. 
In people with DS, the age of dementia onset is considerably earlier, and clinical presentation 
is different to that of the typically developing population, however, the neuropathology of 
the disease is virtually identical, as is the neurodegenerative pathway.  
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For people with DS, treatments of AD have typically focussed on targeting the amyloid 
pathway. Mutations in APP that occur close to the beta-site are known triggers for the 
production of Aβ, including toxic Aβ42 which can lead to early-onset dementia (Selkoe, 
2001). β-site APP cleaving enzyme 1 (BACE 1) is up-regulated in people with DS, resulting 
in increased production of Aβ (Sun, Tong, Qing, Chen, & Song, 2006). Mutations in the 
APP gene have been reported in data from individuals of Icelanders, these mutations have 
been found to protect against AD and cognitive decline in the elderly (Jonsson et al., 2013). 
Results of this study proposed that reducing the β-cleavage of APP would protect against 
AD. A recent study using BACE inhibitors in a rat model found a significant reduction in 
the Aβ levels seen in the brain and in cerebrospinal fluid (Jian Jeffrey Chen et al., 2015), 
however this has not yet been trialled in humans. The γ-secretase enzyme is the last stage of 
APP cleavage before the production of Aβ (Golde, 2005). Netzer et al., (2010) found that 
γ-secretase inhibitors in a mouse mode of DS successfully lowered Aβ levels. Interacting 
proteins with γ-secretase have also been studied, in DS mouse models inhibition of 
γ-secretase activating protein facilitates Aβ production without the toxicity effect (Chu, 
Wisniewski, & Praticò, 2016).  
Targeting the inflammation pathway in AD has also been proposed. Several clinical trials 
using anti-inflammatory drugs have been undertaken and have been shown to prevent Aβ 
aggregation in-vitro in human samples (Akiyama et al., 2000; Prati et al., 2013). As a 
treatment, there have been mixed results, Cuello et al., (2010) found improved behavioural 
problems in a DS mouse model, as well as reduced inflammation and reduced Aβ in the 
brain, whilst Aisen et al., (2003) found in human patients with AD that there were no changes 
in cognition. Immunotherapy is also proposed, including several vaccines to protect against 
synthetic AB42, Aβ protein and passive immunisation with antibodies (Delrieu, Ousset, 
Caillaud, & Vellas, 2012). Schenk et al., (1999) has been successful in preventing Aβ plaque 
formation and over-expression of APP in an AD mouse model. In humans, the results of this 
trial showed slower progression rate brain of pathology with the use of Aβ42 antibodies, 
however this was accompanied by the development of sub-acute meningoencephalitis, 
which resulted in the study being prematurely terminated. Vaccines tested in DS mouse 
models have shown improvements in cognition, and to be able to prevent neuronal atrophy 
without visible side effects (Belichenko et al., 2016). Antibodies including solanezumab, 
ganternerumab, crenezumab and aducanumab are currently undergoing clinical trials. 
Currently no treatment trials have been conducted in human patients with DS. The 
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identification of early biomarkers for AD in people with DS is important as such proxy 
markers for the disease process are necessary if preventative, as opposed to symptomatic, 
treatments are to be evaluated over an acceptable time scale. Biomarkers could be indicative 
of the disease mechanisms and can be a proxy outcome measure in clinical trials aiming to 
prevent or slow the onset of AD.  
 
1.4 The retina in Alzheimer’s disease  
1.4.1 Retinal development and structure 
The retina is derived from the neuroectoderm and retains neuronal, vascular and blood-
neural barrier parallels with the brain throughout life. This link to the brain, coupled with 
the fact that the retina is the only organ of the body that is visible using non-invasive imaging 
technology, has made it an attractive option for imaging markers and pathology of 
neurological diseases (Nguyen et al., 2017). As an extension of the brain, it is suggested that 
AD changes occurring in the brain may also occur in the retina (Parnell, Guo, Abdi, & 
Cordeiro, 2012).  
The retina is part of the CNS and is derived from the neural tube, diverging from the brain 
during early development (Guo, Duggan, & Cordeiro, 2010; Huseyinoglu et al., 2013; 
Parnell et al., 2012; Salobrar-García et al., 2016). The major development of the eye takes 
place during the foetal stage, between the third and tenth weeks. The optic vesicles develop 
on the side of the developing forebrain and extend towards the surface ectoderm. As they 
grow, the connections to the forebrain become the optic stalks, which eventually form the 
optic nerves. The developing optic vesicles and stalks have grooves called the choroidal 
fissure, through which blood vessels supply the optic cup and lens. The choroidal fissure 
will ultimately fuse, enclosing the vessels in the optic stalk. The optic cup is a double layered 
structure which splits into two unequal layers (Reese, 2011). The smaller outer layer 
develops first and melanin granules appear at around 4.5 weeks, becoming the pigment layer. 
The inner layer is thicker and more complex, ultimately forming the neural retina, cells begin 
to differentiate into photoreceptors essential for night and colour vision at around six weeks. 
Above these, towards the inner eye, Müller cells and bipolar neurons are formed, followed 
by the innermost level which includes the axons of the ganglion cells (Sung & Chuang, 
2010). Ganglion cell fibres fill the optic stalk as it becomes the optic nerve. At birth the 
photoreceptors are still not fully matured, visual acuity will continue to improve for some 
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time. The retina preserves its connection with the brain through the fibres in the optic nerve. 
The transparency of the eye means that the retina is the only tissue in the body where neurons 
can be imaged completely non-invasively. 
 
Figure 1.4 Biological arrangement of the eye, cells and retina. (A) Diagram of the eye, 
(B) diagram of the organisation of retinal cells; Rod, Cone, Bipolar Cell, 
Horizontal cell, Amacrine cell, Ganglion cell, Müller cell, and, (C) transverse 
section of the human retina. Figure reproduced from Sung & Chuang, (2010) 
page 954.  
The optic cup has two walls, an inner and outer wall, which form the layers of the retina. 
The pigmented retinal layer develops first, from the outer wall of the optic cup. The neural 
layer of the retina is formed from the inner wall of the optic cup. These neural layers are 
divided into several discrete layers and contain numerous cell types including rods, cones, 
bipolar and ganglion cells, in addition to the supporting tissue. The retina is divided into 
different areas with laminated layers composed of different cell types (Figure 1.5). The 
retinal pigment epithelium (RPE) is a single layer of cuboidal cells closest to the choroid, it 
has many functions, including light absorption and phagocytosis of photoreceptor membrane 
segments and is able to communicate with the immune system in order to activate or halt 
immune system responses (Bok, 1993). The nuclei of the photoreceptors (rods and cones) 
constitute the outer nuclear layer (ONL), whilst the nuclei of the bipolar, amacrine, 
horizontal and Müller cells are found in the inner nuclear layer (INL). The nuclei of the 
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ganglion cells form the ganglion cell layer (GCL) and the nerve fibre layer (NFL) contains 
the axons of the ganglion cell nuclei. The outer plexiform layer (OPL) comprises the 
processes and synaptic terminals of photoreceptors, horizontal and bipolar cells. The inner 
plexiform layer (IPL) contains the processes and terminals of bipolar, amacrine and ganglion 
cells. The foveal pit is responsible for sharpest central vision but is least sensitive to light. 
All other space in the retina which is not occupied by neurons and blood vessels is concerned 
with the processes of the Müller glial cells (Swaroop & Zack, 2002). 
 
Figure 1.5 Optical coherence tomography (OCT) scan showing a cross-sectional image 
of the different retinal layers. Figure reproduced from Ikram, Cheung, Wong, 
& Chen, (2012) page 921.  
In people with DS it is assumed that the embryological formation of the eye and the retina 
is the same as in typically developing foetuses. Despite the increased rates of ocular 
disorders seen in children and adults with DS, there is no research to indicate that there are 
any developmental differences in eye development. Features of the eye which have been 
noted as different in people with DS include; the number of blood vessels which cross the 
margin of the optic nerve, in many studies the number has been shown to be increased in 
people with DS (Caputo et al., 1989; Da Cunha & Moreira, 1996; Kim et al., 2002; Williams, 
Mccormick, & Tischler, 1973). This has been referred to as a spoke-like appearance. 
Williams et al., (1973) found that there was an average increase of 4.2 vessels in the DS 
group (males and females aged between 10-25 years) compared to an age-matched control 
group. This increase in blood vessels number has not been shown to impact visual acuity 
(Da Cunha & Moreira, 1996). In addition to this, thicker retinal layers have been identified 
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in a DS mouse model (Laguna et al., 2013). Increased retinal thickness was attributed to the 
extra copy of the DYRKA1A gene which is inherited in triplicate on chromosome 21 in DS. 
With deletion of this extra copy retinal layers were not dissimilar in thickness from diploid 
mice. Overall there is no research to suggest that the structure of the retina should be 
different in people with DS. There are known differences in the development of the DS brain 
which, considering the connection between the brain and the retina, and that they are formed 
from the same tissue, may indicate that there could also be differences in retinal formation 
which are so far unreported.  
 
1.4.2 Age-related retinal diseases 
Ageing has a profound impact on almost every aspect of our bodies; the eyes are no 
exception to this and vision loss and blindness are dramatically increased in older age. 
Around middle age the lens begins to lose flexibility, reducing our capability to focus on 
near objects and our sharp visual acuity. For the majority of people this is compensated for 
by wearing reading glasses or bifocal lenses, but it is seldom fully restored. Vision loss is 
further worsened if cataracts or other ocular diseases are also present, in these cases, surgery 
or further intervention, is often required. Muscle weakening becomes a large problem for 
the eyes as we get older, decreased muscle strength results in drooping eyelids which 
obscure vision and slow pupil size changes, resulting in increased sensitivity to light 
(Krinsky-McHale et al., 2012). Most frequently reported ocular diseases in elderly people 
include; cataracts, age-related macular degeneration (AMD), open-angle glaucoma, 
detachment of the retina and visual impairment (Klein & Klein, 2013). AMD and glaucoma 
are particularly relevant in the discussion of AD as in the eyes these diseases can present 
with some similar pathology to that identified in the eyes of patients with AD. 
Differentiating between the three diseases will be crucial when evaluating the potential of 
the retina as a biomarker in AD.  
Age-related macular degeneration is a result of damage to the macula region of the retina, 
risk of AMD can be increased by smoking and genetic factors. It is a painless disease that 
gradually builds from selective areas of blurred vision, to blindness in the central field. 
Glaucoma causes damage to the optic nerve and vision loss, this disease causes severe pain 
in the eye, blurred vision, dilated pupils, redness and nausea. Risk factors include; increased 
eye pressure, high blood pressure, obesity and family history of the disease. If treated early 
18 
 
it is possible that the disease can be slowed or stopped using medications, laser treatments 
or surgeries that are aimed at reducing the eye pressure. Glaucoma is the second-leading 
cause of blindness worldwide.  
Glaucoma and AMD, as well as AD, present with depositions of Aβ, retinal damage, 
oxidative and metabolic stress and glial activation (Krantic & Torriglia, 2014). Similarities 
are greater between AD and glaucoma than between AD and AMD (see Figure 1.6). The 
location of retinal damage and glial activation is important, damage to the optic nerve head 
(ONH) is particular to glaucoma, whilst retinal ganglion cell loss and nerve fibre loss 
damage relate to both AD and glaucoma. An increase in intra-ocular pressure is specifically 
associated with glaucoma (Krantic & Torriglia, 2014). Crucially, cognitive impairments 
seen in AD are not evident in patients with glaucoma or AMD. In people with DS, who have 
a genetic predisposition for AD pathology and almost certainty of expressing Aβ plaques, 
there is a greater probability that amyloid-related retinal pathologies are part of the AD 
process, rather than caused by other retinal diseases. 
 
Figure 1.6  Venn diagram showing similarities and differences in the presentation of 
glaucoma AMD and AD in the retina. Figure reproduced from Krantic & 
Torriglia (2014), page 241.  
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1.4.3 Retinal markers in neurological diseases 
Many neurological diseases have been found to show visual symptoms and to have the 
potential for ocular biomarkers. In multiple sclerosis (MS), one of the primary 
manifestations in the eye is optic neuritis, which affects 70% of MS patients (Balcer, Miller, 
Reingold, & Cohen, 2015). Optical coherence tomography (OCT) studies in MS have 
identified reductions in macular thickness and volume (Parisi et al., 1999) and have revealed 
that there is a RNFL thickness threshold, patients with RNFL thickness under this threshold 
have a dramatically higher risk of disability (Martinez-Lapiscina et al., 2016). RNFL 
thinning in the temporal quadrant has been identified as the most useful measure in MS 
(Graham et al., 2016; Outteryck, Majed, Defoort-Dhellemmes, Vermersch, & Zéphir, 2015), 
as this region has shown the most sensitivity and specificity for detecting disease progression 
(Graham et al., 2016) and for distinguishing from other diseases (Outteryck, Majed, Defoort-
Dhellemmes, Vermersch, & Zéphir, 2015). In addition to assessments of retinal thickness, 
clinical assessments of contrast sensitivity and colour vision have been found to be useful 
in detecting MS patients with optic neuritis. In Parkinson’s disease, studies have reported 
RNFL and macular thinning (Bittersohl et al., 2015; Chorostecki et al., 2015; Garcia-Martin 
et al., 2012). The majority of studies have reported that, as with MS, the temporal RNFL 
quadrant is most affected (Pasol, 2011), although thickening of the OPL has been reported 
compared to healthy controls (Chorostecki et al., 2015). Other measures including contrast 
sensitivity and visual field tests have been found to successfully differentiate patients with 
Parkinson’s disease from controls. 
 
1.4.4 Retinal changes in Alzheimer’s disease 
The retina shows evidence of change during the course and progression of AD, which are 
summarised in this section. Often the first complaints of patients with AD are associated 
with changes in their vision (Berisha, Feke, Trempe, McMeel, & Schepens, 2007). Visual 
impairments in people with AD include; reduced visual acuity and visual attention, deficits 
in perceiving shape from motion, poor object and face recognition, delayed pace of visual 
processing and reduced visual sensory impairments such as contrast sensitivity or 
achromatopsia (Koronyo, Salumbides, Black, & Koronyo-Hamaoui, 2012; Parisi, 2003). 
These visual changes are likely a response to some of the many alterations in the retina 
which occur during AD.  
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Retinal ganglion cell loss and optic nerve degeneration in patients with AD was first reported 
by Hinton, Blanks & Miller, (1986), in a histological research study which showed 
widespread axonal degeneration of the optic nerve fibres of 80% of patients as well as a 
reduction in ganglion cells and the thickness of the RNFL. This study also evaluated retinal 
Aβ deposits, however these were not found in the AD patients. Blanks, Torigoe, Hinton, & 
Blanks, (1996) continued this research, finding that the neuronal cell count in the GCL was 
reduced by 36% in eyes from people with a diagnosis of AD compared to age-matched eyes 
from people without evidence of AD. It was reported that the largest loss was seen in the 
superior and inferior quadrants and a 43% reduction of cells in the central fovea was found 
between AD and control participants (Blanks, Schmidt, et al., 1996). A more thorough report 
on RNFL reduction in AD can be found in section 1.5. 
Presence of amyloid-beta plaques has been identified in the retina both in histopathological 
studies in animals, where amyloid-beta accumulation has been shown in all retinal layers 
and in the retinal blood vessel walls (Du et al., 2015; Dutescu et al., 2009; Kam, Lenassi, & 
Jeffery, 2010; Perez, Lumayag, Kovacs, Mufson, & Xu, 2009; Shimazawa et al., 2008). 
Deposits were shown to significantly increase with age in the mouse models (Ning, Cui, To, 
Hsiao Ashe, & Matsubara, 2008). These deposits have also been seen in human patients with 
AD (Frost et al., 2014; Koronyo-Hamaoui et al., 2011; Koronyo et al., 2017). However other 
research has suggested that Aβ does not accumulate in the eye. Michael et al., (2013) and 
Ho et al., (2012) were not able to show evidence of Aβ deposits in the lens, retina or other 
structures of the eye in patients with AD, whilst they were able to detect Aβ in brain samples 
using the same techniques, from which the authors concluded that Aβ either does not deposit 
in the eye in a manner which is reflective of the brain, or presents in lower levels or different 
forms. In vivo examinations of the retina have yielded further evidence of amyloid-beta, 
Hintersteiner et al., (2005) used near-infrared with fluorescence dye, which penetrates the 
blood-brain barrier and binds to amyloid plaques, to demonstrate significant Aβ binding in 
transgenic AD mice brains, which was confirmed by post-mortem analysis. Other studies 
using curcumin staining in mouse models have shown promising results in both the brain 
(Garcia-Alloza, Borrelli, Rozkalne, Hyman, & Bacskai, 2007; Yang et al., 2005), and the 
retina. Koronyo-Hamaoui et al., (2011) provided the first evidence of Aβ plaques in the 
retinas of AD transgenic mouse models in vivo. They reported that the in-vivo plaque size 
detection was very similar to the sizes observed by immunostaining ex-vivo. Aβ plaques 
were detected in the retinas and brains of the AD transgenic mice, but not in wild type control 
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mice. An age-dependent correlation between plaque deposition in the retina and the brain 
was found which indicated that there was increased accumulation in both alongside disease 
progression. One of the key findings of this study is that plaques were detectable in the 
mouse retina at the age of two months, and not in the brain until five months of age, implying 
that retinal Aβ could be an early marker for Aβ in the brain. More recently, a new 
technology, NeuroVision (NeuroVision Imaging LLC), has been designed which is able to 
image retinal Aβ in-vivo. This technology uses curcumin fluorescence to produce micron 
level high-resolution images of the retinal plaque deposits. Curcumin is a component of 
turmeric which binds to the Aβ protein with natural yellow colouring and fluoresces under 
blue-light excitation. The NeuroVision Retina HD is a fundus camera with a filter 
specifically matched to the fluorescence characteristics of curcumin. Quantitative analysis 
of Aβ plaque number (µm2) and distribution are derived from the collected images. Emission 
signals of the plaques are compared to the background signals in the retinal tissue to 
determine the signal-to-background ratio. NeuroVision calculates the retinal amyloid index 
in a blinded fashion for each subject. Using this technology Aβ has been identified in the 
retinas of patients with AD (Frost et al., 2014; Koronyo-Hamaoui et al., 2011; Koronyo et 
al., 2017). These deposits mirrored the quantity identified in the brain in histological 
examinations (Koronyo et al., 2017). Koronyo et al., (2017) found that in twenty patients 
with a diagnosis of mild cognitive impairment (MCI) between the ages of 66-84 years, Aβ 
plaques were imaged and compared to the images of age-matched controls. This study 
showed higher deposit number and clusters of Aβ deposits in the periphery of the superior 
and inferior quadrants and along the blood vessel walls compared to healthy controls. In 
adults with DS, Rafii et al. (2015) has identified the presence of Aβ in the retina using the 
same technology as Koronyo et al (2011). Twelve participants between the ages of 30 and 
60 years with DS and without presence of dementia were included in this study. Results 
showed that there was significant evidence of retinal Aβ (based on the retinal amyloid 
imaging scale) in all participants, it was also noted that the distribution of Aβ in the retina 
showed a tendency to distribute close to the blood vessels. No correlations were found 
between age and retinal Aβ index in this study, the authors attribute this to a small age range 
(30-60 years), furthermore no correlations were found between Aβ and cognitive scores. 
The importance of retinal imaging would be increased if it can be shown that AD-related 
changes occur in the retina prior to in the brain, as has been suggested by AD-transgenic 
mouse model research (Koronyo-Hamaoui et al., 2011). 
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The presence of Aβ close to the retinal blood vessels may have additional effects on the 
blood vessels. Other changes seen in the blood vessels include a slower retinal blood flow 
in patients with AD and systematic changes in parameters such as increased blood pressure 
(Waldstein et al., 2008) and arterial stiffness (Elias et al., 2009). Increased blood pressure in 
transgenic mice has been associated with higher concentrations of Aβ plaques in the brain 
(Golzan et al., 2017) suggesting a direct relationship between Aβ and retinal changes. 
Furthermore, changes in retinal blood vessels have been correlated with declining cognition 
(Golzan et al., 2017). 
Deposits of drusen are frequently seen in the eyes as we get older. Drusen containing Aβ 
has been localised to drusen found exclusively in individuals with AMD, whilst drusen in 
healthy patients does not contain Aβ (Dentchev, Milam, Lee, Trojanowski, & Dunaief, 
2003). In AMD, drusen are one of the earliest visible clinical changes, Peripheral drusen 
have been found to be significantly associated with AD patients (Aslam et al., 2014; Lengyel 
et al., 2015; Ritchie et al., 2011). These studies investigated the similarities in retinal features 
between AMD and AD and found that distribution of the Aβ containing drusen was 
specifically located in the peripheral retina in people with AD. In a longitudinal study, Aslam 
et al., (2014), analysed drusen and cognitive ability in healthy controls and patients with AD 
over the course of two years, findings showed increased drusen in all participants, however 
this progression was significantly more prevalent in the AD patients.  
In people with AD there are noticeable changes in the optic disc and the optic nerve. In the 
optic disc there are changes in the colour of the disc pallor, becoming a pale yellow in colour 
rather than the typical pink tones. Optic atrophy and disc cupping is also seen in patients 
with AD (Kiyosawa, Bosley & Chawluk, 1989; Sadun, Borchert, DeVita, Hinton, & Bassi, 
1987). Optic disc cupping is another feature which is one of the primary characteristics of 
another retinal disease, glaucoma, and is also evident in Parkinson’s disease (Ikram et al., 
2012). In the optic nerve, there is a decline of nerve axons, predominantly affecting the 
large-diameter axons (Syed, Armstrong, & Smith, 2005; Tsai et al., 2014).  
Finally, there is evidence of Aβ deposits in the lens of the eye in patients with AD. The 
levels of Aβ identified in the lens is comparable to those seen in the brain (Goldstein et al., 
2003). Several types of cataracts are associated with an increase in insoluble proteins 
(Frederikse et al., 1996) and these are also characteristic of people with AD. In a DS study, 
a link has been established between the risk of cataract formation and AD, showing a link 
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between lens pathology based on the distribution and accumulation of Aβ in this area 
(Moncaster et al., 2010). However, in typically developing AD lenses of donor with AD 
have not consistently found evidence of Aβ, Michael et al., (2013) was unable to locate Aβ 
whilst Goldstein et al., (2003) and Moncaster et al, (2010) provided strong evidence of Aβ 
in AD lens cataracts. 
 
1.4.5 Retinal structure in Down’s syndrome 
Investigations of retinal structure in people with DS using OCT are very limited, a literature 
search of PubMed and Scopus databases revealed a total of just five studies (Table 1.1). Of 
these studies, two were case studies focussing on individuals with particular ocular 
abnormalities, which cannot be applied more generally (Altun, Altun, Kurna, Olcaysu, & 
Aki, 2014 and Aziz, Ruggeri, & Berrocal, 2011), furthermore these studies did not report on 
retinal thickness.  
Two studies, O’Brien et al., (2015) and Weiss, Kelly, & Phillips, (2016) conducted cross-
sectional OCT examinations in children with DS and compared findings to typically 
developing children. Retinal thickness was assessed in both studies. O’Brien et al., (2015) 
found thicker fovea and macular in DS children (17 children aged between six and 16 years). 
The foveal pit was noticeably shallower in images of the retina and significantly thicker in 
the DS group (281±17µm compared to 246±21µm in the control group). Macular quadrants 
were significantly thicker in all except the temporal quadrant. Inner retinal layers were more 
similar in thickness between groups, whereas the outer layers again showed increased 
thickness in children with DS. One of the limitations reported by the authors was that due to 
low quality of the images they were unable to provide full segmentation of individual layers. 
It was proposed that thicker macular could be a primary pathology related to the disorder. 
Weiss et al., (2016) conducted a smaller OCT study in seven children with DS (age seven 
to 15 years). This study reported that all retinal layers appeared normal in all eyes, but that 
the fovea was increased in thickness specific to the ONL in the DS group.  
The final study examined five eyes of three adult participants with DS (29.2±16.6 years) 
using OCT (Laguna et al., 2013). The OCT component of this study was secondary to 
investigations of retinal thickness in a mouse model of DS (Ts65Dn) and optical biopsies of 
DS retinas. From the OCT examinations, they reported that retinal structure was not 
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dissimilar to age-matched controls. From the biopsies of 16 retinas, it was reported that the 
fovea and inner macular (all quadrants) were thicker than control retinas, although a 
significant difference was only seen in the fovea region. The DS mouse model component 
of the study also showed evidence of thicker retinal structure when compared to wild type; 
particularly the inner retinal layers, whilst the outer retinal layers were more similar in 
thickness (Laguna et al., 2013). One of the genes in triplicate in the Ts65Dn mice is Dryk1a, 
a separate mouse model, mBACtgDyrk1a, containing specific trisomy of this gene was also 
used in this study, and exhibited increased retinal thickness similar to that of the Ts65Dn 
mouse. However, removal of the third copy of this gene resulted in normal retinal thickness. 
This study suggests that the inhibitory effect of Dryk1a on apoptosis during development 
may be responsible for the increased thickness of the retina.  
Due to the limited research in DS it is difficult to reach a conclusion on retinal structure; it 
appears that there is a trend towards increased thickness in some retinal areas, although this 
deduction is predominantly based on findings in children with DS. In adults in the typically 
developing population there is strong evidence of age-related thinning of the retina, and of 
significant thinning in AD patients (discussed in detail in section 1.4). Adults with DS 
present with accelerated ageing and have high prevalence of AD, therefore, may be more 
likely to show increased retinal thinning. To date there has been no large-scale research on 
retinal thickness in adults with DS. This study is the first to build on the findings of OCT 
research conducted in typically developing AD into adults with DS.  
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Author Sample (DS) Main findings 
Altun, Altun, Kurna, 
Olcaysu, & Aki. 
(2014) 
1 patient, aged 15 years Reduced retinal nerve fibre layer (RNFL) thickness in the right eye. Case study of a 
patient with unilateral morning glory optic disc anomaly. 
Aziz, Ruggeri, & 
Berrocal (2011) 
1 patient, aged 3 years Absence of the retinal pigment epithelium and atrophy if the neurosensory retina 
consistent with diagnosis. Case study of a patient with bilateral macular coloboma. 
Laguna et al. (2013) 3 patients, mean age 29.2 ± 
16.6 years 
Thicker neural retina than controls, significantly thicker only in the central fovea 
region. 
O’Brien et al. (2015) 17 children with DS aged 6-
16 years 
Thicker central subfield thickness and inner and outer layers of the macular in the DS 
group. 
Weiss, Kelly, & 
Phillips (2016) 
7 children with DS aged 7 – 
14 years 
Retinal layers appeared normal in all eyes, the fovea showed thickening in the outer 
nuclear layer and central fovea thickness was larger than in non-DS children. 
Table 1.1 OCT examinations conducted in DS populations
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1.5 A systematic review of retinal nerve fibre layer thinning in patients 
with Alzheimer’s disease. 
1.5.1 Literature search  
A systematic literature review was undertaken to explore the published research that has 
used OCT technology to investigate RNFL thickness in patients with AD. The search terms 
and criteria for the inclusion pathway are illustrated in Figure 1.7. Scopus and PubMed 
databases were searched to identify published articles in patients with AD or MCI. Meta-
analyses were not included for this literature review although references were screened for 
overlooked literature. Non-human studies and reviews were excluded, as were articles where 
the primary aim was to compare or develop OCT methodologies, and those that did not 
compare retinal measures between at least one patient group and a control group. Screening 
of the article title and abstracts was conducted as a primary eligibility check before thorough 
investigations of the articles. A total of 36 original research articles were retained for 
examination. These were further sub-divided into those involving patients with AD and 
controls, and those which also included an MCI patient group. The full list of retained 
articles can be found in Table 1.2.  
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Figure 1.7 Article identification process for the systematic literature review – conducted 
20th May 2017.  
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Author Sample Cognitive testing Key findings 
RNFL thickness comparisons between AD and age-matched control groups 
Bambo et al., 
(2015) 
56 patients with AD 
56 age-matched controls 
Mini mental state 
examination (MMSE 
Folstein, Folstein, & 
McHugh, 1975) 
RNFL average and all quadrants except the temporal were 
significantly thinner in the AD group.  
Berisha, Feke, 
Trempe, 
McMeel, & 
Schepens, (2007) 
9 patients with AD 
8 age-matched controls 
MMSE Only the superior quadrant was significantly thinner in the AD group.  
Cunha et al., 
(2016) 
24 patients with AD 
24 age-matched controls 
MMSE Superior and inferior quadrant RNFL thickness significantly thinner 
in AD group.  
Eraslan et al., 
(2015) 
20 patients with AD 
20 age-matched controls 
MMSE Significant reduction in the RNFL average and superior-nasal 
thickness of the AD group when compared to the controls.  
Garcia-Martin et 
al., (2016) 
150 patients with AD 
75 age-matched controls 
MMSE AD patients had significantly reduced thickness in the RNFL average, 
temporal superior, temporal inferior, temporal compared to controls.  
Garcia-Martin et 
al., (2014) 
20 patients with mild AD 
28 age-matched controls 
MMSE RNFL thickness did not differ between groups. 
Gharbiya et al., 
(2014) 
21 patients with AD 
21 age-matched controls 
MMSE RNFL thickness in all quadrants was not significantly different 
between groups. 
Gunes et al., 
(2015) 
40 patients with AD 
40 age-matched controls 
MMSE RNFL average and all quadrants significantly thinner in the AD group 
when compared to controls. 
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Author Sample Cognitive testing Key findings 
Iseri et al., 
(2006) 
14 patients with AD 
15 age-matched controls 
MMSE Average RNFL and all quadrants exempting the temporal were 
significantly thinner in the AD group. 
Kang & Kim, 
(2013) 
8 patients with AD 
8 age-matched controls 
n/a RNFL average, nasal and inferior were significantly thinner in the AD 
group.  
Kirbas et al., 
(2013) 
40 patients with AD 
40 age-matched controls 
MMSE RNFL average and the superior quadrant significantly thinner in AD 
group.  
Kromer et al., 
(2014) 
22 patients with AD 
22 age-matched controls 
MMSE RNFL thickness in the nasal superior sector significantly thinner in 
the AD group.  
Larrosa et al., 
(2014) 
151 patients with AD 
61 age-matched controls 
MMSE RNFL average, nasal, nasal-inferior, temporal-inferior and temporal 
superior were significantly thinner in the AD group.  
Lu et al., (2010) 22 patients with AD 
22 age-matched controls 
n/a RNFL average, superior and inferior quadrants significantly thinner 
in the AD group 
(Marziani et al., 
2013) 
21 patients with AD 
21 age-matched controls 
MMSE All measures of RNFL were significantly reduced in the AD group.  
Moreno-Ramos, 
Benito-León, 
Villarejo, & 
Bermejo-Pareja, 
(2013) 
10 patients with AD 
10 age-matched controls 
MMSE Significant RNFL thickness decrease in AD group compared to 
control group.  
30 
 
Author Sample Cognitive testing Key findings 
La Morgia et al., 
(2015) 
21 patients with AD 
74 age-matched controls 
MMSE Average and superior RNFL measures significantly thinner in the AD 
group.  
Trebbastoni et 
al., (2016) 
36 patients with AD 
36 age-matched controls 
MMSE RNFL average and superior and inferior quadrants showed significant 
reduction in thickness compared to controls over a period of 12 
months, inferior quadrant decline was most prominent and correlated 
with cognitive decline.  
Parisi et al., 
(2001) 
17 patients with AD 
14 age-matched controls 
n/a RNFL average and all quadrant measures were significantly thinner 
in the AD group.  
Polo et al., 
(2014) 
75 patients with AD 
75 age-matched controls 
MMSE Average RNFL and superior, inferior, inferior-nasal and inferior-
temporal sectors thinner in AD group.  
Polo et al., 
(2017) 
24 patients with AD 
24 age-matched controls 
MMSE RNFL average and superior quadrant measures significantly thinner 
in the AD group.  
Salobrar-garcia 
et al., (2015) 
23 patients with AD 
28 age-matched controls 
MMSE RNFL average and all quadrants significantly thinner in the AD 
group.  
Moschos, 
Markopoulos, 
Chatziralli, 
Rouvas, & M 
Moschos, (2012) 
30 patients with AD 
30 age-matched controls 
n/a Mean foveal thickness and superior and inferior quadrants 
significantly thinner in the AD group.  
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Author Sample Cognitive testing Key findings 
MCI group RNFL thickness comparisons to age-matched control groups and AD groups 
Ascaso et al., 
(2014) 
18 patients with AD 
21 patients with MCI  
41 age-matched TD 
controls 
MMSE RNFL was thinner in MCI patients compared to controls, and again 
thinner compared to the AD patients.  
Cheung et al., 
(2015) 
100 patients with AD 
41 patients with MCI 
123 age-matched controls 
n/a There was no difference in the RNFL between MCI and AD measures. 
AD and MCI groups differed significantly from the controls in RNFL 
average and quadrant measures.  
Ferrari et al., 
(2017) 
39 patients with AD 
27 patients with MCI  
17 patients with dementia 
of the frontal type (DFT) 
49 age-matched controls 
MMSE All groups showed significant reduction of RNFL when compared to 
controls. There was no significant difference between the MCI and 
AD groups however it was noted that the MCI group had thinner 
RNFL than those identified as mild AD.  
Gao, Liu, Li, 
Bai, & Liu, 
(2015) 
25 patients with AD 
26 patients with MCI 
21 age-matched controls 
MMSE AD and MCI groups showed thinner RNFL measures than the control 
group for the average, and superior quadrant. Furthermore average 
RNFL, and the inferior quadrant were significantly thinner in the AD 
group compared to the MCI group. AD compared to controls showed 
significantly thinner results for the average and the superior, inferior 
and temporal quadrants.  
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Author Sample Cognitive testing Key findings 
Kesler et al., 
(2011) 
30 patients with AD 
24 patients with MCI 
24 age-matched controls 
MMSE MCI and AD groups both showed significantly thinner RNFL than the 
control group for the average, superior and inferior quadrants. There 
were no statistical differences between the AD and MCI groups.  
Knoll et al., 
(2016) 
20 patients with MCI 
20 age-matched controls 
Test battery of the 
Uniform data set 
(Esteveiz-Gonzalez, 
Kulisevsky, Boltes, 
Otermin, & Garcia-
Sanchez, 2003) 
No significant differences found for any RNFL measures between 
groups. 
Liu et al., (2015) 19 patients with severe AD 
24 patients with moderate 
AD 
24 patients with mild AD 
26 patients with MCI 
39 age-matched controls 
MMSE MCI and mild AD groups were significantly thinner than the control 
group in the superior and average RNFL measures, for these regions 
moderate and severe AD also significantly thinner than MCI. Severe 
AD also showed significantly thinner inferior quadrant than both 
control and MCI groups.  
Oktem et al., 
(2015) 
35 patients with AD 
35 patients with MCI 
35 age-matched controls 
MMSE Significant thinning with relationship to age was detected. Both MCI 
and AD groups had significantly thinner RNFL average compared to 
controls, there was no significant difference between MCI and AD 
RNFL measures.  
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Author Sample Cognitive testing Key findings 
Paquet et al., 
(2007) 
12 patients with severe AD 
14 patients with mild AD 
23 patients with MCI 
15 age-matched controls 
MMSE All patient groups showed significantly thinner average RNFL 
measures when compared to the control group. Mild AD group 
showed non-significantly thicker RNFL average than MCI group.  
Pillai et al., 
(2016) 
21 patients with AD 
20 patients with MCI 
34 age-matched controls 
Montreal Cognitive 
Assessment (MOCA; 
(Nasreddine et al., 
2005))  
No statistical significant differences were reported in any RNFL 
measures between any groups.  
Senthilkumar & 
Prabna, (2016) 
14 patients with AD 
(glaucoma) 
12 age-matched controls 
n/a RNFL average and all quadrants significantly thinner in the AD 
group. Note that this article does not distinguish how patients with AD 
were identified and does not make a distinction between AD and 
glaucoma.  
Shen et al., 
(2014) 
23 patients with MCI 
52 age-matched controls 
MMSE-Chinese No significant difference between the RNFL measures of the groups. 
MCI group showed an inverse association between cognitive function 
and the inferior quadrant. Patients with a thicker inferior quadrant 
performed worse in cognitive tests.    
Zhu, Ren, Wang, 
& Zhang, (2014) 
10 patients with AD 
47 patients with MCI 
167 age-matched controls 
MMSE RNFL average temporal and superior quadrants were significantly 
thinner in MCI and AD groups compared to controls, only the 
temporal quadrant was significantly thinner in AD group compared to 
MCI groups.  
Table 1.2 Key information of studies included in the literature review. 
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1.5.2 Summary and review of identified articles 
This literature review has evaluated the differences in RNFL thickness between patients with 
AD, MCI and control groups. From the studies identified, further investigations were 
undertaken into the associations between retinal thicknesses and cognitive test scores and 
into supplementary areas of the retina that may have been investigated, such as the macular 
and retinal layers.  
 
 Thinner RNFL in patients with Alzheimer’s disease 
Findings from the literature review indicate that there is a significant difference between the 
RNFL thickness of AD patients and age-matched control groups. All but three of the studies 
reported thinner RNFL in the AD patients (Bambo et al., 2015; Eraslan et al., 2015; Garcia-
Martin et al., 2016; Gunes et al., 2015; Iseri et al., 2006; Kang & Kim, 2013; Kirbas et al., 
2013; Larrosa et al., 2014; Lu et al., 2010; Marziani et al., 2013; Moreno-Ramos et al., 2013; 
La Morgia et al., 2015; Parisi et al., 2001; Polo et al., 2017; Salobrar-Garcia et al., 2015). 
Those which did not see thinner RNFL in AD patients found no differences between groups 
(Garcia-Martin et al., 2014; Gharbiya et al., 2014; Pillai et al., 2016), although one of these 
studies (Garcia-Martin et al., 2014) reported significantly thinner RNFL in AD patients in a 
later study with a larger sample (Garcia-Martin et al., 2016). The number of studies that did 
not show significant results is consistent with expectations based on hypothesised power of 
80% for these studies. Furthermore, lack of significant findings in these three studies is not 
likely to be due to sample size, as studies with smaller sample sizes such as Moreno-Ramos 
et al., (2013) and Kang & Kim, (2013) with eight and ten participants per group respectively, 
found significant differences in the average RNFL thickness between groups.  
Within the RNFL there are four quadrants that are frequently measured. Of the studies 
evaluated in this review, three did not provide quadrant analysis (Moreno-Ramos et al., 
2013; Oktem et al., 2015; Paquet et al., 2007). From those that did, quadrant analyses almost 
always showed that all of the quadrants were significantly reduced in thickness in patients 
with AD (Gharbiya et al., 2014; Gunes et al., 2015; Parisi et al., 2001; Salobrar-Garcia et 
al., 2015; Senthilkumar & Prabna, 2016). The superior quadrant was most likely to show 
evidence of thinning in the AD group (Berisha et al., 2007; Eraslan et al., 2015; Kirbas et 
al., 2013; Liu et al., 2015; La Morgia et al., 2015; Polo et al., 2017) and the inferior quadrant 
the second most likely, however, thinning in this region was often accompanied by 
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significant thinning in the superior quadrant (Cunha et al., 2016; Kesler et al., 2011; Liu et 
al., 2015; Lu et al., 2010; Moschos et al., 2012). The majority of research indicates that the 
superior quadrant may be the most, and earliest, area of the retina implicated in AD. 
Although both the inferior and nasal quadrants were reported as thinner in patients AD, no 
studies found thinning of either quadrant without there also being significant thinning of the 
superior quadrant (Kang & Kim, 2013; Kromer et al., 2014; Larrosa et al., 2014). Liu et al., 
(2015) found that the nasal quadrant was reduced in thickness only in severe AD, suggesting 
that reductions in the nasal quadrant are later in the disease process. The temporal quadrant 
was found to be significantly thinner in just one study (Garcia-Martin et al., 2016) and in 
other studies was identified as the only quadrant not to show evidence of thinning (Bambo 
et al., 2015; Iseri et al., 2006). This suggests that the temporal quadrant is more resilient to 
fibre loss than other quadrants. Resilience in the temporal quadrant is unexpected as 
Parkinson’s disease and MS have shown specific thinning in this area (Graham et al., 2016; 
Pasol, 2011). Identifiable differences such as these in the retinal presentation of neurological 
diseases are imperative if retinal measures are to be used as early markers for the screening 
of AD. Ultimately, this research suggests that in patients with AD, RNFL thickness is 
generally reduced, and the superior quadrant shows the most evidence of thinning in 
comparison to age-matched control groups. Additional thinning, particularly in the inferior 
quadrant, follows after thinning of the superior quadrant.  
 
 RNFL changes in MCI  
Thirteen of the studies identified in the literature search included a MCI patient group. 
Comparing differences between retinal thicknesses of the MCI group to controls, and also 
between MCI and AD groups is important to establish the earliest changes in the retina in 
the AD progression. The majority of studies in patients with MCI found a significant 
reduction in the average RNFL thickness compared to control groups (Ascaso et al., 2014; 
Cheung et al., 2015; Ferrari et al., 2017; Gao et al., 2015; Kesler et al., 2011; Liu et al., 2015; 
Oktem et al., 2015; Paquet et al., 2007; Zhu et al., 2014). Evidence of significant differences 
in retinal thickness between the AD and MCI groups was not as robust, with equal numbers 
of studies finding no significant differences between groups (Cheung et al., 2015; Knoll et 
al., 2016; Oktem et al., 2015; Pillai et al., 2016), and significantly thinner RNFL in the AD 
group compared to the MCI group (Ascaso et al., 2014; Gao et al., 2015; Liu et al., 2015; 
Zhu et al., 2014). Two studies identified further subgroups within the MCI/AD 
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classifications. Paquet et al., (2007) subcategorised the AD group based on scores from the 
mini-mental state examination (MMSE; Folstein et al., 1975), which resulted in a third group 
in between AD and MCI termed “mild dementia”. Findings showed no differences between 
AD and mild AD patient groups, but a significant difference between AD and MCI groups 
was found. These results suggest that the gradual changes in RNFL thickness are too small 
to be further sub-divided.  
Quadrant analysis for MCI was assessed in all but three of the papers identified (Ferrari et 
al., 2017; Oktem et al., 2015; Paquet et al., 2007). Ascaso et al., (2014) and Cheung et al., 
(2015) found that all quadrants were significantly reduced in thickness in the MCI patients 
compared to the control group, however, no differences were found between the MCI and 
AD groups. Reduction of thickness was specifically noted in the superior quadrant (Gao et 
al., 2015; Liu et al., 2015). Likewise, Kesler, Vakhapova, Korczyn, Naftaliev, & Neudorfer, 
(2011) found that the inferior and superior quadrants were both significantly reduced in the 
MCI group compared to the control group. Zhu, Ren, Wang, & Zhang, (2014) reported a 
reduction in the average, temporal and superior quadrant thickness in both MCI and AD 
patients. Results from studies including an MCI patient group suggest that the pattern of 
change is very similar to that seen in the AD group, and reinforces the theory that 
degeneration in the superior quadrant is the most profound and likely to be the first site to 
show signs of change, and that retinal changes can be seen in the early stages of AD. 
 
 Macular changes in AD 
As well as the peripapillary RNFL, several of the studies identified also investigated macular 
thickness. Decreased macular thickness was found in patients with AD when compared to 
controls (Cunha et al., 2016; Giménez, Dudekova, Gómez, & Lajara, 2016; Moschos et al., 
2012; Polo et al., 2017), as was in MCI patients in compared to controls (Cunha et al., 2016; 
Liu, Ong, Hilal, Miin, & Wong, 2016; Moschos et al., 2012; Polo et al., 2017). Several 
studies investigated macular quadrants, and all but one (outer macular inferior quadrant) 
were reported to be thinner in patient groups (Cunha et al., 2016; Polo et al., 2017). Moschos, 
Markopoulos, Chatziralli, Rouvas, & Moschos, (2012) reported significantly thinner fovea 
in AD patients. Controversially, Ascaso et al., (2014) found that although AD patients 
showed significantly thinner macular than controls, the MCI group had significantly thicker 
macular than both the AD and control groups. Thicker macular persisted in the MCI group 
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in both the fovea and in the the average of the inner macular but not the outer macular. 
Conclusions made from this research were that this finding could be a result of retinal cell 
activation and swelling. Reichenbach et al., (2007) has reported the activation of perifoveal 
Müller glial cells, with consequent swelling in the early stages of retinal degeneration. 
Müller cells are closely linked with retinal neuronal cells, forming much of the non-neuronal 
retinal space and are susceptable to inflammation (Bringmann & Wiedemann, 2011). 
Neuronal swelling is a pathological hallmark of several neurodegenerative diseases, 
including AD (Fujino, Delucia, Davies, & Dickson, 2004) and may result in retinal 
thickening in the early stages of AD, which is later followed by thinning as inflammation 
induces programmed cell death processes such as apoptosis.  
 
 Retinal thickness and cognitive change  
The relationship between cognitive ability and retinal thickness was investigated in the 
majority of the studies identified, typically the MMSE (Folstein et al., 1975), was used to 
determine cognitive status. The MMSE is one of the most widely used tests in the screening 
of dementia in the typically developing population. Studies mostly reported that there was 
no relationship between cognitive score and retinal thickness (Eraslan et al., 2015; Ferrari et 
al., 2017; Gao et al., 2015; Gharbiya et al., 2014; Gunes et al., 2015; Iseri et al., 2006; Kesler 
et al., 2011; Kirbas et al., 2013; Kromer et al., 2014; La Morgia et al., 2015; Paquet et al., 
2007; Polo et al., 2017). Of the few studies that did identify a relationship, lower MMSE 
scores were invariably correlated with thinner retina (Ascaso et al., 2014; Cunha et al., 2017; 
Garcia-Martin et al., 2014; Moreno-Ramos et al., 2013; Oktem et al., 2015; Trebbastoni et 
al., 2016). Within these studies there was extreme variability in the extent of the association 
found. Moreno-Ramos et al., (2013) reported the strongest significant correlation (r= .963, 
p< .05), whilst others reported lower significant correlations (r= .33, Cunha et al., 2017; and 
r- .34, Garcia-Martin et al., 2014). Trebbastoni et al., (2016) conducted a longitudinal study 
in which the rates of MMSE decline were evaluated after one year, this study was able to 
associate cognitive decline with greater fibre loss in the inferior quadrant. The inferior 
quadrant was also identified as having the strongest correlation with MMSE scores (r= .37), 
followed by the superior quadrant (r = .22) whilst the temporal and nasal quadrants were not 
significantly correlated (Cunha et al., 2017). Conversely, Ascaso et al., (2014) found a 
significant positive relationship between MMSE score and the thickness of the nasal and 
superior quadrants, as well as global RNFL, but no relationship with the inferior quadrant. 
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A small number of the articles also included MMSE correlations with the macular region. 
Cunha et al., (2016) found a stronger correlation with MMSE and retinal thickness in the 
macular (r= .49) than in the RNFL. Iseri et al., (2006) and Ferrari et al., (2017) did not find 
a relationship between RNFL thickness and MMSE scores, but both studies reported a 
positive correlation between the thickness of the GCL-IPL macular layers and MMSE 
scores. Garcia-Martin et al., (2014) identified a positive relationship with the GCL. 
However, Ascaso et al., (2014) found opposite results, reporting no relationship between 
MMSE scores and macular region thickness or volume in MCI or AD patients.  
In studies where cognitive tests other than the MMSE were applied to the patient groups 
(Knoll et al., 2016; Shen et al., 2014) an inverse relationship between cognitive tests and 
RNFL thickness was identified, suggesting that thicker retina was associated with lower 
cognitive ability. Both studies highlighted the inferior quadrant as the region showing the 
strongest correlations. Shen et al., (2014) found that thicker inferior quadrant was worse 
correlated with poorer overall cognitive function and specifically with poorer episodic 
memory. Knoll et al., (2016) found that in tests of delayed story recall and word-list learning 
those with poorer scores also displayed thicker retina. These findings suggest that the MMSE 
is not comprehensive enough to identify all retinal and cognitive relationships. The MMSE 
is a short, 10-item scale that is easy to deliver in people with cognitive problems thereby 
increasing its appeal. The issue with applying results from these studies which have used 
less standardised materials is that there are no replications of the findings.  
 
 Conclusions 
Conclusions from this literature review indicate that there is an association between retinal 
thickness and AD. The majority of studies assessed in this literature review have found 
significantly thinner RNFL and macular regions in patients with AD and, often, in patients 
with MCI, suggesting that retinal changes occur at an early stage of the disease. The superior 
quadrant is highlighted as the quadrant of the RNFL showing the most thinning in patients 
with AD. Concerning for the use of the retina as a biomarker for AD is that there appeared 
to be little evidence of correlation between retinal thickness and cognitive change. The 
inferior quadrant showed the most association with cognitive scores and decline. However, 
conflicting results in the literature have seen both a thinner inferior quadrant associated with 
lower MMSE scores, and a thicker inferior quadrant associated with decline in episodic 
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memory, story recall and word list recall. The confusion surrounding this topic indicates that 
more research is needed in order to fully understand the involvement of the RNFL in AD. 
 
1.6 Aims and hypotheses 
The primary aim of this thesis is to evaluate the potential of studying retinal thickness in 
adults with DS as a potential marker of AD related change. To achieve this, retinal thickness 
was examined using OCT technology and dementia status was investigated using informant 
interviews, neuropsychological tests and, in collaboration with another study in the same DS 
cohort, amyloid deposition in the brain. Natural ageing in the retina will also be investigated 
in the DS group in relation to typically developing control groups.  
Overall hypotheses:  
 People with DS will have thinner retina than age-matched typically developing 
controls and retinal thinning will be more pronounced with age in the DS group. 
 Retinal thickness will correlate with cognitive performance. 
 Cortical thickness will positively correlate with retinal thickness.  
 Individuals with DS with a diagnosis of dementia, and those with “positive brain Aβ 
binding” will show thinner retinal measures than those without. 
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Chapter Two: 
Methods and materials 
2.1 Chapter summary 
The methodologies used in data collection and analysis are described in this chapter. All 
results chapters (chapters three, four and five) share data on retinal image acquisition and 
DS participant recruitment. Results chapters consider; investigation of retinal thickness in 
adults with DS in comparison to typically developing controls, and in relation to ageing, 
cognition and dementia in DS. Retinal and cortical thickness associations and retinal 
thickness in the presence and absence of fibrillar amyloid-beta (Aβ) binding in the brain are 
also explored.  
 
2.2 Collaborations 
This study has been conducted in the Cambridge Intellectual and Developmental Disabilities 
Research Group (CIDDRG) as part of the Defeat Dementia in Down’s syndrome (DiDS) 
studies at the University of Cambridge. DS participant recruitment was conducted in 
collaboration with an electroencephalography (EEG) study conducted by Dr Jennings. 
Neuropsychological tests and dementia interview data were jointly collected and used in 
both studies. Data from a previous neuroimaging study, DiDS, was used in the analysis of 
Chapter Five. This neuroimaging study investigated brain structure and Aβ in adults with 
DS over the age of 30 years using MRI and PET imaging and was conducted by Dr Wilson 
and Dr Annus.  
Ophthalmic support for this study was provided by researchers at the Imperial College 
Ophthalmic Research Group (ICORG), Western Eye Hospital, London. Professor Cordeiro 
(Professor of Retinal Neurodegeneration and Glaucoma Studies) was an advisor on this 
project, and Dr Normando (Ophthalmologist and Glaucoma Specialist) conducted the OCT 
scans and provided medical expertise and analysis guidance.  
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2.3 Approvals from Regulatory Authorities 
Ethical approval for this study was granted by the National Research Ethics Committee East 
of England – Cambridge Central, on November 3rd 2014 (see appendix A). Research and 
development approvals were granted by Cambridge University Hospital NHS Foundation 
Trust and Cambridge and Peterborough Foundation Trust. This project was conducted 
within the conventions of the Declaration of Helsinki (2013).  
 
2.4 Study design 
This cross-sectional study aimed to investigate retinal thickness in people with DS in relation 
to age, cognition, and dementia status. Retinal thickness was examined in all participants 
using OCT; scans investigated the thickness of the peripapillary retinal nerve fibre layer 
(RNFL), and the macular and posterior pole regions including the segmented retinal layers 
of the posterior pole. Neuropsychological tests were used to measure cognitive functioning 
in areas known to decline with dementia, an IQ test and an informant interview for dementia 
status were conducted in the DS group, for control participants a dementia screening 
assessment was completed. Finally, in a sub-set of DS participants with previous 
neuroimaging data, cortical and retinal thickness relationships were assessed in the presence 
and absence of Aβ binding in the brain, as an indicator of developing dementia. 
 
2.5 Study population 
2.5.1 Participant identification 
For this study three groups of participants were recruited; people with DS over the age of 18 
years, an age-matched typically developing control group and a typically developing group 
older than the DS group (57 years and over).  
Participants with DS were recruited nationally and at least one home visit was made to each 
participant to explain the study. Identification of people with DS was through one of three 
avenues. Firstly, participants who had previous involvement in another of the DiDS research 
studies were invited to take part in this study. All these participants had previously signed a 
consent form agreeing to be contacted about future studies. Secondly, recruitment through 
the Down’s syndrome association (DSA), the DSA have been very supportive of all of the 
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DiDS studies for over five years, forwarding materials and identifying participants. 
Recently, the DSA have supported all of our public engagement events. Public engagement 
events were the final recruitment strategy utilised in this study. In order to raise awareness 
about our research, three open day events have been held. On world Down’s syndrome day 
(21st March) 2015 and 2016 an open day was held in Cambridge and an additional public 
event was held at the DSA headquarters in July 2016. At these events, members of the public, 
people with DS and their families were invited to meet the researchers and talk about current 
research. Posters were presented by the researchers explaining what the studies involved and 
current findings and people were able to ask questions and discuss any concerns they had 
about the research project. The event held in Cambridge in 2016 also produced a short video, 
where participants were asked about their involvement in the research and how they felt 
about taking part in research. This video can be viewed at https://youtube/pB7iqWUXQlM. 
These events also included crafts, activities and refreshments, which were provided by the 
Owl Café, part of the Papworth Trust in support of learning disability.  
The age-and-gender matched control group and older control group were principally 
identified as family members and/or carers of the individuals with DS who were taking part. 
After initial recruitment through this method, emails were sent to University of Cambridge 
students and staff to increase participation of particular age-groups. People who were 
interested contacted the researcher by email to express interest in the study.  
 
2.5.2 Recruitment procedure 
Once a participant was identified, contact was made from the researcher to the participant 
or their family member or carer by phone. The study was briefly explained and if they were 
interested an information pack was sent to the participant. This included three information 
sheets so as to appeal to all levels of understanding; a standard version of the information 
sheet (appendix B), an easier-read version created using Widgit symbols (communication 
aid for those with intellectual disability (ID), appendix C), and, a picture booklet with fewer 
words and images of several aspects of the study (appendix D). Participants and their 
families were given at least one week to read through the materials before a follow up call 
was made by the researcher to ask if they were interested in proceeding. If the participant 
was happy to continue the researcher arranged to visit the participant at their home to discuss 
the study in further detail, and to check that the participant understood the procedure and 
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could provide informed consent (for the DS consent form see appendix E). For participants 
who were not able to give their informed consent a consultee process was initiated. In these 
cases, either a personal consultee, someone who knew the individual with DS as a friend or 
family member, or a nominated consultee, for example a doctor or keyworker of the 
individual, was given an information sheet and a declaration form to sign (personal consultee 
documents, appendices F and G; for nominated consultee documents, appendices H and I).  
Control and comparison group participants were approached either in person or via email. 
If interested in the study they received an information sheet (see appendix J) and were given 
the opportunity to ask any questions. If they wished to participate in the study they were 
asked to sign the consent form (see appendix K).  
All participants were aware that taking part in the study was voluntary and that they were 
able to change their minds and leave the study at any time. The home visit to participants 
with DS was an important part of the study recruitment procedure, allowing the participant 
to meet the researcher in a comfortable environment and giving them and their carer the 
chance to ask questions about the study. Participants were recruited nationally and were 
required to make a single visit to one of the three testing sites for the retinal examination. 
Home visits for recruitment and cognitive testing are shown in Figure 2.1.  
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Figure 2.1 Home visit recruitment map. Red pins refer to participant locations and blue 
pins to the testing sites.  
 
2.5.3 Capacity to consent  
Capacity to provide full informed consent was assessed by the researcher. Participants were 
given as much time as necessary to make a decision about whether to take part and were 
encouraged to ask questions. Consent procedure was always undertaken in the presence of 
a parent or carer whom the participant trusted and who could oversee that there was no 
coercion. Participants were required to read through the information sheet with the 
researcher and to answer simple questions regarding the nature of the study, i.e. what would 
be expected of them, what the risks and benefits were and that they understood that they did 
not have to take part in the study and could change their minds at any time. If the researcher 
believed that the participant did not have capacity to provide fully informed consent to the 
study, but that they had expressed a desire to take part, then a consultee process was invoked.  
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2.5.4 Inclusion and exclusion criteria 
Inclusion criteria  
 Diagnosis of DS (DS group) 
 At least 18 years of age (DS and age-matched control group) 
 At least 57 years of age (older comparison group) 
Exclusion criteria 
 No active psychiatric or neuropsychiatric illness (other than dementia in the DS 
group) 
 No eye surgery within the last three months 
 No diagnosis of diabetes mellitus 
 No nystagmus or latent nystagmus 
 No diagnosis of current or previous retinal disease 
 No retinal detachment or vitreoretinal procedure 
 No evidence of severe cataracts  
Inclusion and exclusion criteria were checked with all participants ahead of scheduling home 
visits or study visits.  
 
2.5.5 Sample size calculation 
The primary aim of this study is to investigate retinal thickness in relation to AD in people 
with DS. To achieve this, one of the analysis procedures undertaken compared retinal 
thickness in people with DS to that of age-matched typically developing controls and 
examined age-related changes in retinal thickness. Previously completed OCT research in 
people with DS is sparse, the largest study in the literature included 17 children with DS and 
18 age-matched typically developing children (O’Brien et al., 2015). This study provided 
acceptable power of 0.80 and permitted detection of ≥ 10μm inter-ocular difference in retinal 
thickness. In addition to this study, literature in the non-DS AD population was assessed in 
order to establish the necessary parameters for the current study. Analysis of studies 
comparing RNFL thickness in patients with AD compared to controls (shown in appendix 
L) was conducted in order to determine the sample size for this study. 
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Sample size for a (two-tailed) two-sample t-test comparison was calculated. Given the 
comparisons identified in the literature we conservatively assume an effect size of D=1, 
along with α=0.05 and power=0.9 and calculate a sample size of 23 participants per group 
(using G*Power version 3.1.9.2, as described in Faul, Erdfelder, Buchner, & Lang, 2009). 
Given the use of the non-parametric Mann-Whitney U test in Moschos et al., (2012), we 
inflate this sample size to 24 per group (based on the asymptotic relative efficiency of 3/π 
of the Mann-Whitney compared to the t-test, as reported in  Lehmann, 1975: 23/(3/π)≈24). 
Finally, we assume a drop-out/loss of information of 20% indicating a need to recruit a 
minimum of 30 people per group (30/0. 8≈30), giving a total recruitment of 90 people.  
In summary, this study aimed to recruit a minimum of 30 participants with DS, aged 18 
years and older with no upper age limit, and a minimum of 30 non-DS control participants 
inclusive of expected dropout rates. As an additional component, 30 typically developing 
participants older than the DS group were recruited as a comparison group. This older group 
were combined with the age-matched typically developing controls to create a larger age 
range for increased understanding of natural ageing changes in typically developing people 
in certain analyses. The recruitment need was re-assessed as data collection progressed, due 
to the number of failed scans in the DS group recruitment was increased to account for this 
in order that the study achieve acceptable power.  
 
2.6 Optical coherence tomography  
2.6.1 Equipment 
Camera model Spectralis Heidelberg Retinal Angiography + OCT (Spectralis OCT; S3600) 
was used for all retinal examinations in this study (see Figure 2.2). Heidelberg Eye Explorer 
version 1.9.10.0, Heidelberg Engineering, Spectralis Viewing Module version 6.3.4.0 
(Heyex) software was used to view and process the data. Images were automatically centred, 
averaged and segmented as part of this software. Segmentation was manually assessed for 
each participant and corrected where necessary by the researcher using the Heyex viewing 
module tools under the guidance of Dr Normando. From Heyex, retinal thickness values 
were extracted manually into statistical programming software IBM SPSS Statistics. 
During scanning the automatic retinal tracking (ART) mode was enabled in this camera 
which ensures that scans are acquired comprehensibly without excessive artefacts from eye 
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movement. In addition, this camera includes TruTrack eye tracking technology. TruTrack 
creates a reference image of the eye based on the location of the blood vessels and forces 
the scan to continue only when the eye was correctly aligned. This greatly reduces artefacts 
caused by movement in the data, but can increase the length of the scan. Pupil dilation was 
not required for participants in this study due to the high-resolution capabilities of the camera 
model used.  
 
Figure 2.2 Heidelberg Spectralis OCT machine used in this study. 
 
2.6.2 Operational procedure 
Optical coherence tomography is a medical imaging technique using light to capture 
micrometre-resolution images from within the biological tissue of the eye. This technology 
is based on interference between signals from the object under investigation and the 
reference signal (Podoleanu, 2012). OCT uses low-coherence interferometry to produce a 
two-dimensional image of optical scattering from the internal tissue (Huang et al., 1991). 
The scanning resolution of OCT is similar to that of a confocal microscope and is limited 
only by the coherence length of the light source. OCT resolution is superior to that of both 
MRI and ultrasound as it depends on light, rather than soundwaves or radio waves, which 
both have more interference. OCT can maintain a high-depth resolution even when the light 
opening is small, which is particularly beneficial in the in-vivo measurement of deep tissue.  
49 
 
Light is transmitted to the eye through the use of an interferometer, an investigative tool 
which merges two or more sources of light to create an inference pattern. The infrared light 
is transmitted through the pupil; this then penetrates through all the transparent layers of the 
retina. The light scatters and returns through the pupil, from which the detectors can analyse 
the interference of light returning from the layers compared to the pattern of light returning 
from a reference path, such as a mirror (see Figure 2.3). During OCT, the interferometry is 
able to record the optical path length of the photons received, enabling clear 3D images of 
samples by rejecting the background signal whilst collecting light received directly from the 
surfaces of interest. 
 
Figure 2.3 Diagram showing the working principle of OCT (image reproduced from 
Yolcu, Faruk Sahin, & Gundogan, 2013, page 24). 
 
In the medical community OCT is a well-established technique for obtaining images of the 
anterior segment of the eye and the retina, and is often used for assessing axonal integrity in 
MS (Dorr et al., 2011), macular degeneration (Keane et al., 2012) and more recently, 
glaucoma. Advantages of OCT technology include; safety, ease of administration and low 
cost. OCT has both high depth and transversal resolution, resulting in high speed acquisition 
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of images. Advances in technology have encouraged its development in a variety of 
applications, including research, but medical applications remain dominant.  
 
2.6.3 Considerations in the use of optical coherence tomography technology 
Several studies have examined the reproducibility and repeatability of OCT technology in 
reference to the assessment of RNFL measurements in normal healthy participants, as well 
as in patients with glaucoma, retinal diseases and hypertensive eyes. Overall, a very high 
intra-class correlation coefficient (ICC) has been identified by these studies, ranging 
between 0.9 and 0.99 indicating very high reliability between scan measurements (Carpineto 
et al., 2003; Kim, Yoo, Jeoung, & Park, 2015; Lee, Kim, Jo, & Kim, 2015; Leung et al., 
2008; Leung et al., 2009). Studies specifically undertaken to provide repeatability measures 
of the segmentation process of the retinal layers have also found very positive results. 
Çetinkaya, Duman, Duman, & Sabaner, (2017) conducted an inter-examiner study where 60 
healthy eyes were measured four times by two independent examiners, the repeatability and 
reproducibility measures for the segmentation of the RNFL and retinal layers were very high 
(ICC >.96 in all areas) and the study concluded that it was “virtually impossible” to 
distinguish between measurements taken by different examiners. In individuals with 
cognitive impairment, Loh et al., (2017) showed a high inter-visit reproducibility in the 
RNFL and inner retinal layer thicknesses of cognitively stable patients with AD and MCI 
over the course of one year.  
There are many artifacts which can affect the measurements of RNFL thickness, these are 
critically important to identify and resolve as misinterpretation of the OCT results can lead 
to misdiagnosis of diseases. There are several factors which can influence the thickness of 
the retina as reported by both OCT and histology. Individual differences in ocular features 
and diseases are discussed in this section, followed by a summary of some of the more 
common features and those which specifically affect the OCT measures.  
 
Individual differences 
The size of the optic disc has been found to influence retinal thickness, studies have shown 
that individuals with larger and more myopic eyes had greater mean RNFL thickness 
(Bundez et al., 2007; Savini, 2005). Histological studies in monkeys have also shown 
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increased numbers of axons in those with larger optic discs (Quigley, Coleman, & Dorman-
pease, 1990), although this has not been replicated in human samples (Varma, Skaf, & 
Barron, 1996). Aside from the increased number of axons creating a thicker RNFL, Bundez 
et al., (2007) also theorised that the increased thickness seen in OCT could be created by the 
fixed circular RNFL scan which may show an artificially thicker measure if the retinal axons 
are closer to, or at a different incident plane to, the scanning beam. Macular pigment, which 
plays a critical role in protecting the macular from harmful blue light, may also artificially 
increase retinal thickness. Liew et al., (2006) reported that optical density of the macular 
pigment has a significant positive relationship with the retinal thickness as measured by 
OCT (r= .30). Later studies have supported this, finding that specifically the foveal region 
of the macular shows increased thickness with high density of macular pigmentation (van 
ver Veen, Ostendorf, Hendrikse, & Berendschot, 2009). These studies were completed in 
healthy control participants, in people with DS, three case studies have reported 
pigmentation diseases in people with DS. In one study a 47 year old male with DS was 
diagnosed with bilateral congenital hamartomas of the retinal pigment epithelium, a rare 
anomaly which results in jet black lesions which cover the full retinal thickness of the 
macular areas (Alexander & Ramirez-Florez, 2008). The second and third case studies were 
of  DS individuals of a younger age, a 12 year old male and a nine year old female (Hayasaka 
& Hayasaka, 2004; Yamaguchi & Tamai, 1990). Both of these patients had bilateral 
congenital macular colobloma that included pigment clumps at the macular. Additional 
presence of other ophthalmic diseases was not reported, and these studies did not report on 
the patients’ retinal thickness. Presence of plaques containing Aβ in the retina is another 
feature which may increase retinal thickness, and which is particularly relevant to AD 
studies. Although Aβ plaques have been identified in both mouse and human retinas, there 
are no studies which have investigated the relationship between burden of retinal amyloid 
and retinal thickness measures. Studies which have correlated retinal thickness with cerebral 
Aβ have shown there to be decreased retinal thickness with increase of cerebral Aβ (Golzan 
et al., 2017). Some of the more commonly occurring artifacts in OCT are recognised below 
as well as attempts made to resolve these issues.  
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Age 
The age of the patient affects the retinal thickness observed. As previously discussed, there 
is a significant age-related attrition of the RNFL. Data which does not account for age, or 
which is subject to errors in the entering of birth dates can implicate the results and lead to 
erroneous interpretations. In this study age was an important factor and all attempts were 
made to account for and correctly enter this information.  
 
Signal strength 
A reduction of signal strength usually occurs from a media opacity and this can lead to a 
loss in retinal layer features and artifacts in layer segmentation processing. Most common 
causes of reduced signal strength include dry eye, corneal opacities, cataracts and vitrael 
opacities. Studies have shown positive relationships between signal strength and RNFL 
thickness in healthy patients, amounting to as much as a RNFL thickness decrease of 2µm 
per unit of signal strength decrease (Vizzeri, Bowd, Medeiros, Weinreb, & Zangwill, 2009). 
Opacities were controlled for in this study and those with severe cataracts were excluded.  
 
Signal quality 
The quality indexes of the OCT scans were assessed for inclusion purposes. This scale 
ranges from 0-40 and the threshold for acceptability is >15 (Huang et al., 2012). In this study 
the signal strength of all retained scans was deemed to be acceptable. Those with a quality 
index <15 were excluded from the study and data was not entered into any analyses.  
 
Improper alignment 
Incorrect alignment of the OCT images can lead to segmentation errors and artificial 
thickening or thinning of the retinal layers. This is majorly a problem during repeat scans 
and can introduce variability if the alignment is not precise. The SD-OCT TruTrack 
technology has worked to vastly reduce this issue. Alignment errors can also occur during 
the automatic segmentation procedure however, therefore it is necessary to check and 
manually re-centre the scans if necessary. De-centring of the image can cause truncation, 
which reduces the thickness reported by the OCT. This problem is emphasised in patients 
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with disc edema, tilted optic nerves or significant cupping as the RNFL is difficult to capture 
on a single B scan due to varying heights, however it is still a relevant factor for all patient 
and healthy groups (Chen & Kardon, 2016).  
Segmentation errors 
Heyex viewing module software provides automatic segmentation of the retinal layers and 
automatically centralises the scan to either the optic nerve head (ONH) or the fovea, 
depending on the particular scan. Segmentation errors can be influenced by poor signal 
strength and various ocular diseases that were controlled for in this study (Ho et al., 2009). 
Prior to analysis all scan segmentations were checked and manually adjusted where 
necessary after consultation with the lead ophthalmologist. 
 
Axial length 
Ambiguous findings are sometimes presented during OCT scans due to the shape of an 
individual’s eyes. Shorter eyes typically present with thicker RNFL values due to camera 
magnification, whilst longer eyes can cause artificially thinner RNFL measures (Kaliner, 
Cohen, Miron, Kogan, & Blumenthal, 2007).  
 
Saccades 
Excessive eye movement or blinking during the scan can cause incorrect alignment errors 
leading to erroneous measures which can be misinterpreted as progressive thinning. The 
OCT camera model used in this study has a built-in eye tracking function, TruTrack, which 
greatly compensates for eye movement by relying on blood vessel registration or iris 
tracking. The use of the eye tracker significantly improves the reproducibility of RNFL 
measurements (Langenegger, Funk, & Töteberg-Harms, 2011). 
 
Heyex normative database 
The Heyex viewing module software includes a normative database that is age-matched to 
the individual undergoing examination. The normative database consists of 284 healthy 
individuals with an age range of 18-84 years (mean= 46.5 years). Ethnicities include; 43% 
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Caucasian, 24% Asian, 18% African American, 12% Hispanic, 1% Indian, and 6% mixed 
ethnicity. The raw data for the normative group is not commercially available; therefore it 
was necessary to have an additional age-matched control group for making group 
comparisons between people with and without DS.  
The colour grading system used in the Heyex viewing module is representative of the 
normative database. Retinal thicknesses which fall within the green area are within the 5th – 
95th percentile for age, within the yellow region are the 1st -5th percentiles and the red area 
are those below the 1st percentile (see Figure 2.4). 
 
Figure 2.4 Example of the normative database line (shown in green) against the 
individual participant data (black).  
 
2.7 Retinal scans 
Differences in retinal thicknesses between people with DS, age-matched controls and an 
older comparison group were explored in this study. Three areas of the retina were evaluated, 
the RNFL, macular, and the retinal layers.  
 
2.7.1 Retinal scanning procedure 
All retinal examinations for all participants were completed using the Spectralis OCT and 
were conducted by Dr Eduardo Normando (University College London and Imperial 
College Healthcare NHS trust). Informed consent was gained before scanning commenced 
and the procedure was fully explained to the participant. Retinal scans were conducted at 
one of three locations; 
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 Douglas House, Department of Psychiatry, Cambridge University 
 ICORG Unit, Western Eye Hospital, London 
 Down’s Syndrome Association Headquarters, Langdon Down Centre, 
Middlesex 
The OCT scanner is set up on an adjustable table. After the participant is seated the OCT 
table is moved towards them until they can comfortably reach the chin rest. The chin rest is 
aligned dependent on eye level and the forehead rest adjusted to suit the participant. The 
camera is manually positioned in front of the selected eye and the participant is asked to 
look inside the camera lens at a blue light, if they are unable to see the light, an external 
fixation point (an adjustable arm with a light) was used to attract the participants gaze. Once 
the participant had fixated on the light they were asked to keep looking straight ahead and 
to try not to move their eyes. Participants were reminded that they could blink, but to look 
straight ahead at the light afterwards, and to ignore any red lights they may see within the 
camera.  
Two scans were completed for each eye, four scans in total. If necessary, scans were repeated 
an additional one time each if the signal quality was low, highest quality scans were retained. 
Scans were not completed sequentially across participants. Breaks were given after each 
individual scan and additional breaks during the scan if necessary. All scans were completed 
in one visit, if a participant was unable to successfully complete a scan during the testing 
visit, that scan was considered lost. Scan procedure lasted approximately 10-20 minutes for 
the DS participants. Duration of the scans were dependent on the amount of head movement, 
distractions, the number of breaks the participant needed to take and their individual ability 
to keep their gaze fixated. Average scan time for the control group was less than five 
minutes. After the scans were finished the participant was thanked and allowed to leave, 
there were no after effects of the scan procedure.   
 
2.7.2 Scan sequences 
Retinal areas of interest were derived from literature reviews of studies in AD and of the 
few studies examining retinal thickness in children with DS. Two scan types were invoked 
in this study, peripapillary retina (referred to as the RNFL scan) and retina (referred to as 
the posterior pole and macular scans). Thicknesses of these three areas were evaluated. 
Figure 2.5 shows a digital retinal photograph of the eye and how these three areas relate 
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within the eye. Macular and posterior pole scans are acquired at the same time using a box 
scan, from this, data is automatically generated for both regions of the retina. 
 
Figure 2.5 Digital photograph of the retina. The RNFL (red circle), inner and outer 
macular (green circles) and posterior pole area (blue box) assessed in this 
study have been highlighted (not to scale). Original figure reproduced from 
Frost, Martins, & Kanagasingam, (2010), page 7. 
 
 Retinal nerve fibre layer scan 
The RNFL scan derived the thickness of the RNFL retinal layer in a 12 degree (3.2mm) 
circumference surrounding the ONH (see Figure 2.6(a)). This scan was centred on the ONH 
with 30 degree angle. Glaucoma application and high speed resolution and automatic 
tracking mode (ART) were enabled. ART enables multiple frame scanning of the same 
location, which are averaged for enhanced noise reduction. Additional data gathered from 
this scan included scan quality and eye length. OCT provides detailed topography of the 
retinal layer identified during the scan. Manual adjustments to the line can be made in case 
of automation malfunctions.  
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Figure 2.6  Images showing the RNFL images acquired. Figure (a) shows the ONH with 
the RNFL image line surrounding it. Figure (b) demonstrates the sectioning 
of the RNFL line with corresponding quadrants; superior (S), temporal (T), 
inferior (I) and nasal (N). Figure (c) shows the circle stretched into a line and 
the thickness of the RNFL represented between the red and blue lines.  
 
Data for the RNFL scan is produced and automated averages of each section are given (see 
Figure 2.7). These measures are compared to the normative database (section 2.6.3) and 
stratified dependent on thickness classification in comparison to others of their age. 
Individual values are given in black and the expected value based on the normative database 
in green. Areas are shown as green (inside normal limits), yellow (borderline), or red 
(outside of normal limits). It is important to note that “borderline” and “outside of normal 
limits” refers to thinner values than expected, rather than thicker values.  
Heyex automates the average thickness for the global (360°) RNFL and for the six areas 
within. Of these six areas, the temporal superior and nasal superior values were averaged to 
N T 
S 
I 
(c) 
(b) (a) 
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create a single thickness measure for the “superior quadrant” and the temporal inferior and 
nasal inferior values averaged to create the “inferior quadrant”, as is typical in previous 
literature. The averages of these quadrants were manually computed. All output values are 
measured in micrometres (µm).  
In addition to the classification chart, a RNFL thickness profile graph (Figure 2.8) is 
automatically computed. This graph shows the topography of the entire RNFL, rather than 
the averages of each sector. From this graph, mapping of blood vessels and other retinal 
features can be accomplished as the area shown in Figure 2.6(b) is the retinal photograph of 
the same area and is positioned directly above the profile graph on the viewing screen with 
a connecting reference line.  
 
Figure 2.7 Peripapillary RNFL thickness classification chart 
 
 
Figure 2.8 RNFL thickness profile graph. Individual participants’ RNFL measure is 
shown on the black line and compared to the averaged normative data of a 
typically developing cohort of the same age (green line).  
 
{Inferior quadrant} 
{Superior quadrant} 
Green:  Within normal range 
Yellow:  Borderline  
Red:   Outside of normal limits 
 
Key 
G Global (360° RNFL thickness) 
T Temporal quadrant 
TS Temporal Superior 
NS  Nasal Superior 
N Nasal quadrant 
NI  Nasal Inferior 
TI  Temporal Inferior 
 
59 
 
 Macular scan 
The area covered in the retinal box scan comprises the macular and the posterior pole, this 
scan is centred on the fovea. Throughout this thesis the macular and posterior pole data will 
be referred to separately. The retina scan uses high speed resolution with retina application 
and a scan angle of 30 degrees. ART mode was enabled and eye length was recorded. Scan 
quality is not automatically generated, however each of the 61 scan lines that make up the 
box scan have an individual quality index number.  
              
Figure 2.9  Examples of images produced for macular and retinal layer data. (a) box scan 
area centred on the fovea, (b) macular region within the box scan and, (c) 
segmentation of retinal layers. 
The macular region is categorised into three areas; the fovea (1mm ring), the inner macular 
(3mm ring) and the outer macular (6mm ring; see Figure 2.10). Each of the inner and outer 
macular rings are subdivided into quadrants (superior, inferior, nasal and temporal; see 
Figure 2.11). In this study the fovea, inner and outer macular averages are evaluated first; 
additional analyses will consider the quadrants of the inner and outer rings if appropriate. 
As with the RNFL scan, macular data is averaged between the two eyes to provide one value 
composite for each region for each participant.  
(a) (b) (c) 
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Figure 2.10  Automated macular thickness colour map. Warmer colours represent thicker 
areas and cooler colours reflect thinner areas. The three circles represent 
macular areas; smallest (1mm) ring is the fovea area thickness, inner macular 
area is within the second ring (3mm) and the largest ring is the outer boundary 
of the outer macular area (6mm). 
 
 
 
 
Figure 2.11  Example of macular scan output and quadrant division. Thickness measures 
for each region are shown in black and volume in red. Quadrants include the 
superior (S), temporal (T), inferior (I) and nasal (N).  
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 Posterior pole scan 
The posterior pole scan comprises the area surrounding the macular up to the optic disc. This 
scan is also centred on the fovea but encompasses a larger area than the macular (30° x 25°), 
as shown in Figure 2.12. Each retinal layer has a colour grading system detailing thinner and 
thicker retina. As with the macular, warmer colours represent thicker retina and thinner 
retinal measures are in cooler colours. Each box within the 8x8 grid shows the mean 
thickness value for that area.  
 
Figure 2.12 Posterior pole retinal scan. This images shows the average thickness of all 
retinal layers. The colour scale shows thicker retina in warmer colours and 
thinner areas in cooler colours. 
After acquisition, all data was quality screened and pre-processed, including manually 
centred and adjusted where necessary. Segmentation processing was performed on all scans 
to delineate the retinal layers (see Figure 2.13). Further exploration of the images was 
completed to confirm correct segmentation and adjusted if necessary. The layers of the retina 
are divided into those which make up the inner layers and those which make up the outer 
layers. Inner layers consist of the nerve fibre layer (NFL) to the INL and outer layers consist 
of the outer plexiform layer (OPL) to the RPE.  
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Figure 2.13 Segmentation of the retinal layers within the posterior pole scan.  
Presentation of retinal data varies significantly within the published literature. Some studies 
have chosen to present the data from eye scans independently, reporting both a left and right 
eye, randomly chosen either the left or the right eye, pre-selected either the left or right eye 
only, averaged data from both eyes and presented one set of values. This last methodology 
has been chosen for this study when presenting the data of the RNFL and macular regions. 
Before deciding on this method paired comparisons were conducted for all retinal regions 
which showed that overall there were no significant differences between the measures of the 
left and right eyes. Data for these comparison tests can be seen in appendix M. 
For the posterior pole data, each of the seven retinal layers, plus the average of the inner 
layers, outer layers and total layers for both eyes, amounts to a total of 1280 data points per 
participant that would need to be manually extracted and averaged. Based on statistical and 
ophthalmological expert guidance it was decided to present the data of the eye with the 
highest scan quality image. Quality index in this scan is reported for each scan line, a total 
of 61 for one eye. An average of these 61 quality indexes for each eye was calculated to find 
the overall quality index and compared to the overall quality calculation for the other eye. 
The eye with the best overall scan quality was retained and entered into analyses. Full details 
of this procedure can be seen in appendix N.  
 
 
Retinal layers key 
Nerve fibre layer (NFL) 
Ganglion cell layer (GCL) 
Inner plexiform layer (IPL) 
Inner nuclear layer (INL) 
Outer plexiform layer (OPL) 
Outer nuclear layer (ONL) 
Retinal pigment epithelium 
(RPE) 
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2.8 Neuropsychological evaluation 
Associations between IQ, cognitive performance and dementia status were assessed in this 
study. A neuropsychological evaluation for the participants with DS was undertaken, 
comprising an IQ test (KBIT-2; Kaufman Brief Intelligence Test, Kaufman & Kaufman, 
2004), and two cognitive function batteries; the Cambridge Cognition Examination 
(CAMCOG) and an executive function  battery. In addition, a dementia screening interview, 
the Cambridge Examination for Mental Disorders of Older People with Down's Syndrome 
and Others with Intellectual Disabilities (CAMDEX; Roth et al., 2014), was conducted with 
the DS participants’ main carer.  
For the control and comparison group participants a dementia screening test, Telephone 
Interview for Cognitive Status (TICS; Brandt, Spencer, & Folstein, 1988) was administered, 
to rule out any possibility of dementia. Neuropsychological measures and the informant 
dementia interview can be found in appendices P-R. 
 
2.8.1 Procedure 
Neuropsychological tests were conducted to provide a comprehensive cognitive assessment 
for the DS participants. These tests were conducted either at the testing site or the 
participants’ homes. Testing procedure ranged between 1-2 hours and was completed over 
one or two visits depending on the participant’s preference. Assessments completed in this 
study are shown in Table 2.1. 
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Assessments completed Estimated time (mins) 
Participants with DS  
CAMCOG (Ball et al., 2004; Hon, Huppert, Holland, & 
Watson, 1999) 
30 
Selected tests from the Cambridge Executive Functioning 
Assessment (Ball et al., 2008) 
30 
KBIT-2 (Kaufman & Kaufman, 2004) 30 
Assessments completed by parent/carer  
CAMDEX informant interview 45 
Control and comparison group participants 
Telephone Interview for Cognitive Status (Brandt et al., 
1988) 
5 
Table 2.1  Neuropsychological assessments completed. 
 
2.8.2 Neuropsychological tests 
 CAMCOG 
The CAMCOG (Ball et al., 2004) was designed to assess cognitive impairment 
characteristics of the general elderly population with reference to dementia. Minor 
modifications have been made to the CAMCOG in order to increase its suitability for people 
with DS. CAMCOG for use in people with DS incorporates the MMSE and can be used to 
determine a global estimate of ability, Spearman’s rank correlation between test scores of 
both measures showed a correlation of 0.96 after exclusion of identical items (Hon et al., 
1999). 
The CAMCOG is divided into the following areas of cognitive function: orientation, 
language, memory, attention and calculation, praxis, abstract thinking and perception. Some 
of these categories are then further divided, i.e.; language is split into comprehension (motor 
response, verbal response and reading) and expression (naming, fluency, definitions, 
repetition and writing) and memory is divided into remote memory, recent memory, 
incidental learning and intentional learning. The subscale scores for the seven categories are 
summed for an overall CAMCOG score with a maximum of 109 points.  
Examples of questions from the CAMCOG include; (1) “What is the name of the princess 
who died in a car crash in Paris?” if no response is given the examiner may follow with a 
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prompt, i.e. “She was married to Prince Charles”, (2) “Please nod your head”, (3) “Copy this 
shape in the space below”. For the full CAMCOG questionnaire and score sheet see 
appendix A.  
 
 Kaufman Brief Intelligence Test 2 
The Kaufman Brief Intelligence Test, second edition (KBIT-2; Kaufman & Kaufman, 2004) 
is a test for approximate IQ consisting of a verbal and a non-verbal component. This test is 
copyright protected and therefore a full version cannot be made available in the appendices. 
For verbal knowledge, a single word is delivered by the examiner to the participant, with a 
choice of six images from which the participant selects the image which best represents the 
word given. In each case there is only one correct answer and no further explanation or 
assistance can be given by the examiner. The second part of the verbal knowledge score is 
a “riddles” test. Here the examiner describes an object or concept and the participant has to 
give the name of what is being described. For example, the examiner would say “What hops, 
eats carrots and has long ears?” and the participant could answer with one of the correct 
answers “rabbit” or “bunny” or an incorrect answer. Examples of correct and incorrect 
answers are given for each riddle; in this case an example incorrect answer would be 
“kangaroo”. Each section of the test has a floor and ceiling score and the test is stopped 
when four consecutive incorrect answers are given. In between the two verbal components, 
the non-verbal component is assessed using matrices, such as choosing which pictures go 
together, which picture is the odd one out, and which picture fits. There are training items 
during this test to prepare participants for the next set of questions. For example, an incorrect 
response in Figure 2.14 would result in the examiner saying, “The rabbit’s ears look like this 
(point to rabbit’s ears) and the elephant’s ears look like this (point to elephant’s ears). So 
these ears go with the elephant. Let’s do it again”.  
Non-standardised scores from the KBIT-2 were analysed in this study. Standardised scores 
are calculated using the individuals age, in people with DS this is not appropriate as mental 
age in DS is often considerably lower than actual age and would dramatically increase the 
floor effect of the test.  
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Figure 2.14 Example of non-verbal matrices question in KBIT-2 
 
 Executive function battery 
The executive function battery for people with ID (Ball, Holland, Treppner, Watson, & 
Huppert, 2008) uses a variety of short memory tests including the following tasks as detailed 
below. A maximum score of 56 is achievable on the executive function battery, for the full 
scoring sheet and procedures see appendix Q.  
Cats and dogs task  
The cats and dogs task (Willner, Bailey, Parry, & Dymond, 2010) measures response 
inhibition and working memory. Initially participants are timed on naming cats and dogs 
correctly, then training is given to name dogs as cats and cats as dogs. Responses are again 
timed and the difference between first and second times recorded.  
Spatial reversal task 
This task measures spatial memory and response inhibition. At the start of the task two coins 
are placed under two boxes, and the participant is asked to guess where the coin is. At this 
stage the participant is always correct and whichever box the participant chooses the other 
coin in removed. The examiner then places a screen in front of the box and pretends to, but 
does not, move the coin. The participant needs to correctly find the coin, in the same place, 
four times before the coin is moved to the other box. At which point, they are scored on 
consecutively choosing the correct (same) box four times.  
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Tower of London Task 
The Tower of London task (Figure 2.15; Krikorian, Bartok, & Gay, 1994) measures planning 
ability and working memory using a peg board and three coloured beads. The aim is to move 
the beads to the correct position in the fewest number of moves, whilst remembering to only 
move one bead at a time. Participants are given three attempts to complete the task and 
points awarded are reduced at each try.  
 
Figure 2.15 Example of the Tower of London task  
 
Weigl sorting task  
This task measures conceptual learning. The participant is presented with nine shapes, three 
circles, three squares and three triangles. One of each shape is coloured red, blue and yellow. 
Participants are asked to sort the items; correct sorts are by colour or shape. The items are 
then mixed up and the participant is asked to sort them a different way, to score maximum 
points the participant must sort the shapes the other way first time.  
 
Scrambled boxes task  
This task measures working memory and response inhibition. To complete this task the 
participant must correctly find three coins within three, and then six, boxes. Each box has a 
different shape on the top and the participant must attempt not to open boxes they have 
already checked and attempt to remember which boxes the coins have been placed in. On 
the first trial boxes stay in the same position, on the second trial they are moved/scrambled 
by the examiner.  
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2.8.3 Diagnosis of dementia  
 CAMDEX 
Dementia status was assessed in people with DS using the Cambridge Examination for 
Mental Disorder of Older People with Down’s Syndrome informant interview (CAMDEX; 
Ball et al., 2004; Holland et al., 1998; Roth et al., 2014; see appendix R). Questions are 
designed to give a detailed overview of a person’s memory, general mental and intellectual 
functioning, general performance, judgement, specific higher cortical functions, personality, 
presence of specific symptoms and relevant previous medical history. The CAMDEX has 
been slightly modified to better address the concerns of individuals with an ID, taking into 
account the pre-existing impairment of cognitive and functional abilities. Most questions 
have a follow up query of “Is this a change?” or “Is this a deterioration?” and then “Slight 
or great deterioration?” to address this. The CAMDEX informant interview assesses a wide 
range of functions including; education, employment, basic skills (speech, understanding, 
reading, writing and basic arithmetic), independent living skills and any deterioration seen 
in any of these categories.  
 
 Telephone Interview for Cognitive Status 
For control participants dementia status was assessed using the TICS (Brandt, Spencer, & 
Folstein, 1988). This test is copyright protected and therefore a full version cannot be made 
available in the appendices. The TICS was developed as a telephone alternative to the 
MMSE (Folstein et al., 1975), which is one of the most widely used screening instruments 
for the detection of cognitive impairment (Nelson, Fogel, & Faust, 1986). The TICS aimed 
to solve the problem of participant dropout rate due to inability or reluctance to return for 
in-person assessment. This would also increase cost-effectiveness for large-scale studies. 
TICS correlates highly with the MMSE r= 0.86 (p< .001) and has high test-retest reliability, 
and high sensitivity and specificity for cognitive impairment in a clinic sample of AD 
patients (Järvenpää, Rinne, & Räihä, 2002).   
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2.9 Brain imaging 
In the final results chapter (chapter five) exploratory analyses are conducted to examine the 
relationship between retinal and cortical thickness measures, and retinal-cortical thickness 
relationship differences based on the presence of fibrillar Aβ binding in the brain. These 
analyses were undertaken on a reduced sample of the participants with DS included in the 
retinal imaging study (n=18). Cortical thickness was assessed using MRI and brain Aβ 
binding was assessed using Pittsburgh compound [11C] (PIB) and PET imaging 
approximately two years prior to the retinal imaging study. Cortical thicknesses and binding 
data were collected and analysed by collaborators with the project. All retinal thickness data 
comparisons with imaging data were completed as part of this PhD. 
 
2.9.1 Procedure 
 MRI neuroimaging 
Adults with DS underwent a 45 minute structural MRI scan on a 3-Tesla Siemens 
MAGNETOM Verio scanner (Siemens AG, Germany). Acquired MRI data were used for 
co-registration to the PET data and to detect regions of interest. The imaging protocol 
included whole-brain, T2-weighted, half-fourier acquisition, single-shot turbo spin echo 
sequence to assess for vascular pathology and incidental lesions. Full methodology of the 
MRI imaging acquisition can be seen in Annus et al., (2017).  
Average measures from the cortical regions of interest were gathered from the MRI imaging 
data. Cortical surface analysis was performed in FreeSurfer (version 5.3; available from 
http://surfer.nmr.mgh.harvard.edu/). FreeSurfer calculates cortical thickness using an 
estimate of the width of the cortical grey matter (the procedure used for cortical thickness 
analysis is described in; Dale, Fischl, & Sereno, 1999 and Fischl & Dale, 2000). FreeSurfer 
automates hemisphere-specific data of the cortical surface together with individual 
participant atlases to enable anatomical localisation. Cortical thickness represents the closest 
distance between white matter surface (grey and white matter boundary) and pial surface 
(grey matter and cerebrospinal fluid boundary) at each vertex within the surface model (see 
Figure 2.16). Cortical maps are not restricted to the volumetric MRI voxel resolution and 
can be modified to create an individual, but comparable, surface coordinate system.  
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Figure 2.16 Schematic showing cortical thickness calculations. Measurements are taken 
from between the pial surface (red line) and the white matter surface (yellow 
line). This figure has been reconstructed from FreeSurfer tutorial materials 
(available at https://surfer.nmr.mgh.harvard.edu/fswiki/Tutorials).  
 
 PET imaging  
Participants with DS underwent a 90 minute dynamic PET scan with [11C]-PIB (produced 
at the WBIC radiochemistry laboratory with high radiochemical purity (>95%) and specific 
activity (>150 GBq/μmol) under Good Manufacturing Practices conditions). Full details on 
data acquisition have been published previously (Annus et al., 2016). Scan data was acquired 
in 3D mode on a General Electrical Medical Systems advanced PET scanner. Binding 
potential maps were created using the simplified reference tissue model (Gunn, 
Lammertsma, Hume, & Cunningham, 1997). Grey matter tissue from the cerebellum was 
used as reference tissue. The cerebellum was chosen as the reference tissue as per the pilot 
study (Landt et al., 2011), and as the cerebellum is relatively free of fibrillar Aβ (Lalowski 
et al., 1996; Mann, Jones, Prinja, & Purkiss, 1990). Statistical parametric mapping, version 
8 (www.fil.ion.ucl.ac.uk/spm/software/) was used to co-register the mean realigned image 
to the MRI and manually draw regions of interest. [11C]–PIB PET was used to investigate 
the load and distribution of fibrillar Aβ in people with DS and to assign adults with DS to 
Aβ positive and negative groups. All brain imaging data was collected by radiographers at 
the WBIC. Scans were examined by a neurologist at the WBIC and analysed by WBIC 
physicists together with research assistants from the CIDDRG. No pathology outside of 
AD-related atrophy was reported.  
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Mean cortical Aβ load was calculated for each participant by taking a mathematical average 
of the non-displaceable binding potential (BPND) data across all cortical regions of interest. 
Reconstruction and the kinetic modelling of the raw PIB data were conducted by Dr Hong 
and Dr Fryer at the WBIC, University of Cambridge. A positive region was defined as 
having binding potential two standard deviations above that of the PIB negative group. This 
study also included 10 age-matched control participants to ensure that measures deemed PIB 
negative in the DS population would also be considered negative in the general population.  
 
Figure 2.17 Scatterplot representation of the striatal binding potential for all participants 
included in the DiDS neuroimaging study. Classification of the groups were 
as either positive or negative. Figure reproduced from Annus et al., (2016), 
page 541.  
 
2.10 Statistical analyses 
Statistical analysis was performed using IBM SPSS statistics 22. Analysis was completed in 
a top-down method first examining the global value of each measure (global RNFL, fovea, 
inner and outer macular and inner and outer retinal layers) and then by investigating 
individual layers and specific quadrants of those areas with significant differences or of 
particular interest.  
All data was tested for normal distribution and outliers using Shapiro-Wilk tests and 
visualisation of the data, significant values (p< .05) were deemed not normally distributed. 
Outlier sensitivity analyses (repetition of tests with and without outliers) were conducted 
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where necessary. Independent and paired student t-tests, and ANOVAs were used to 
compare data and Pearson’s bivariate correlations were used to explore associations between 
data. Non-parametric tests (i.e. Mann Whitney U tests and Spearman’s correlations) were 
used when necessary and when tests of normality were not met. Further analyses to compare 
correlations between groups were conducted using Fisher’s exact correlation tests. Effect 
sizes were calculated using the below equation as reported in (Rosnow & Rosenthal, 2005).  
r = √
𝑡2
𝑡2+𝑑𝑓
 
 
There were large multiple comparison effects in this study. These were controlled for by 
applying the Bonferroni correction to the p-values as indicated in previous published 
literature. Significant p-values to the level of the Bonferroni correction are indicated 
throughout this chapter with an asterisk. Each of the three retinal regions had a different 
number of related retinal areas, therefore three different significance levels were used in this 
study (see Table 2.2). The Bonferroni correction was calculated by dividing the uncorrected 
p-value (0.05) by the number of related regions within each retinal region. Adjusted p-values 
were applied throughout all data analyses of all results chapters.  
 
Region Areas within each region Total 
Uncorrected 
p-value 
Adjusted 
p-value 
RNFL 
Global, temporal, inferior, nasal and 
superior  5 0.05 0.010 
Macular 
Fovea, quadrants of the inner ring and 
quadrants of the outer ring 8 0.05 0.005 
Posterior 
pole 
NFL, GCL, IPL, INL, OPL, ONL, 
RPE 7 0.05 0.007 
Table 2.2 Table showing the adjusted p-values for different retinal areas based on the 
Bonferroni multiple comparisons correction.
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Chapter Three: 
Retinal thickness in adults with Down’s syndrome in 
comparison to typically developing adults 
3.1 Chapter introduction 
In this results chapter, retinal thickness in adults with Down’s syndrome (DS) is considered 
in comparison to retinal thickness of age-matched controls and older controls, as well as in 
relation to advancing age. Retinal thickness was measured using optical coherence 
tomography (OCT) scanning, regions of interest included the peripapillary retinal nerve 
fibre layer (RNFL), the macular, and the retinal layers of the posterior pole. Previous 
research in typically developing adults has shown evidence of age-related degeneration in 
the retina, specifically resulting in thinner RNFL, and is considered part of normal ageing. 
In patients with AD and MCI the retina shows further thinning compared to age-matched 
controls.  
 
3.2 Background 
The retina is an extension of the central nervous system (CNS) and shares its embryological 
origin with the brain, as well as many of its anatomical and physiological features (Ikram et 
al., 2012). As the brain is structurally different in people with DS compared to typically 
developing people, for example smaller overall brain volume and larger subcortical grey 
matter volume (Pinter et al., 2001), it is possible that there may also be structural differences 
within the retina. Previous research has recognised the potential of the retina as a valuable 
site for visualising changes related to the onset of AD. Despite this, very few research studies 
have considered retinal structure or thickness in people with DS, and none as part of 
investigations into dementia.  
Retinal thinning is considered to be part of normal ageing (Bundez et al., 2007; 
Poinoosawmy, Fontana, Wu, Fitzke, & Hitchings, 1997). Thinning rates of -0.16µm 
and -.38µm have been reported in the typically developing population between the ages of 
five and 90 years, with higher rates of decline seen after the age of 50 years (Parikh et al., 
2007; Poinoosawmy et al., 1997). Within the RNFL, the superior and temporal quadrants 
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show the most significant changes (Poinoosawmy et al., 1997; Varma, Skaf, & Barron, 
1996), and the inferior quadrant in the most resistant to thinning (Parikh et al., 2007). Normal 
age-related thinning of the macular has also been reported, predominantly findings have 
shown the inner macular to be more affected, with an average decrease of -0.18µm per year, 
in comparison to the outer macular, with an average decline of -0.03µm per year (Garcia-
Martin et al., 2016; Iseri et al., 2006). However some studies have found no significant age-
related thinning of the macular (Guedes et al., 2003).  
Retinal thinning is also established in people with MCI and AD (Garcia-Martin et al., 2014; 
Kesler et al., 2011; Parisi et al., 2001; Polo et al., 2017), a literature review of this research 
is presented in section 1.5. The RNFL is the most commonly reported retinal area with 
significantly thinner values seen in the global RNFL and in the quadrants (Berisha et al., 
2007; Gunes et al., 2015). The superior quadrant is the most susceptible to thinning in MCI 
and AD patients (Eraslan et al., 2015), and unlike in normal ageing, the inferior quadrant is 
more affected in AD (Cunha et al., 2016) and the temporal quadrant shows the least amount 
of change (Iseri et al., 2006). Although assessed in fewer studies, the macular also shows 
significant thinning in AD and MCI patient groups (Cunha et al., 2016; Moschos et al., 
2012). Controversially, one study has shown increased macular thickness specific to MCI 
patients (Ascaso et al., 2014).  
People with DS have a very high prevalence of developing early-onset AD (see section 1.3; 
Coppus et al., 2006; Holland, Hon, Huppert, Stevens, & Watson, 1998; Visser, Aldenkamp, 
Van Huffelen, & Kuilman, 1997), with almost 100% showing the neuropathological features 
by the age of 50 years (Head et al., 2007; Mann & Esiri, 1989; Wisniewski et al., 1984). It 
can be argued that the pathological features of AD are an inevitable part of ageing in people 
with DS. Studies which have looked at the DS retina using OCT include five studies which 
are covered in more detail in section 1.2.5. Two of these are case studies investigating 
specific ocular diseases in individuals, another two are OCT examinations of DS children 
and the final study investigates three participants with DS including 2 adults. This final study 
found thicker paramacular, significantly thicker fovea region and inner nuclear layer (INL) 
when comparing to non-DS controls (Laguna et al., 2013). This study also found that thicker 
inner layers of the retina were reported in trisomic TsDyrk1a+++ mice, removal of the third 
Dryk1a gene decreased the thickness of the retina to normal values. Dyrk1a has an inhibitory 
effect of cell death and apoptosis during development (Laguna et al., 2008) which may 
account for altered cellularity. The two studies investigating the retina in children with DS 
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both found a thicker fovea in children with DS when compared to controls (O’Brien et al., 
2015; Weiss et al., 2016), in addition O’Brien (2015) reported thicker areas in the outer 
retinal layers and macular. Weiss et al. (2016) reported that retinal structure was not 
significantly different in children with DS. Histological data has shown that general 
organisation of the retina is the same between DS and control groups (Laguna et al., 2013), 
although most studies in this area are limited to case studies of individuals with particular 
ocular diseases, and others have not commented on retinal structure (Ginsberg, Bofinger, & 
Roush, 1977; Sergovich, Madronich, Barr, Carr, & Langdon, 1963).  
 
3.3 Aims 
The overarching aim of this project is to determine whether the retina has the potential to 
provide an early biomarker site for changes relating to AD in people with DS. This study is 
the first known to provide cross-sectional analysis of retinal thickness using OCT in adults 
with DS. The particular aims of the study reported in this chapter were to: 
 Assess the acceptability and feasibility of OCT as an imaging technique in adults 
with DS. 
 Compare the thickness of the RNFL, macular and individual retinal layers in people 
with DS to an age-matched typically developing control group and an older typically 
developing comparison group.  
 Evaluate age-related changes in retinal thickness in the DS group and compare this 
to age-related changes in the typically developing group. 
 
3.4 Hypotheses 
 Retinal measures will be thinner in the DS group compared to the age-matched 
control group and will be more similar to the older age comparison group.  
 Age-related retinal thinning will be exacerbated in people with DS. 
 Superior and inferior RNFL quadrants will show particular thinning effects in the 
DS group. 
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3.5 Methodology 
Full details of the study population, OCT materials, scan procedure and data presentation 
can be found in Chapter Two, sections 2.5, 2.6 and 2.7.  
 
3.5.1 Study design 
This study was a cross-sectional design comparing retinal thicknesses of adults with DS over 
the age of 30 years to an age-matched control group and older-age comparison group. All 
participants with DS had the characteristic phenotype of DS. Trisomy-21 was confirmed 
from medical history or physical characteristics. All participants in this study were 
considered to have capacity to consent to research and informed consent was gained from 
all participants.  
Associations between age and retinal thickness were investigated in the DS and control 
groups. Additional investigations in the DS group were conducted based on suggestions 
from previous research that those over the age of 40 years exhibit abnormal Aβ binding in 
the brain (Annus et al., 2016). Analyses were conducted between groups of DS individuals 
under 40 years, and over 40 years.  
 
3.5.2 Retinal scan procedure 
Full details of the equipment and procedure of the retinal scans are presented in section 2.6. 
All retinal examinations were completed on the Spectralis Heidelberg Retinal Angiography 
+ OCT (Spectralis OCT; S3600). Retinal examinations for all participants were conducted 
by Dr Eduardo Normando at one of three locations; 
 Douglas House, Department of Psychiatry, Cambridge University 
 ICORG Unit, Western Eye Hospital, London 
 Down’s Syndrome Association Headquarters, Langdon Down Centre, 
Middlesex 
All scans were completed in one visit and scan procedure lasted approximately 10-20 
minutes for the DS participants. Average scan time for the control group was less than five 
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minutes. After the scans were finished the participant was thanked and allowed to leave, 
there were no after effects of the scan procedure. 
Data analysis was undertaken using IBM SPSS Statistics software and Heidelberg Eye 
Explorer version 1.9.10.0, Heidelberg Engineering, Spectralis Viewing Module version 
6.3.4.0 (Heyex). OCT examinations completed in this study included a RNFL scan, and a 
macular and posterior pole scan. Each of these retinal regions will be considered 
independently in the analysis of this chapter. The RNFL is divided into five sections, 
including the four quadrants, superior, inferior, nasal and temporal, and the global RNFL 
thickness. The RNFL and macular data are presented as an average of the values from both 
eyes, whilst the posterior pole data of the eye with the highest quality index scan is presented. 
Macular and posterior pole scans are centred on the fovea. The macular scan provided 
thickness data of the fovea, and the inner and outer macular area. The inner and outer 
macular are sub-divided into quadrants as with the RNFL scan, analysis of the macular 
quadrants were completed if there were significant results in the overall average of the 
macular. The posterior pole thickness data included the macular areas but also a wider area, 
for this data, the retina was segmented into inner and outer layers, which were analysed 
along with thickness data of the whole retina. In cases where there were significant results 
within the averaged layers, these were further divided into individual layers. Inner layers 
consist of the nerve fibre layer (NFL), ganglion cell layer (GCL), inner plexiform layer (IPL) 
and inner nuclear layer (INL). Outer layers consist of the individual outer plexiform layer 
(OPL), outer nuclear layer (ONL) and retinal pigment epithelium (RPE) layer. Full details 
of the retinal scans are shown in section 2.7. 
 
3.5.3 Participant demographics 
Fifty participants with DS were included in the data analysis of this study. There were 63 
control participants in total, within this group, participants were sub-divided into those 
whose ages matched those of the DS group (between 18 and 56 years), forming the age-
matched group, and those who were older than 57 years and who formed the older 
comparison group.  
Adults with DS over the age of 18 years were approached to take part in this study, in total 
60 participants consented to the study. Four participants were excluded from the study for 
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meeting at least one of the exclusion criterion and two participants withdrew consent before 
scanning. Four participants were excluded post-scanning for data quality below the 
threshold deemed acceptable by Heidelberg (<15 quality index rating; Huang et al., 2012). 
Control participants were age-and-sex balanced with the DS group. Thirty-seven 
participants were recruited within the age range of the DS cohort; one participant was 
excluded due to low quality data, leaving a total of 36 participants. A comparison group of 
typically developing adults older than the DS group were recruited to test for similarities in 
retinal thickness, owing to the accelerated ageing seen in DS. The oldest DS participant was 
56 years therefore all control participants 57 years and older were entered into the older 
comparison group. This group consisted of 27 participants. Demographics of all participants 
are shown in Table 3.1.  
 
 N Males, females Mean age (range) 
DS group 50 28, 26 36.76 (18-56) 
Control group 36 13, 24 37.27 (21-56) 
Comparison group 27 7, 20 68.33 (57-91) 
Total recruited 118 48, 70 Range 18-91 years  
Table 3.1 Demographics of the study groups 
 
3.6 Results 
3.6.1 Tolerability of retinal examinations  
 Pilot study 
One of the aims of this study was to establish whether OCT scanning technology is suitable 
for use in adults with DS. This was first assessed in a pilot study of nine participants who 
completed the full scanning procedure. Fixation problems led to a loss of one out of 18 eyes 
culminating in a 95% success rate which was acceptable to continue to the main study where 
tolerability was continually assessed. It was not deemed necessary to make any changes to 
the scanning protocol at this time.  
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 Cross-sectional study 
For the cross-sectional study an additional 51 participants with DS were recruited, 60 
participants in total, after exclusions and withdrawals a total of 50 participants were retained 
across both the pilot and cross-sectional studies. Total loss of all data due to poor quality 
was 7.4%, which is considered acceptable. If a participant was able to complete one of the 
scans with acceptable quality they were retained in the study. Completion rates differed 
substantially between the types of scans applied (see Table 3.2). The RNFL scan had a 
higher success rate with 47 participants completing the right eye scan and 42 participants 
completing the left eye scan, only one participant was unable to complete the RNFL scan in 
either eye. The macular/posterior pole scan had a higher loss rate, 38 participants completed 
the right eye scan and 33 participants completed the left eye scan. In the control group one 
individual’s data was excluded from both eyes and all scans due to poor quality. 
 
 Total N 
Scans completed 
(right eye, left eye) 
Success rate 
(right eye, left eye) 
RNFL data 50 47, 42 94%, 84% 
Macular/posterior pole data 50 38, 33 76%, 66% 
Table 3.2 Scans completed in the DS group. 
 
Scan procedure in the DS participants took between five and 20 minutes. This was often 
considerably longer than the average five minutes taken for the control participants. In 
general, participants with DS did not find the scanning procedure uncomfortable or 
distressing, although some reported that it was difficult to keep looking at the light. Retinal 
scans were not undertaken in any specific order during testing and no preference was given 
as to which eye was scanned first. Almost all participants were able to complete the RNFL 
scans and more than 50% completed the macular and posterior pole scans. This indicates 
that OCT technology is acceptable and feasible in the DS, with the expectation that there 
will be higher loss and slower scan times in comparison to control participants. Tolerability 
seen in the pilot study was not replicated in the cross-sectional study. Future studies in this 
area should make reasonable adjustments and improvements to the scanning protocol, as 
discussed in the limitations, for DS participants in order to reduce the number of failed scans.  
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3.6.2 RNFL thickness  
Global RNFL data was normally distributed; however outliers were identified in both the 
DS group and the control group. Outlier sensitivity analysis was performed which showed 
that there was no impact on the significance value with the removal of outliers, additionally 
there did not appear to be anything specific about those participants identifying them as 
candidates for removal, therefore outliers were retained. 
 
There was a statistically significant difference in the thickness of the global RNFL measure 
between groups as determined by one-way ANOVA (F(2,111) = 47.46, p< .001. Post-hoc 
analyses showed that the global RNFL was significantly thicker in the DS group compared 
to the age-matched control group (p< .001) and compared to the older comparison group (p< 
.001). There were no significant differences between the thickness measures of the age-
matched control group and the older comparison group (p= .407). Means, standard 
deviations (SD) and ranges for all groups are shown in Table 3.3. 
 
Study group N 
Mean ± SD 
(µm) 
Minimum, maximum 
values (µm) 
DS group 47 116.44 ± 12.7 77, 143 
Age-matched control group 36 98.44 ± 7.58 81.5, 122 
Older comparison group 31 94.81 ± 10.08 80, 120 
Table 3.3 Descriptive data of the global RNFL thickness measures. 
 
 Axial length 
Axial length was assessed in our population of participants with DS as it has been shown 
that shorter and longer eyes can alter the thickness measurement of the OCT scan (Kaliner 
et al., 2007). It was found that three of the participants had short eyes, two had long and one 
had extra-long. Global RNFL thickness measures were identified for each of these 
participants individually to see if excessive thin or thick measure were reported. None of the 
participants identified expressed measures considered to be outliers, nor were these 
measures at the range limits of the DS global RNFL mean (77-143 micrometres (µm)) 
therefore there was no indication that axial length impacted the data in this study. 
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Figure 3.1 Box-plot of the spread of global RNFL thickness values between groups. 
Data shows that there are significantly thicker measures in the DS group 
compared to the control group and the older comparison group.  
 
Figure 3.1 shows a relatively even distribution of values within groups, with similarly low 
measures between the two control groups and considerably higher thickness values in the 
DS group. The finding of significantly thicker global RNFL measures in the DS group 
compared to both the control group and the older comparison group is contrary to 
predictions. It was hypothesised that the DS group would show thinner measures than the 
control group and would have retinal thickness values that were statistically similar to the 
older comparison group. The older control group showed slightly thinner global RNFL than 
the age-matched control group, as expected.  
 
* 
n.s. 
* 
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 Peripapillary quadrant analysis 
The unexpected results of the global RNFL thickness have indicated that the peripapillary 
is thicker in DS, further analysis of the RNFL quadrants is required to determine whether 
this thickness is evenly represented across the quadrants or whether there is heterogeneity 
between quadrants. It was originally hypothesised that the superior quadrant would show 
increased thinning in the DS group in comparison to other quadrants. 
 
Normality tests showed that data was normally distributed for all quadrants in both groups, 
except for the temporal quadrant in the DS group. One participant was identified as an 
extreme outlier, this individual had a measure of 151µm in the temporal quadrant where the 
range of the rest of the DS group was between 65 and 125µm (mean 93µm). This participant 
was female, 40 years and showed no evidence of dementia or low cognitive performance in 
areas associated with dementia. Due to the extremity of this result this case was removed 
from analysis.  
 
 
Within-group quadrant analysis 
Within group repeated measures analysis of the quadrants identified that in the DS group 
there were significant differences between the thickness measures of the quadrants (F(2.66, 
119.84)= 330.29, p< .001). Mauchley’s tests for Sphericity was assumed (χ2(5)= 7.69, p= 
.174) however the Greenhouse-Geisser correction was applied for caution. Further 
comparisons between quadrants were conducted using student t-tests which identified that 
all quadrants were statistically significantly different from one another in the DS group (all 
quadrants to all quadrants, p< .001).  
 
In the control group there was also a significant difference between the quadrants as 
determined by within groups repeated measures analysis (F(2.08, 72.89), = 193.41, p< .001) 
with the Greenhouse-Geisser correction applied as Mauchley’s test of sphericity was 
violated (χ2(5)= 21.56, p= .001). Further comparisons using student t-tests between the 
individual quadrants showed that there were no significant differences between the temporal 
and nasal quadrants (p< .410) or between the superior and inferior quadrants (p< .055). 
However nasal and temporal quadrants were both significantly thinner than both the superior 
and inferior quadrants (p< .001).  Interpretation of the quadrant measure means indicated 
that the quadrants were not of homogenous thickness in either group. In the control group 
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thinnest to thickest ranking was as follows; temporal, nasal, superior, and inferior. This 
ranking was identical in the DS group apart from that the nasal and temporal quadrants were 
reversed.  
 
 
 
 
 
 
Figure 3.2 Schematic showing thickness order within the RNFL quadrants between 
groups. Same colours indicate no statistical differences within groups 
between the thickness values whilst different colours indicate statistically 
significant differences. Warmer colours represent thicker areas.  
 
Between-groups quadrant analysis  
Multivariate ANOVA statistics were conducted to determine statistical differences within 
quadrants between the two groups. There was a statistically significant difference in the 
quadrant thickness based on study group (F(2)= 77.00, p< .001). Univariate tests identified 
that there were statistically significant differences between the temporal (p< .001), superior 
(p< .001) and inferior (p< .001) quadrants of the RNFL between DS and the age-matched 
control group. The nasal quadrant was not statistically significantly different between groups 
(p= .915).  
Large effect sizes (< .50; Cohen, 1992) were reported in the temporal, superior and inferior 
quadrants, this indicates that the effect accounts for 25% of the variance. A low effect size 
(r= .01) was reported in the nasal quadrant.  
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RNFL Quadrant 
Mean (µ) ± SD 
P DS group (N=46) Control group (N=36) 
Nasal 74.93 ± 14.89 74.59 ± 13.24 .952 
Temporal 93.00 ± 13.05 71.31 ± 12.61 < .001* 
Superior 142.01 ± 19.04 121.40 ± 12.15 < .001* 
Inferior 154.70 ± 22.7 126.33 ± 15.26 < .001* 
Table 3.4 RNFL quadrant differences between groups. *Results significant to the 
Bonferroni adjusted p-value. 
 
Figure 3.3 Line chart showing RNFL quadrant measures across groups. Apart from the 
nasal quadrant all quadrants were significantly thicker in the DS group.  
 
These results show that the superior, inferior and temporal quadrants of the RNFL are 
significantly thicker in people with DS in comparison to age-matched controls; only the 
nasal quadrant is not significantly thicker in people with DS.  
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 RNFL correlations with age 
Within groups correlations were conducted to examine age-related changes in the retina 
between DS and control participants. We anticipated that the control group would show a 
trend towards thinning retina alongside increased age. Since the most RNFL loss is seen in 
typically developing people over the age of 50 years it was expected that the relationship 
would not be strong enough in the age-matched control group age range (18-56 years) to 
show significant loss. For the DS group, we expected to see a larger decline in RNFL loss 
with age that would start at a younger age and be more similar to the slope of decline seen 
in the older comparison group.  
 
 DS group (N= 46) Age-matched control 
group (N= 36) 
 R p r P 
Global (average of all quadrants) -.041 .786 -.246 .148 
Temporal average .083 .584 -.163 .341 
Superior average  -.079 .601 -.027 .877 
Nasal average .001 .998 -.128 .455 
Inferior average  -.056 .714 -.238 .162 
Table 3.5 Correlation statistics of age and RNFL quadrant  
 
In the control group, there were small negative non-significant correlations between the 
RNFL measures and age, and a negative correlation between the inferior quadrant and age. 
Although there were no significant correlations for the age-matched control group there 
appeared to be a trend towards thinning in all regions, as was expected. In the DS group 
there were no significant correlations or trends between age and RNFL measure. This is 
contrary to our predictions that people with DS would show accelerated ageing in retinal 
thickness.  
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 All controls (N = 67)  
RNFL region r P 
Global average of all quadrants -.262 .032 
Temporal average .247 .044 
Superior average  -.673 <.001* 
Nasal average .479 <.001* 
Inferior average  -.681 <.001* 
Table 3.6 Correlations between RNFL quadrant thickness and age in the combined 
control group. *Results significant to the Bonferroni adjusted p-value. 
 
Significant age-related correlations were identified when the older comparison group was 
included with the age-matched control data. This combination of groups gave a larger 
sample of 67 participants with an age range of 21-91 years. Large significant negative 
correlations (r= -.681 (p< .001) and r= -.673 (p< .001)) were seen in the inferior and superior 
quadrants respectively and a significant positive correlation of r= .470 (p< .001) was seen 
in the nasal quadrant. This data suggests that age-related thinning is seen in the superior and 
inferior quadrants but increased thickness was seen in the nasal quadrant. Evidence of a 
thinning retina, principally in the superior and inferior quadrants are supportive of previous 
literature in this area. The temporal quadrant and the global measure both showed small 
correlations that were not significant to the Bonferroni correction (p> .01).  
Fisher’s r-z transformation was calculated for comparison between the DS and full control 
sample correlation values. This statistic would determine whether there was a statistically 
significant difference the two groups’ correlations. Results showed that there were 
significant differences between the correlations of the DS group and the combined control 
groups for the superior, inferior and nasal quadrants (p<= .01). This implies that the lack of 
age-related decline seen in the RNFL of the DS group is significantly different to age-related 
changes seen in typically developing adults. There were no significant differences between 
the correlations of the DS and age-matched control group only. 
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Figure 3.4 Scatterplot showing age-related differences between groups for the RNFL 
inferior quadrant. 
 
 Comparisons between DS age groups 
Findings from our collaborative brain imaging study have shown a marked change in Aβ 
binding in adults with DS after the age of 39 years (Annus et al., 2016). With this in mind, 
further age-related changes were investigated by dividing the participants into two age 
groups, older DS (40–56 years) and younger DS (18–39 years). Retinal thickness of these 
groups were compared using student t-tests. It was predicted that the older DS group would 
show more evidence of thinning RNFL than the younger DS group.  
 
Comparisons showed that there were no significant differences in the RNFL global measures 
(t(39)= .876, p= .386), or the quadrant measures between the older and younger groups. This 
finding reinstates that no age-related differences were found in the DS group and that the 
expected age-related decline seen in the typically developing population is not seen in DS. 
The boxplot shows a larger spread of data in the older age group (see Figure 3.5). 
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Figure 3.5 Boxplot showing no significant differences in RNFL thickness between the 
older and younger DS participants. 
 
 
 
3.6.3 Posterior pole thickness  
 Averaged retinal layer comparisons  
Analysis for the posterior pole data was completed using the eye with the highest quality 
index per participant. The averaged values for the overall retinal thickness and averages of 
the inner and outer layers are presented in Table 3.7. Data was normally distributed and there 
were no outliers.  
KEY FINDINGS: The key finding from the RNFL data analysis is that the global RNFL 
and the superior, inferior and temporal quadrants are significantly thicker in the DS 
group, which is opposite to hypotheses. In addition, age-related retinal thinning was not 
identified in the cross-sectional sample of DS participants as was seen in the control 
group (combined age-matched and older groups).  
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 Mean ± SD  
 DS group (39) Age-matched 
control group (37) 
P 
Total retinal thickness average 313.23 ± 15.49 299.5 ± 13.09 < .001* 
Inner layers thickness average 236.40 ± 14.72 222.15 ± 12.28 < .001* 
Outer layers thickness average  77.25 ± 1.43 78.19 ± 2.03 .014 
Table 3.7 Posterior pole thickness measures. *Results significant to the Bonferroni 
adjusted p-value. 
 
One-way ANOVA results showed that there were significant differences between the groups 
for the average of all retinal layers (F(1, 75) = 17.352, p< .001) and for the average of the 
inner layers (F(1, 75) = 20.14, p< .001). The DS group had significantly thicker mean values 
for total and inner retinal layers, whilst for the outer layers there was no difference between 
groups. Medium effect sizes were calculated for the total (r= .43) and inner (r= .46) layers, 
outer layers showed a small effect size of r= .28. To determine in more detail the structural 
arrangement of thickness within the DS retina, the retinal layers were independently 
analysed.  
 
 Individual retinal layers comparisons 
One-way ANOVA showed statistically significant differences in three of the four inner 
retinal layers and two of the three outer layers (Table 3.8). As with previous results, the DS 
group displayed significantly thicker retina in the majority of measures. Within the inner 
layers, only the NFL layer was not significantly thicker in the DS group. In the outer layers 
the RPE layer was not significantly thicker and the ONL was significantly thinner in the DS 
group (F(1, 75) = 16.55, p< .001). Whilst the finding of thinner ONL supports our original 
hypothesis, this results goes against the findings seen so far in this study. 
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 Mean ± SD  
Retinal layer DS group (n=39) 
Age-matched control 
group (n=37) p 
Inner layers 
NFL 40.85 ± 6.99 41.33 ± 4.23 .722 
GCL 40.89 ± 3.94 33.42 ± 2.40 <.001* 
IPL 34.58 ± 2.73 27.66 ± 1.95 <.001* 
INL 40.63 ± 3.06 32.11 ± 2.59 <.001* 
Outer layers 
OPL 28.15 ± 3.20 26.08 ± 1.87 .001* 
ONL 51.14 ± 7.65 59.55 ± 10.26   <.001* 
RPE 13.20 ± 1.01 12.84 ± 0.93 .118 
Table 3.8 Individual retinal layer thickness measures between groups. *Results 
significant to the Bonferroni adjusted p-value. 
 
The ONL is the only region which has shown thinner values in people with DS, it was 
identified that that there was one outlier in each of the groups within this layer; this was 
further investigated in case the outliers were driving this reverse result.    
The outlier in the DS group had much thicker ONL that the other participants, and the control 
participant thinner ONL, suggesting that removal of these outliers would only serve to 
heighten the difference between the groups. Nevertheless, to check the impact of these 
outliers, outlier sensitivity analysis was completed. With the removal of the outliers there 
was no change in the result of the independent t-test, still showing significantly thinner ONL 
in the DS group (p< .001) with a mean difference between groups of 10.58µm. Outliers were 
retained for the final analyses. The effect size between groups for the ONL was r= .427 
which is a medium effect size supporting that there is a real difference between the two 
groups.  
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Figure 3.6 Outer nuclear layer thickness differences between groups. 
 
 Retinal layer correlations with age 
Posterior pole thickness of all individual layers was correlated with age for both groups. It 
was predicted that the layers most likely to show an association with ageing in the DS group 
would be those that were not statistically thicker than the control group (NFL, ONL and 
RPE).  
Results of these correlations in the DS group found no significant correlations between any 
of the retinal layers and age. Of the three retinal layers that were not significantly thicker in 
the DS group, there were no significant correlations (Table 3.9). The ONL showed a trend 
towards a positive correlation with age, which is contrary to the hypothesis that the DS retina 
will show thinning with age and controversial in that the ONL was the only area of the retina 
to be significantly thinner in the DS group.  
* 
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No significant correlations with age were found in the control group. Trends towards 
negative correlations were seen in the GCL (p= .012), and the IPL (p= .033). All retinal layer 
correlations with age for both groups can be seen in appendix O.  
 
 DS group (n=38) Control group (n=37) 
Retinal layer r p r P 
NFL -.087 .596 -.305 .066 
RPE .160 .329 .311 .061 
ONL .338 .035 -.236 .159 
Table 3.9 Correlations between age and retinal layers. Retinal layers included are those 
which were not significantly different in thickness between the DS and the 
control group.  
 
Using Fisher’s r-to-z transformation the differences between the two correlation coefficients 
were assessed between the groups. There were no significant differences between the 
coefficients for the RNFL (p = .342) or the RPE (p = .502), however the ONL (p< .0126) 
differed significantly between groups indicating that age-related thickening of the ONL may 
be exclusive to the DS group.  
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Figure 3.7 Age-related trajectory in ONL thickness.  
 
The scatterplot in Figure 3.7 shows differences in cross-sectional age-related ONL 
thicknesses between the two groups. In the DS group there is a non-significant positive 
relationship with age (r= .338, p= .035) indicating increased thickness with age, whilst in 
the control group there is a non-significant negative correlation with age (r= -.236, p= .159).  
The difference between the two correlations is significantly different (p< .0126). 
 
 
 
 
 
KEY FINDINGS: The key finding from the posterior pole region analysis is that the 
ONL is significantly thinner in the DS group compared to the age-matched control 
group. Although this result is supportive of the hypothesis, it is also opposite to all other 
retinal thickness analyses in this study. In addition, contrary to predictions, the ONL 
shows increased thickening with age, all other retinal areas showed no correlation.  
 
94 
 
3.6.4 Macular thickness  
In the DS group, macular thickness data was not normally distributed in the fovea; non-
parametric statistics are therefore applied as appropriate. The hypothesis for the macular 
region was that the DS group would show thinner average macular retina measures than the 
age-matched control group. Demographics of the macular retina thickness findings are 
presented in Table 3.10.  
 
Macular region 
Mean ± SD (µm) 
p DS group (N=37) 
Age matched control 
group (N=36) 
Fovea 302.39 ± 26.64 274.72 ± 18.56 < .001* 
Inner macular 355.15 ± 19.81 345.95 ± 13.47 .026 
Outer macular  322.68 ± 13.44 303.49 ± 13.44 < .001* 
Table 3.10 Macular thickness comparisons between groups. *Results significant to the 
Bonferroni adjusted p-value.  
 
One-way ANOVA showed a significant difference between the DS and control groups (F(1, 
76) = 12.148, p< .001). Between subjects effects showed significant differences in the fovea 
(p< .001) and the outer ring (p = < .001) but no differences in the inner ring (p = .026), see 
Figure 3.8. 
The fovea and outer macular are significantly thicker in participants with DS, the inner 
macular is thicker in the DS group but this difference was not statistically significant. Figure 
3.8 shows that the fovea has much lower values and smaller range in the control group. 
Figure 3.9 demonstrates the comparison between an individual with DS and an age-and-sex 
matched control participant, warmer colours indicate thicker values.  
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Figure 3.8 Box plot showing differences in macular thickness between groups. 
 
 
 
 
Figure 3.9 Heyex produced thickness colour maps between (a) DS participant and,         
(b) age-and-sex matched control participant. 
 
(a) DS male, 43 years  (b) Control male, 46 years (a) DS male, 45 years 
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 Quadrant comparisons between groups for the inner and outer macular regions  
Quadrant analysis within the macular rings was conducted to investigate homogeneity of 
thickness across the macular using paired samples t-tests. Normality tests showed that only 
the DS group superior quadrant of the inner macular was not normally distributed, no 
outliers were established. Non-parametric tests were used when analysing this quadrant. 
 
 Mean ± SD 
P 
Region DS group (N=37) Age-matched control 
group (N=37) 
Inner macular    
Temporal 342.36 ± 21.10 334.84 ± 13.37 .067 
Superior  360.62 ± 23.04 352.24 ± 14.75 .017 
Nasal 359.21 ± 23.20 352.43 ± 15.14 .135 
Inferior 359.21 ± 24.33 346.30 ± 14.27 .343 
Outer macular    
Temporal 307.69 ± 16.64 292.57 ± 13.15 < .001* 
Superior 322.87 ± 19.09 306.65 ± 13.61 < .001* 
Nasal 335.85 ± 20.88 322.22 ± 16.43 .002* 
Inferior 316.87 ± 16.19 296.54 ± 15.47 < .001* 
Table 3.11 Descriptive data for the inner and outer macular retina quadrants. *Results 
significant to the Bonferroni adjusted p-value. 
 
Results of the independent student t-tests between groups are shown in Table 3.11. These 
results found that in the inner macular region all quadrants were thicker in the DS group 
than the age-matched control groups; however none were significantly thicker than the 
control group. For the outer macular all quadrants were significantly thicker in the DS group. 
 
 Macular thickness correlations with age  
Age and thickness correlations were conducted for the fovea, inner and outer macular. As 
with previous retinal areas there were no significant correlations in the DS group (Table 
3.12). In the age-matched control group there were no significant correlations, however all 
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correlations were negative. Macular quadrant correlations were not conducted as there was 
no evidence of age-related change in the DS macular.  
 
 DS group (N=37) 
Age-matched control group 
(N=36) 
Region r p R p 
Fovea .215 .189 -.189 .262 
Inner macular .023 .891 -.354 .031 
Outer macular -.067 .686 -.274 .101 
Table 3.12 Correlations between macular regions and age. 
 
Fisher’s r-to-z transformation was used to assess the significance of the difference between 
the correlations for each macular region. There were no significant differences for any 
macular regions, indicating that age-related change in the macular is not statistically 
different between DS and age-matched controls. The inner macular correlation for the 
control group appears to be trending towards a significant negative correlation whilst in the 
DS group there was no trend. To test this, the older comparison group was added to the age-
matched control group and correlational analysis with age conducted for the inner ring, a 
significant negative correlation of -.437 (p< .001) was found which did differ significantly 
to the DS correlation when Fishers r-to-z transformation was applied (p=.01).  
 
 
 
 
KEY FINDINGS: Key findings in the macular region are that the fovea and outer 
macular are significantly thicker in the DS group. No correlations were seen with age in 
the DS group, indicating an absence of age-related decline which was seen in typically 
developing controls.  
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3.7 Summary of findings 
The aims of this chapter were threefold; firstly, to establish that the OCT methodology is an 
acceptable and feasible research method for use in people with DS. There was significant 
variability in individual focus for the scans, the RNFL scan had a much higher success rate 
than the macular/posterior pole scan. This suggests that a marker determined from the RNFL 
scan would be easiest to achieve in this population, however there are potential changes that 
could be made to the scanning protocol that would improve the success rate of the 
macular/posterior pole scan in the DS group, further studies are needed in order to refine the 
OCT protocol in people with DS and potential changes are discussed in section 3.8.1 Overall 
there was a loss of less than 25% for the macular scan indicating that for the majority of 
individuals both scans were achievable.  
Secondly, retinal thickness measures in the DS group were compared to age-matched 
controls and to an older comparison group. Hypotheses for these comparisons were that the 
DS group would show thinner retina than both control groups, and that the superior and 
inferior quadrants of the RNFL would be most affected, as has been found in non-DS AD 
research. Contrary to hypotheses the findings showed that instead of thinner retina, the DS 
group had significantly thicker retinal regions in almost all areas when compared to the age-
matched controls and the older comparison group. The older comparison group were 
originally included as a group where the expectation was that the DS group would show 
similar retinal thickness, due to the accelerated ageing seen in DS. However, results have 
shown that both the age-matched and older control groups have significantly thinner retina 
in comparison to the DS group. These findings indicate that people with DS have thicker 
retina than typically developing people. 
Finally, the association between retinal thickness and age was assessed. In the DS group we 
found no significant correlations in any of the retinal areas assessed other than the ONL, 
which showed a significant positive relationship with age. This finding is again contrary to 
our hypothesis and suggests that the retina is not affected by age, or shows increased 
thickening with age. In the control group we saw trends towards thinner retina with 
increasing age as was expected and is supportive of findings in the typically developing 
literature, furthermore, when the age range was expanded to include the older comparison 
group many of the trends became significant. The result of this analysis indicates that people 
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with DS may have an atypical presentation of ageing of the retina, which is either shown as 
thickening of some areas or by an absence of thinning. 
 
3.8 Discussion 
Retinal thinning has been seen in studies investigating AD, with emphasis on thinning in the 
superior and inferior quadrants (Cunha et al., 2016; Kesler et al., 2011; Liu et al., 2015; Lu 
et al., 2010; Moschos et al., 2012). Nasal and temporal quadrants have been less frequently 
shown to be thinner in AD (Bambo et al., 2015; Iseri et al., 2006). In this study the only 
quadrant that was not significantly thicker in the DS group was the nasal quadrant. Initially, 
this seemed to suggest that the nasal quadrant could be more susceptible to age-related 
thinning than the other quadrants, however correlational analysis found no associations 
between the nasal quadrant thickness and age. Likewise no correlations were found with age 
for any of the other RNFL areas in the DS group, whilst in the age-matched control group 
there were trends suggesting thinning with age, as was expected, and which were heightened 
when the older comparison group were included.  
The macular region and retinal layers are less frequently researched than the RNFL in AD 
literature. Studies which have investigated these areas have typically found that the macular 
shows evidence of age-related decline and significant further thinning in those with AD and 
patients with mild cognitive impairment (MCI; Cunha et al., 2016; Giménez, Dudekova, 
Gómez, & Lajara, 2016; Liu, Ong, Hilal, Miin, & Wong, 2016; Moschos, Markopoulos, 
Chatziralli, Rouvas, & Moschos, 2012; Polo et al., 2017). A controversial study in this area 
found thicker macular measures in patients with MCI (Ascaso et al., 2014). MCI patients 
showed thicker retina than both controls and AD patients, this data implies that thickening 
of the macular region may be an early event in AD disease progression and, as the disease 
advances, thinning of the retina becomes evident. This study supports the findings of our 
study, in that thicker macular, rather than thinner, is seen. As this was seen only in MCI 
there is a suggestion that this presentation of pathology may be part of early-stage AD. 
Comments from Ascaso et al., (2014) suggested that thickening of the macular may be 
caused by swollen neurons. Inflammation has been identified as one of the earliest hallmarks 
of several neurodegenerative diseases including AD (Fujino et al., 2004). This is supportive 
of the finding that thicker macular was only found in the MCI patients.  
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In the DS population it is also possible that inflammation, as an early AD-related pathology, 
could be responsible for the thicker retinal regions seen. This may also be related to 
inflammation caused by AD pathology as it is expected that many of the older DS group 
would have evidence of AD pathology particularly amyloid-beta (Aβ) deposits. Adults with 
DS and AD have extensive brain inflammation (Head et al., 2007). In AD research, studies 
have shown that there are significantly thinner retinal layers in AD compared to age-matched 
controls. This has predominantly been shown in the  NFL, GCL, IPL and the ONL (Garcia-
Martin et al., 2016). In people with DS the only research on retinal layers has been conducted 
in children, these studies found some evidence of thicker retina (O’Brien et al., 2015; Weiss 
et al., 2016), although not to the scale of generalised thickening across the retina that has 
been seen in this study. Findings of thicker retina in children imply that this may be a 
developmental feature of people with DS, although increasing thickness with age is 
suggestive that age-related pathologies are impacting on retinal structure.  
The findings of these results raise two important issues in evaluating retinal thickness in 
people with DS. The first is that adults with DS were shown to have almost universally 
thicker retina in comparison to age-matched control participants and the second being 
accelerated ageing seen in DS. Whilst increased thickness found in DS children has not been 
linked with poorer eyesight or any detrimental effects (O’Brien et al., 2015), it is important 
to understand the underlying pathology that is causing increased thickness. It is possible that 
thicker retina is characteristic of people with DS; however this theory does not explain why 
this study found increased thickness with age in the ONL, and absence of normal age-related 
thinning in any retinal area. Another potential reason for thicker macular in people with DS 
has been identified by Wang et al., (2014), who found that children with cataracts displayed 
thicker fovea than children without cataracts. People with DS have a high prevalence of 
cataracts both in adult and childhood which could explain thicker macular in this area. This 
study excluded adults with DS with severe cataracts but did not exclude those with mild 
cataracts; therefore foveal thickness may be inflated in those with mild cataracts. If indeed 
thickening of the fovea is a reflection of cataracts this would still not explain the many other 
thicker retinal areas seen in this study in adults with DS. O’Brien et al., commented that due 
to limitations in the software used they had been unable to provide individual retinal layer 
analysis therefore had this been achieved there may have been evidence of further areas 
showing atypical thickness.  
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Increased thickness or lack of thinning could be a mask for underlying pathology. People 
with DS have a life-long over production of Aβ (Ballard, Mobley, Hardy, Williams, & 
Corbett, 2016), which may cause increased thickness, both as a primary result of the 
deposition and build-up of plaques in the retina, but also through a secondary measure as 
Aβ is known to trigger other events such as increased inflammatory response, microglial 
activity and apoptosis. Increased Aβ has been reported in the brains of children with DS as 
young as two years (Mehta, Capone, Jewell, & Freedland, 2007; Mori et al., 2002; Teller et 
al., 1996). Lifelong overproduction of Aβ would suggest that adults would have more retinal 
amyloid than children. This suggests that there may be patterns of thickness in the retina 
associated with age with some areas being affected earlier in life. Retinal amyloid has been 
seen in typically developing patients with AD (Koronyo-Hamaoui et al., 2011) and Rafii et 
al., (2015) are the first group to have studied the presence of Aβ in the retinas of adults with 
DS. This study used an oral supplement of curcumin that naturally binds and stains Aβ which 
can then be imaged non-invasively. The results of this study found significantly increased 
retinal amyloid in comparison to age-matched control participants and suggested that retinal 
Aβ is present in adults with DS without presence of dementia. The distribution of Aβ in the 
retina appeared to cluster around blood vessels, this is particularly interesting as people with 
DS have an increased number of vessels across the margin of the optic nerve (Kim, Hwang, 
Kim, & Yu, 2002; Ljubic, Trajkovski, & Stankovic, 2011; Williams, Mccormick, & 
Tischler, 1973), this feature has not been associated with vision loss, or any affect to the 
individual and does not require any management, but may play a role with the deposition of 
Aβ and further explain increased thickness around the optic nerve head (ONH). Findings 
from Rafii et al., (2016) support the concept that Aβ could be responsible for thickening of 
the retina either directly or non-directly.  
The findings of this study suggest that the DS retina does not exhibit the normal signs of 
age-related degeneration. Based on comprehensive knowledge of accelerated ageing in 
people with DS and evidence of ageing in many other physical and mental aspects (Zigman, 
2013), it is unlikely that people with DS are exempt from ageing effects in the retina. It is 
more likely that the DS retina is affected by ageing, but that these effects are not presented 
in the same manner as in the typically developing population. Future studies should look to 
correlate presence of Aβ and location of depositions with measures of retinal thickness. The 
potential effects of overproduction and deposition of Aβ in the retina are considered in more 
detail in the general discussion chapter.  
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3.8.1 Limitations 
Improvements to the methodology of the study  
This study was able to recruit a fairly large sample of people with DS. A control group 
balanced for age and sex were recruited, and the mean values of age and sex were not 
significantly different between the groups. The age range of 18-56 years is reasonably 
representative of the lifespan of people with DS. It is possible that a larger age range 
(including children and older people with DS) would have allowed for more significant age-
related correlations to be seen. In addition, imaging the retina in children would have been 
beneficial in further understanding the developmental potentiality of thicker retina. Another 
limitation of the age range in people with DS is that inevitably there will be a sample bias 
in the people who volunteered to take part in the study. Older adults with DS are more likely 
to have dementia and may not have the capacity in terms of travel and support to take part 
in studies, thereby limiting our data sample.  
 
Improvements to the scanning protocol for improved data acquisition 
There were several improvements that could have been made to the study. Scan completion 
was variable in the DS group, with many people struggling to remain fixated throughout the 
examination. There are several reasons why people many may have struggled with fixation. 
Firstly, there were several distraction factors, although attempts were made to keep the room 
quiet and dark there were often people walking around and talking outside the room – 
particularly at the Western Eye Hospital site as there were other studies being conducted in 
other rooms. At both sites parents or carers were invited to sit in the room with the participant 
if they preferred to, whilst this was initially suggested in order to make the participant more 
relaxed, the parent or carer would often talk to the participant and distract them from the 
task. In future studies more effort would be made to keep the room quiet and it would be 
suggested that parents or carers would only be in the room if the participant was distressed. 
It would have been preferable to have conducted the scans in a sequential order, this would 
have allowed us to see whether first or second scans were better completed as there may 
have been either an effect of tiring or an effect of practice in the participants. In order to 
improve the quality of the data collected, pupil dilating drops would be applied in future 
studies, whilst dilation was not necessary for the collection of data in this study, the effects 
of slight movements can be reduced if the pupils are dilated.  
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Additional technology  
Findings from this study have shown that there may be underlying pathology in people with 
DS that is leading to thicker retinal structure. Additional optical scanning methodologies 
would be useful in investigating this further. Since the start of this study Aβ has been 
visualised in people with DS using recent technology, NeuroVision. Rafii et al., (2015) have 
used this technology to successfully image Aβ in the retina, in this study the combination of 
Aβ analysis and retinal thickness would have allowed for pattern analysis for Aβ deposition 
and corresponding areas of retinal thickness.  
 
3.9 Conclusion 
The results of the analyses of this chapter have shown that there is a significantly thicker 
retina in the DS group when compared to age-matched controls. The retina in people with 
DS also appears to undergo atypical ageing. These findings were contrary to our predictions 
that people with DS would have thinner retina and show increased and earlier age-related 
thinning of the retina. These predictions were based on results in normal ageing and in AD 
patient groups, along with evidence of accelerated ageing and high prevalence of early onset 
AD in people with AD. Possible causes of increased retinal thickness in people with DS 
have been discussed, including developmental characteristics of DS, and AD-related 
pathology including Aβ and Aβ induced pathology. These theories are considered in more 
detail in the general discussion along with the findings of the following results chapters.  
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Chapter Four: 
Associations between retinal thickness and assessments of 
cognitive decline and dementia 
4.1 Chapter Introduction 
The aim of this chapter is to examine the relationship between retinal thickness, cognition, 
and dementia in adults with Down’s syndrome (DS). Cognitive assessments were completed 
using the Cambridge Cognition Examination (CAMCOG) and an executive function battery, 
onset of dementia was assessed using the Cambridge examination for mental disorders of 
older people with DS and others with intellectual disabilities (ID) informant interview 
(CAMDEX). In this chapter, analyses are undertaken to examine the associations between 
cognitive performance and retinal thickness, as well as to establish retinal thickness 
differences in DS individuals with and without a diagnosis of dementia.   
 
4.2 Background 
One of the dominant characteristics of DS is the presence of an ID; typically people with DS 
have a mild-moderate ID however there is substantial variation in the extent of disability 
between individuals. Abnormalities and slow development in learning, memory and 
language are characteristic (Lott & Dierssen, 2010). Spatial working memory, particularly 
in sequential spatial tasks (Lanfranchi, Carretti, Spanò, & Cornoldi, 2009) is impacted, as is 
verbal short term memory, and explicit long-term memory (Brown et al., 2003; Hodapp & 
Dykens, 2005). Executive function is poorer in people with DS (Kittler, Krinsky-McHale, 
& Devenny, 2006; Luria, 1966). Visuospatial short term memory and implicit long term 
memory has been found to be more often preserved (Lanfranchi, Baddeley, Gathercole, & 
Vianello, 2012; Laws, Glynis, Bishop, & Dorothy, 2003).  
In sporadic Alzheimer’s disease (AD) the earliest changes relating to onset of dementia are 
almost always memory-related, however in people DS the early signs are more akin to 
changes seen in “dementia of the frontal type” (DFT; Ball et al., 2006; Gregory & Hodges, 
1993). It is hypothesised that as the frontal lobes are underdeveloped in DS (Pinter et al., 
2001), neuropathological changes may have earlier effects on the cognitive functions 
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associated with this area (Holland, Hon, Huppert, & Stevens, 2000; Mortimer, 1988). In DS, 
the earliest dementia related changes seen are often in personality and behaviour, including 
withdrawal, apathy and stubbornness (Holland et al., 1998). Holland et al., (1998) reported 
that many individuals who failed to meet the criteria for AD met the behavioural criteria for 
DFT, and later progressed to a diagnosis of AD within five years (Ball et al., 2006). 
Diagnoses of DFT are higher in younger participants (<45 years). Cognitive tasks that are 
used in the assessment of dementia in DS have been traditionally devised for educational 
assessment, rather than neuropsychological assessment, therefore do not cover the full range 
of cognitive abilities known to decline in dementia, and are not always designed so that floor 
and ceiling effects can be avoided (Hon et al., 1999). The CAMCOG neuropsychological 
test aims to address these issues, and is used together with the CAMDEX informant 
interview (Roth et al., 2014). CAMCOG is a brief neuropsychological battery which has 
been extensively used to assess a range of cognitive functions including; language, praxis, 
memory, orientation, abstract thinking, attention and perception. All of these are items 
included in the Mini Mental State Examination (MMSE (Folstein et al., 1975), however they 
are tested more rigorously in the CAMCOG. 
Due to ID and low IQ in people with DS, cognitive functioning is predictably decreased, 
and it is often difficult to disentangle developmental cognitive deficiency from changes that 
may be due to the onset of dementia. CAMCOG scores alone are not sufficient to confirm a 
diagnosis of dementia in people with DS. As discussed in section 1.3.3, assessing dementia 
in people with DS presents with a range of complications, some of which are due to the 
presence of ID (Aylward, Burt, & Thorpe, 1997), which has led to varied prevalence rates 
of dementia being reported (Coppus et al., 2006; Lai & Williams, 1989; Oliver & Holland, 
1986; Sekijima et al., 1998; Tyrrell et al., 2001; Visser, Aldenkamp, Van Huffelen, & 
Kuilman, 1997). As presentation of dementia in people with DS is different to that of 
typically developing people, changes in behaviour and personality are often overlooked, 
memory changes are more readily noted, but these often occur later in the progression of 
AD in people with DS. Certainly by the time memory changes are seen, but also most 
probably at the time that changes in personality and behaviour are seen, it is very likely that 
AD neuropathology is already established in the brain (Bateman et al., 2012).  
Generally, people with DS are not aware enough of their own capabilities and limitations to 
give an account of recent changes in their functioning levels; therefore, in the majority of 
cases, reliance is placed on the individual’s friends, relatives and carers. This can be 
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problematic, often changes relating to dementia are gradual and those who spend a lot of 
time with the individual will have difficulties pinpointing the start of change, on the other 
hand, particularly in the case of those in residential care, high turnover of staff or low contact 
hours mean that changes can be overlooked and not efficiently reported (Holland & Walpert, 
2016). Structured interviews, such as the CAMDEX, are used to identify changes. Interviews 
are completed with a person who has known the individual with DS well for a minimum of 
six months. These interviews are designed to establish differences between the individual’s 
capabilities now, from a time before the changes started. This interview can also help 
exclude the pseudo-dementias (i.e. depression, hypothyroidism, psychosis) which often 
present with similar symptoms as dementia (Wells, 1979). For the most accurate testing, the 
best method would be to have CAMCOG and CAMDEX completed at a time where the 
person was “at their best” and not showing any signs of behaviour, personality or memory 
change. This would then be used as a baseline for changes in future assessments.  
The MMSE (Folstein et al., 1975) is the most widely used screening instrument for detection 
of cognitive impairment, however there are many different cognitive tests available. In this 
study, the Telephone Interview for Cognitive Screening (TICS; Brandt, Spencer, & Folstein, 
1988) was used for dementia screening of the control group participants. This test was 
developed with the primary intention of creating a screening assessment with the same 
impact as the MMSE, but which could be used over the phone. The TICS has a very high 
correlation with MMSE (Pearson’s r = .94). The TICS has high test-retest reliability, high 
sensitivity and specificity for cognitive impairment in AD. The main advantage of the TICS 
is that there is a lower dropout rate as the burden on the participant is reduced. This is 
particularly relevant in people with dementia who may not be able to travel easily.  
To date, no research has compared the cognitive status or onset of dementia with retinal 
thickness in people with DS. In sporadic AD, several studies have assessed the relationship 
between retinal thickness and cognitive status, most commonly using the MMSE. The 
findings of this research have mixed results, with some studies being unable to show any 
associations between cognitive scores and retinal thickness, whilst others which have found 
lower MMSE scores are correlated with thinner retinal measures. There is large variability 
in the strength of the associations seen across the literature. Moreno-Ramos, Benito-León, 
Villarejo, & Bermejo-Pareja, (2013) reported a high correlation between poorer cognition 
and thinner retina of r= .96, whilst (Cunha et al., 2017) reported a much lower value of r= 
.33. Some studies have recognised the inferior quadrant of the RNFL as being the most 
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associated with lower MMSE scores (Ascaso et al., 2014; Berisha et al., 2007). The inferior 
quadrant, along with the superior quadrant were also found by many studies to be the most 
likely to show thinning in the AD and mild cognitive impairment (MCI) patient groups 
(Eraslan et al., 2015; Liu, Duggan, Salt, & Cordeiro, 2011; La Morgia et al., 2015). Outside 
of the MMSE, other cognitive tests have been associated with the temporal quadrant of the 
RNFL (Knoll et al., 2016; Shen et al., 2014). In contrast to all other cognitive associations 
found, these studies reported that thicker retina was associated with poor cognitive function. 
More robustly, findings have shown differences between age-matched healthy controls and 
AD patients retinal thickness in the RNFL (e.g. Garcia-Martin et al., 2016; Larrosa et al., 
2014; Marziani et al., 2013) and the macular (e.g. Cunha et al., 2016; Khawaja et al., 2016; 
Moschos et al., 2012; Polo et al., 2017) indicating that cognitive scores may not be sensitive 
enough to correlate with retinal thickness.  
Due to the nature of ID in people with DS it is important to distinguish between cognitive 
ability as a developmental factor and cognitive performance, affected by onset of dementia. 
To accomplish this, retinal thickness measures were correlated with IQ (developmental 
cognitive ability) and cognitive tests that are specifically designed to assess areas known to 
decline with age and neurodegenerative disease. 
 
4.3 Aims  
 To assess the association between developmental cognitive ability (IQ) and retinal 
thickness in people with DS.  
 To investigate the relationship between cognition as a measure of age-related decline 
(CAMCOG and executive function scores) and retinal thickness. 
 To compare retinal thickness of individuals with DS and a diagnosis of dementia to 
DS without dementia as determined by the CAMDEX informant interview. 
 
 
4.4 Hypotheses 
Hypotheses have been formed based on literature from non-DS patients with sporadic or 
late-onset AD. In addition to the hypotheses stated, exploratory analysis was undertaken in 
the retinal areas that were highlighted in the previous results chapter.  
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 Cognitive performance will positively correlate with retinal thickness. 
 The superior and inferior regions of the RNFL will correlate with cognitive scores. 
 Participants identified as having a diagnosis of dementia or having significant 
functional or behavioural change will show thinner retinal measures than age-
matched DS participants without dementia.  
 
4.5 Methodology 
Full details of the study population, neuropsychological test materials, retinal scan 
procedures and data presentation can be found in Chapter Two, sections 2.5, 2.7 and 2.8.  
 
4.5.1 Procedure 
Neuropsychological tests were conducted to provide a comprehensive cognitive assessment 
for the DS participants. These tests were conducted either at the testing site or the 
participants’ homes over one or two visits depending on the participant’s preference. 
Full details of the neuropsychological tests are given in section 2.8. In summary, tests 
applied in the DS group included the CAMCOG and an executive function battery to assess 
areas known to experience decline in people with dementia. The Kaufman Brief Intelligence 
Test-2 (KBIT-2; Kaufman & Kaufman, 2004) was used to measure IQ. Neuropsychological 
testing lasted approximately one to two hours, this was often split over two sessions. For the 
control group, dementia screening assessments were completed using the TICS, this test 
takes around five minutes to complete and was either conducted in person or via telephone 
call.  
Scoring and assessment of the neuropsychological tests were completed by the researcher. 
Non-standardised KBIT-2 scores were analysed rather than standardised scores. 
Standardised scores are influenced by age, giving a floor effect at 40 points. Non-
standardised scores of the KBIT-2 were used in this analysis to remove the issue of floor 
effects in a population of adults with ID who typically show lower mental age. 
Dementia interviews for the DS participants were completed with the individual’s main 
parent or carer. In most cases, this was a parent. Interviews were completed at the 
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individual’s home or testing site and lasted approximately 30-60 minutes. Assessment of the 
dementia interviews were completed by two consultant psychiatrists independently. 
Generally, participants with evidence of decline in two or more areas which did not meet 
the criteria for pseudo-dementias were given a diagnosis of dementia. Control participants 
were screened for dementia using the TICS assessment. This test was conducted by the 
researcher either at the testing site or over the phone, and lasted approximately five minutes.  
 
4.5.2 Participant demographics 
Fifty participants with DS completed at least one retinal scan, 46 of these participants also 
completed the CAMCOG and KBIT-2 assessments and 41 participants completed the 
executive function battery. Participants without a neuropsychological test score either 
refused to complete the tests, but still wished to remain in the study, or did not complete the 
battery, incomplete tests were not entered. Dementia interviews were completed for all 
participants. For the control group, all participants completed a short TICS dementia 
screening assessment.  
In total, five participants were identified as having a diagnosis of dementia. The executive 
function battery was not completed by five of the DS group, including two of those with 
dementia. One of the DS participants (male, 53 years) was excluded from the analysis as the 
results of his CAMDEX interview were inconclusive. It was independently agreed by two 
clinical psychiatrists that this individual did not meet the criteria for dementia or pre-clinical 
dementia, but that he was exhibiting peculiar behaviours perhaps as a result of a pseudo-
dementia. CAMCOG scores from this individual were found to remain stable over a period 
of five years (from involvement in previous Defeat Dementia in DS (DiDS) studies in our 
research group), supporting a diagnosis of no dementia.  
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4.6 Results 
4.6.1 Neuropsychological test results 
Table 4.1 shows the descriptive statistics of the DS and control group neuropsychological 
tests.  
 
DS participants N Mean ± SD (µm) Range 
CAMCOG  46 76.96 ± 19.52 17 – 105 
KBIT-2 non-standardised score 46 58.57 ± 21.08 7 - 102 
Executive function score 41 39.80 ± 9.42 13 – 53  
Control participants    
TICS score 69 34.25 ± 2.81 27 - 40 
Table 4.1 Descriptive statistics of the neuropsychological tests 
 
Large ranges were seen in all neuropsychological measures, however floor and ceiling 
effects were not observed which indicates that the measures are capturing true cognitive 
ability.  
Individuals with DS with a diagnosis of dementia include two females aged 47 and 51 years 
and three males aged 49, 56 and 53 years. CAMCOG scores for these individuals ranged 
between 19 and 90, which were within the range of scores seen for the DS group without 
dementia (17-105). There were no significant differences in the scores on the CAMCOG 
battery between individuals with and without dementia (t(44)= 1.731, p= .091), however 
scores were significantly different between the groups for the executive function battery, 
(t(39)= 2.156, p= .037). In both cases the group without dementia had higher average scores 
than the group with dementia.  
Correlations between age and the neuropsychological measures were conducted in the DS 
group in order to establish whether age was a confounding variable. Results showed that age 
was not correlated significantly with the CAMCOG score (r= -.138, p= .354), executive 
function battery (r= -.271, p= .083), or the non-standardised IQ scores (r= -.126, p= .398). 
CAMCOG and executive funtion scores were not normally distributed, which persisted after 
removal of the dementia group from the analysis, non-parametric tests are therefore used to 
analyse results. Non-standardised KBIT-2 scores were normally distributed. 
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For control participants, a score of 26 or lower in the TICS examination is an indication of 
mild impairment or, below 20, or moderately/severely impaired. All control participants 
scored at least 27 points indicating no dementia or mild impairment in the control group. It 
is possible that scores may have been reduced in this study due to, (a) the test being devised 
for use in the US, and, (b) language difficulties in some participants where English was not 
their first language, since all participants scored above the threshold this is not a limiting 
factor for this study but may be considered in future studies. Tests for normal distribution 
showed that the TICS scores for the control group were normally distributed.  
 
4.6.2 IQ associations with retinal thickness 
Non-standardised KBIT-scores were correlated with retinal thickness using Pearson’s 
correlation. Non-significant correlations were reported in all retinal regions (Table 4.2).  
 
 KBIT-2 Non-standardised scores 
Correlation coefficient  P 
Global RNFL .171 .267 
Total retinal layers average -.083 .624 
Fovea .032 .851 
Inner macular -.042 .807 
Outer macular -.166 .334 
Table 4.2 Correlations for non-standardised KBIT-2 scores and retinal 
thickness. 
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Figure 4.1  Histogram showing the non-standardised IQ scores for the DS group.  
The histogram in Figure 4.1 shows the spread of the non-standardised scores (K-BIT scores) 
within the DS population. Results have shown no correlations with retinal thickness, which 
implies that developmental cognitive abilities are not related to retinal thickness and 
therefore the extent of an individual’s ID is not a confounding variable in this study. Data 
shows a skew towards the upper end of the scoring, suggesting that the majority of 
participants included in this study had a mild/moderate ID rather than a severe/profound ID. 
The population sample may not be representative of all people with DS.  
 
4.6.3 Retinal measure correlations with CAMCOG and executive function 
It was predicted that RNFL thickness would positively correlate with CAMCOG and 
executive function scores. Furthermore, it was predicted that the superior and inferior 
quadrants of the RNFL would be implicated with cognitive measures, as has been shown in 
AD literature. Spearman’s rho correlations were used to assess the association between the 
retinal measures and the CAMCOG and executive function battery.  
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 Retinal nerve fibre layer analyses 
No significant correlations were found between any of the RNFL measures and the 
CAMCOG or executive function battery. This study found no relationships with cognitive 
scores in any of the quadrants for the CAMCOG, the executive function battery showed a 
trend towards a small correlation with the superior quadrant.  
 
 CAMCOG Executive function battery 
 r p r p 
RNFL average -.027 .867 .114 .461 
Temporal  -.147 .367 -.186 .227 
Superior  .217 .178 -.270 .076 
Inferior  -.248 .122 -.003 .983 
Nasal  .114 .484 .221 .149 
Table 4.3 RNFL thickness measure correlations with CAMCOG and executive 
function battery scores 
 
 Macular analyses 
For the fovea, inner macular and outer macular there were no significant correlations or 
trends identified between macular thickness and cognitive score. All correlations were 
between -.1 and +.1 indicating no correlations. Based on this finding, individual quadrants 
of the inner and outer macular quadrants were not assessed.  
 
 Retinal layers analyses 
The average thickness of the total retinal layers, inner and outer layers was correlated with 
cognitive scores. Results showed that the outer layers showed a significant correlation with 
the CAMCOG scores. This result indicated that thinner outer layers correlated with lower 
CAMCOG scores, which supports our hypothesis (see Figure 4.2).  
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 CAMCOG Executive function battery 
 r p r p 
Total retina average .140 .409 -.041 .817 
Inner layers average .074 .664 -.094 .599 
Outer layers average .423 .009* .112 .529 
Table 4.4 Average retinal layer thickness correlations with CAMCOG and executive 
function battery scores. *Results significant to the Bonferroni adjusted p-
value. 
 
Further investigation of the individual layers within the outer layers measure showed that 
no layer individually significantly correlated with CAMCOG scores. The outer plexiform 
layer (OPL) showed the closest trend to a significant correlation (r= .312, p= .060). The 
other layers; outer nuclear layer (ONL, r= -.079, p= .644) and RPE (r= .199, p= .238) did 
not show any trends.  
 
 
Figure 4.2 Scatterplot showing a positive relationship between CAMCOG score and 
outer retinal layers thickness.  
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4.6.4 Cognitive subscale correlations  
Previous studies have specifically identified increased inferior quadrant thickness in 
association with certain cognitive measures other than the MMSE. Individual test 
component scores within CAMCOG and executive function batteries were correlated 
against the temporal quadrant thickness. Findings from these correlations showed that there 
were no significant correlations between the inferior quadrant and the individual measures. 
Abstract thinking (measured in CAMCOG) showed a non-significant trend towards a 
positive association (r= .299, p= .046).  
Based on the results of this study, the superior quadrant showed a trend towards an 
association with the executive function battery, the superior quadrant thickness was also 
correlated with the individual tests within the batteries. No significant correlations or trends 
were identified.  
  
4.6.5 Comparisons between groups of DS participants with and without a diagnosis 
of clinical dementia 
Analysis of the CAMDEX informant interviews revealed that five participants met the 
criteria for dementia. Not all participants in this group had completed all retinal scans; 
therefore the n for this group is fewer than five for some regions.  
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 DS with dementia group  
 
DS no dementia group 
(n = 44) 
 N Mean ± SD Range Mean ± SD Range 
RNFL average 5 117.38 ± 19.07 90 – 134 116.05 ± 12.36 77 – 143 
Fovea 3 337.83 ± 20.82 314 – 352 301.36 ± 23.77 231 – 340 
Inner macular 3 364.33 ± 9.61 354 – 373 353.98 ± 20.08 304 – 396 
Outer macular 3 326.67 ± .14 326 – 327 321.15 ± 15.53 277 – 350 
Total layers 4 312.50 ± 12.40 294 – 320 312.97 ± 16.06 263 – 341 
Inner layers  4 237.61 ± 12.93 220 – 251 235.67 ± 15.20 189 – 263 
Outer layers  4 76.97 ± 2.15 74 – 79 77.17 ± 1.48 74 – 80 
Table 4.5 Retinal measure comparisons between DS with dementia group and DS with no dementia group. *Results significant to the 
Bonferroni adjusted p-value. 
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All regions of the macular were noticeably thicker in the DS with dementia group when 
compared to the DS without dementia group, particularly the fovea, which showed a trend 
towards thicker values in the dementia group (p= .016), although only three participants with 
dementia completed this assessment. The calculated effect size for the fovea region was r= 
.39 which is a medium effect size. Other retinal areas were not significantly different. The 
number of participants between groups differs substantially therefore the results of this test 
should be considered with caution.  
 
 
Figure 4.3 Box-plot showing differences in the fovea region thickness between DS with 
dementia and DS without dementia groups.  
The box plot shows a fairly even distribution in the DS without dementia group however in 
the dementia group there is a clear skew of the mean towards the top end of the results 
indicating that those diagnosed with dementia have thicker fovea than those without. Again 
the number of participants in the dementia group is very small therefore these results are 
tentative.  
n.s 
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4.6.6 Comparisons between DS with dementia and an age-and-IQ matched non-
dementia DS group 
The dementia group was matched with a smaller group of participants from the DS without 
dementia group. Cases were matched based on IQ and age, please see Table 4.6. 
  
 N Age 
Mean (range) 
IQ 
Mean (range) 
KBIT-2 raw scores 
DS with dementia 5 51.2 (47 – 56) 48.8 (40 – 63) 105 (85 – 133) 
DS without dementia  5 46.8 (43 – 55) 50.2 (40 – 65) 102.6 (80 – 128) 
Table 4.6 Demographics of the age-and-IQ matched no dementia DS participants to DS 
participants with dementia. 
 
Of these matched groups, three participants in the dementia group and four in the DS without 
dementia group completed the fovea scan. Independent sample t-tests showed that there 
were no significant differences between the groups on age (t(8)= 1.677, p= .132), or the non-
standardised by age KBIT-2 scores (t(8)= -.206, p= .842).  
Fovea thickness was compared between these matched groups (see Table 4.7). It was found 
that there was not a significant difference between the groups (t(5)= 2.131, p= .086) but that 
there was a trend suggesting thicker fovea in the dementia group and again a medium effect 
size was reported (r= .38).  
 
DS groups N Fovea mean ± SD 
DS without dementia group  3 311.25 ± 12.47 
Dementia group 4 337.83 ± 20.82 
Table 4.7 Mean and standard deviation of fovea thickness between matched DS groups. 
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Figure 4.4 Box-plot showing the differences between foveal thicknesses for matched 
DS groups.  
 
Within the retinal layers and cognitive scores analysis it was identified that the outer layers 
showed a significant positive relationship with CAMCOG scores. In this analysis outer 
retinal layer thickness is compared between the dementia and DS without dementia groups 
using independent samples t-tests.  
These comparisons (four participants per matched group; see Table 4.8) showed no 
significant differences between any of the retinal layers or the retinal average between 
groups, however, the ONL was found to be thinner in the dementia group (t(6)= -2.289, p= 
.062) and a large effect size of r= .78 was reported indicating that despite the non-significant 
p value there is a substantive difference in the ONL thickness of the two groups. The ONL 
was previously identified both as being thicker in people with DS than controls, and with 
increasing with age in DS. Non-matched (all DS without dementia) group (n=44), showed 
no significant differences in the ONL thickness of the dementia group (n=4; t(36)= -.154, p= 
.879). 
n.s 
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DS groups N ONL mean ± SD 
DS without dementia group 4 55.76 ± 4.36 
Dementia group 4 50.66 ± 0.84 
Table 4.8 ONL thickness differences between age-and-IQ matched DS groups with and 
without dementia. 
 
 
 
Figure 4.5  ONL thickness spread differences between dementia and no dementia 
matched DS groups. 
 
 
 
 
ns 
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4.7 Summary of findings 
The aims of this chapter were to examine; (a) correlations between developmental cognitive 
ability (IQ) and retinal thickness, (b) investigate the association between cognitive task 
performance and retinal thickness, (c) examine differences in retinal thickness between DS 
individuals with dementia and those without dementia.  
The results of the analyses completed in this chapter showed that retinal measures were not 
associated with IQ in people with DS, and that, in the majority of cases, retinal measures did 
not correlate with either of the two cognitive batteries tested. The average thickness of the 
outer retinal layers showed a significant correlation with CAMCOG scores, indicating that 
thinner retina was associated with lower cognitive scores. This finding appeared to be 
strongest for the OPL, although not significant. There were no significant differences found 
between the DS with dementia and DS without dementia groups in any retinal region apart 
from the fovea, which was significantly thicker in the dementia group, which is contrary to 
our predications. It was also found that the outer nuclear retinal layer trended towards thinner 
values in the dementia group, which would support our hypothesis.  
  
4.8 Discussion 
Increased retinal thickness as a developmental feature of people with DS has been suggested, 
both by the previous results of this study and by studies in children with DS which have 
found thicker retina when compared to typically developing controls (O’Brien et al., 2015; 
Weiss et al., 2016). An association between IQ and retinal thickness would indicate that the 
extent of learning disability is a determining factor in retinal structure. If this were the case, 
IQ would confound any relationships seen between cognitive performance and retinal 
thickness. The results of this study did not find any relationship between IQ and retinal 
thickness. However, this does not remove the possibility that thicker retina is a 
developmental feature of DS. Future studies should seek to investigate this further.  
The finding of thicker fovea in participants with DS who also had a diagnosis of dementia 
is surprising. It was predicted that those with dementia would show thinner retinal measures, 
as had been reported in those with sporadic AD (Bambo et al., 2015; Eraslan et al., 2015; 
Gunes et al., 2015; Iseri et al., 2006; Kang & Kim, 2013; Kirbas et al., 2013; La Morgia et 
al., 2015; Larrosa et al., 2014; Lu et al., 2010; Marziani et al., 2013; Moreno-Ramos et al., 
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2013; Parisi et al., 2001; Polo et al., 2017; Salobrar-García et al., 2016; Salobrar-Garcia, 
Hoyas, et al., 2015). Studies which have specifically reported foveal thickness found that 
the fovea was either significantly thinner in AD (Cunha et al., 2016; Garcia-Martin et al., 
2014; Iseri et al., 2006), or not different between AD and non-AD groups (Larrosa et al., 
2014; Polo et al., 2017). To date, no studies have reported thicker fovea in patients with 
dementia. Cunha et al., (2016) reported that the strongest correlation with cognition in the 
retina was in foveal thickness and MMSE scores. Despite the fovea showing a trend towards 
thicker values in the DS with dementia group, there were no correlations with cognitive test 
scores.  
The outer layers of the retina were the only area that showed any significant relationship 
with cognition, this was seen with the CAMCOG scores. The layers which make up the outer 
layer average were assessed individually and only the OPL indicated a trend. Very few 
studies in sporadic AD have reported on individual retinal layer thickness. One of those 
which has, Garcia-Martin et al., (2016), found that within the outer layers, only the ONL 
was significantly thinner in people with AD compared to typically developing controls. In 
this study, the ONL was thinner in the DS with dementia group, although again numbers in 
this analysis were very small. The ONL includes the nuclei of the photoreceptors (rods and 
cones). Photoreceptor loss and damage leads to poor vision including night-blindness and 
constriction of the visual field (Mitamura et al., 2012). Photoreceptor loss is also linked with 
ageing. Jackson, Owsley, & Curcio, (2002) reported that by the age of 70 years 
approximately 30% of central rod photoreceptors would be lost. Other studies have found 
that specific thinning in the ONL was seen in the ONL after retinal toxicity was induced in 
a rat model (Fielden et al., 2015). Parnell et al., (2012) reported Aβ plaque deposition in the 
ONL and other areas of the retina in an AD mouse model. So far, this study has reported 
that the ONL is significantly thinner in people with DS compared to age-matched control, 
found to increase in thickness with age, and be reduced in thickness in those with a diagnosis 
of dementia.  
The inferior quadrant of the RNFL was predicted as a particular area which may show 
changes associated with cognitive scores, as had been indicated in research in the typical 
developing population. Knoll et al., (2016) and  Shen et al., (2014) both found that thicker 
RNFL inferior quadrants correlated with poorer cognitive scores and cognitive decline. 
These studies suggest that some thicker areas of the retina could be associated with onset of 
dementia, just as Ascaso et al., (2014) found thicker macular in patients with MCI. The 
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results of this study did not find any correlations between the inferior quadrant and any of 
the cognitive tests or sub-tests.  
 
4.8.1 Limitations  
 Group size 
One of the main limitations from the findings is the very small number of participants in the 
dementia group. It was attempted to resolve the discrepancy in group sizes by creating a DS 
group without dementia who were age-and-IQ matched to the dementia group. The groups 
were successfully matched, however only three and four participants from the dementia 
group had completed the macular and posterior pole examinations. These small numbers 
may be the reason why it was not possible to see significant differences between the groups 
and would need to be replicated in a larger sample. Limitations in our recruitment strategies 
and other difficulties in recruiting older adults with DS and particularly those with dementia 
may have influenced this study. These considerations are discussed in more detail in the 
general limitations section (6.5.3).  
 
 Comparability of cognitive measures 
Cognitive measures used in sporadic AD research and those used in DS are not the same, 
therefore it is difficult to compare these measures. This study found no differences between 
CAMCOG scores in those diagnosed with dementia and those without, this could indicate 
that measures are not sensitive enough to pick up on small changes, individuals were 
wrongly diagnosed, or that disease progression in the individuals with dementia had not 
reached a point where cognitive function had been impacted. There are many different 
approaches taken to diagnosing dementia in people with DS, meaning that across studies 
there is inconsistency in the methodology applied (Nieuwenhuis-Mark, 2009). The semi-
structured informant interview used in this study is recommended by others (Nieuwenhuis-
Mark, 2009), however limitations that the interview results are a reflection of one person’s 
opinion of another person’s functioning level could have detrimental effects on the validity 
of the test results.   
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 Preferential sampling within people with DS 
Although the results of this study suggest that retinal thickness is not related to the extent of 
ID in people with DS, the majority of participants recruited for this study were considered 
to have a mild-moderate ID. This is likely due to our recruitment pool, particularly those 
who had taken part in previous studies with the CIDDRG and would therefore have ability 
levels to be able to comply with the requirements of the studies, and this study also required 
a level of cooperation that perhaps could not have been achieved in those with 
severe/profound ID. Had the study captured a wider range of ID it is possible that different 
results would have been reported.  
 
4.9 Conclusion 
Results of this study showed that, generally, there were no associations between retinal 
thickness measures and IQ or cognitive performance. These findings are generally in 
agreement with research in typically developing patients with AD, which have mostly found 
no relationship with MMSE. However in this study, an augmented relationship was expected 
in the DS group due to the high prevalence of dementia onset and predictable cognitive 
change after a certain age. Retinal areas, including the inferior and superior RNFL quadrants, 
which have been explicitly linked to cognitive change in the typically developing 
population, were not shown to be affected in the DS group.  
Non-significant thicker fovea and thinner ONL were found in the DS group with dementia, 
when compared to the age-and-IQ-matched DS participants without dementia. As discussed 
in the limitations, a study involving higher numbers of adults with a diagnosis of dementia 
will be necessary to provide more conclusive evidence. One of the main issues with 
assessing dementia through changes in behaviour and personality is that this method is only 
able to capture the later stages of the disease, when clinical assessment has been made. Other 
technologies, such as neuroimaging are able to provide data on the onset of AD pathology, 
rather than clinical dementia. 
 
 
 
126 
 
 
127 
 
Chapter Five: 
Retinal and cortical thickness relationships in the presence 
and absence of brain amyloid-beta binding 
5.1 Chapter introduction 
In this chapter, exploratory analyses are undertaken in a subset of retinal imaging study 
participants with Down’s syndrome (DS) who had also taken part in a previous brain 
imaging study within our research group (Defeat Dementia in Down’s syndrome (DiDS)). 
Neuroimaging data using magnetic resonance imaging (MRI) and positron emission 
tomography (PET) to investigate measures of cortical thickness and binding potential of Aβ 
in the brain were collected as part of this collaborative study. This study was conducted two 
years prior to the optical coherence tomography (OCT) study. Participants included in the 
analyses of this chapter completed at least one retinal scan and the brain imaging 
assessments.  
 
5.2 Background 
Alzheimer’s disease (AD) manifests in changes which are predominantly seen in the brain, 
including amyloid-beta (Aβ) deposits and neural atrophy, which can be visualised using 
neuroimaging methods such as PET and MRI. A full confirmation of AD can only be made 
during a post-mortem examination; however neuroimaging techniques are able to provide 
evidence of AD pathology. Pathology is visible in the brain many years prior to onset of 
clinical changes, neuroimaging allows for detection at a much earlier disease stage than 
neuropsychological tests (Lim et al., 2016). The eye, and through it the retina, is the only 
organ of the body that has the same embryological origins as the brain and can be imaged 
non-invasively. Studies in patients with sporadic or late-onset AD have investigated whether 
changes in the eye are linked with AD related brain pathology. Confirmation of a reflection 
of brain pathology in the retina would enable easier screening and may augment the 
diagnosis of probable AD, in addition to identifying an easily accessible site for monitoring 
the outcomes of future treatment trials. In people with DS, there is a unique model of Aβ-
driven AD, which is far less likely to be complicated by aetiological heterogeneity of ageing 
as is seen in the typically developing population.  
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MRI provides detailed measurements of regional and whole brain tissue thickness and 
volume and can be used to quantify brain atrophy, a hallmark of neurodegenerative diseases. 
Patients with AD have reduced hippocampal and entorhinal cortex volumes, reduced grey 
matter and cortical thickness and eventual whole brain measurement reduction (Jack et al., 
2009, 2010). PET imaging has been developed to be highly specialised in the detection of 
Aβ and tau pathology (Bateman et al., 2012). Pittsburgh compound [11C] (PIB) is one of 
several PET radioligands that bind to fibrillar Aβ. Using this technology, Aβ plaques have 
been identified in typically developing adults over the age of 70 years, up to 10 years before 
typical clinical onset of dementia. Magnitude and spatial extent of fibrillar Aβ are associated 
with older age and the genetic risk for late onset AD (Mintun et al., 2006). Neuroimaging 
and neuropathology studies have shown that AD pathology presentation in people with DS 
is very similar to that seen in the typically developing population, (Leverenz & Raskind, 
1998; Mann, 1988; Mann & Esiri, 1989), and that Aβ binding is found in the brain before 
onset of cognitive or functional decline (Annus et al., 2016; Handen et al., 2012; Hartley et 
al., 2014). The principle difference in the DS population is that presence of AD 
neuropathology in the brain is almost certain during the fourth decade (Mann, 1988), 
regardless of future onset of dementia. In a proof of principle study in people with DS all 
participants over the age of 45 years had positive PIB binding (Landt et al., 2011), whilst 
other studies have shown positive binding universally after the age of 39 years (Annus et al., 
2016), and 50 years (Hartley et al., 2014). 
Analysis completed in this chapter will combine retinal imaging data and neuroimaging data 
in the same participants with DS. In transgenic AD mouse model research, Aβ plaques in 
both the brain and retina have been identified (Koronyo-Hamaoui et al., 2011; Tsai et al., 
2014). Koronyo-Hamaoui et al., (2011) quantified the extent of Aβ in the brains and retinas 
of a transgenic mouse model of AD and found that plaques were identifiable through 
curcumin staining at the age of 2.5 months in the retina, and at five months in the brain, 
hence retinal Aβ appeared to precede Aβ in the brain. This finding has not yet been 
confirmed, Chidlow, Wood, Manavis, Finnie, & Casson, (2017) were unable to support any 
findings of associations between brain and retinal pathology. One theory is that the 
sensitivity and increased resolution of OCT has simply allowed for earlier detection, rather 
than that plaques are forming in the retina earlier in the disease process. In either case, this 
study showed that there are advantages in imaging the retina in AD, and more sensitive 
imaging of Aβ would be valuable. A second part of the Koronyo-Hamaoui et al., (2011) 
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study included a small pilot study using post-mortem human tissue samples of patients with 
confirmed AD and probable AD. Findings of this study showed that there was abnormal 
deposition of Aβ in the retinas of the AD patients (using curcumin staining) compared to 
control retinas. Plaques seen in the retina reflected the presence of plaques in the brain. 
Retinal plaques were also seen in probable AD patients who were considered to be in the 
early stages of the disease at time of death. Retinal plaques seen in the probable AD patients 
were described as being more profuse than those which were seen in the brain, which 
supports the concept that retinal Aβ may manifest earlier in the retina. Frost et al., (2014) 
have shown that it is possible to distinguish between PIB positive and PIB negative binding 
groups based on presence of retinal Aβ. This study found that there was a strong correlation 
between the retinal Aβ index and brain Aβ burden identified using PET imaging (r= .762, 
p< .001).  
Changes in brain morphology can also been associated with retinal structure. The cortex 
shows progressive thinning with age in typically developing adults and further thinning in 
those with AD (Fortea et al., 2011). Sabuncu et al., (2011) found that thinning cortical 
regions are a sensitive marker of pre-clinical AD, with an acceleration period occuring 
during the early stages of the disease. Cortical thickness has been used to differentiate 
between AD, MCI and non-AD patients (Bakkour, Morris, & Dickerson, 2009; Desikan et 
al., 2009; Li et al., 2012). Macular volume reduction in patients with AD has been associated 
with reduced volume in the medial temporal lobe (Casaletto et al., 2017). Results of the 
collaborative brain imaging study showed that overall thicker cortical regions were seen in 
the DS participants  compared to age-matched controls (Annus et al., 2017). However, 
participants with DS who were also identified as PIB positive had thinner cortical measures, 
similar to age-matched typically developing controls, whereas the PIB negative participants 
had significantly thicker cortices than the control group. Cortical thinning patterns in the 
PIB positive group were identified as being similar to those seen in non-DS AD patients 
(Annus et al., 2017).  
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5.3 Aims 
The aim of this chapter is to assess whether the retina is reflective of the brain in relation to 
changes associated with the onset of AD pathology. Retinal thickness was examined 
between groups of adults with DS who are identified as having either positive or negative 
binding of Aβ in the brain as measured using PIB. Cortical thickness was correlated with 
retinal thickness and compared between the PIB groups.  
  
5.4 Hypotheses 
Hypotheses for this exploratory chapter are based on both literature from the typically 
developing population in AD and findings from the previous chapters of this thesis and the 
brain imaging study findings; 
 The retina in those participants with DS who have negative PIB binding will be 
significantly thicker compared to those who are PIB positive.  
 The retina in participants with DS who have positive PIB binding will be 
significantly thicker than the retinas of age-matched typically developing control 
participants.  
 There will be a positive correlation between the thickness of cerebral cortex and that 
of the retina. 
 
5.5 Methodology  
Full details of the retinal scans, data presentation, neuroimaging scans and analysis 
procedures can be found in Chapter Two, sections 2.7 and 2.9. 
The data collected in this chapter was completed in collaboration with another DS project in 
our research group, the aim of which was to investigate brain atrophy and Aβ binding in DS 
adults with relation to AD. This collaborative study used MRI and PET to image the brains 
of adults with DS over the age of 30 years. This project was conducted as part of the PhD 
theses of Dr Liam Wilson and Dr Tiina Annus.  
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Analysis in this chapter is completed in a subset of 18 DS participants who took part in the 
retinal and brain imaging components of both studies, comparisons to control groups are 
made for retinal thickness measures only.  
 
5.5.1 Study design 
Participants with DS were recruited for the brain imaging study via one of the following 
sources; clinical and social services for people with intellectual disabilities (ID) in England 
and Scotland, the Down’s syndrome association (DSA), social care providers such as the 
Home Farm Trust and Craegmoor, and, a number of clinicians in NHS Trusts across 
England. These services were actively involved in distributing information about the study 
to individuals with DS and their families.  
 
 Inclusion criteria 
Inclusion and exclusion criteria for the OCT study is as reported in section 2.5.4 Brain 
imaging study inclusion criteria comprised; 
 Aged 30 years or older 
 Diagnosis of DS 
 Mild to moderate learning disability 
 No contraindications for MRI scans 
 No co-existing psychiatric illness (e.g. depression), except dementia 
 No ferromagnetic implants or other contraindications to having an MRI scan. 
 
5.5.2 Participant demographics 
Participants included in the brain imaging study were over 30 years of age and had a 
clinically confirmed diagnosis of DS. Presence of co-existing active psychiatric illnesses, 
other than dementia, resulted in exclusion from the study. All participants were screened for 
MRI safety and individuals with irremovable metallic or ferromagnetic objects were 
excluded. In total, 18 participants were identified who had useable data from both studies. 
All participants signed informed consent forms allowing the use of data from both studies 
collaboratively. Participants were identified as either PIB negative or PIB positive based on 
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the results of the PET imaging of Aβ binding, stratification was completed as described in 
section 2.9.1.2. Demographics of participants whose data are included in these analyses are 
shown in Table 5.1. 
 
 N Sex  
Males, females 
Brain scan age 
(mean, range) 
Retinal scan age  
(mean, range) 
Brain imaging time 1 group 
PIB negative  12 8, 4 35.91, 35-46 38.66, 34-37 
PIB positive  6 3, 3 49, 39-55 51, 42-56 
Table 5.1 Demographics of DS participants who also completed imaging assessments 
 
In both groups there was a significant difference between ages of those in the negative and 
positive PIB groups (t16= 4.98, p< .001). This is expected due to the increased prevalence of 
Aβ deposition and AD in older age. There were no significant differences between the 
genders of the two groups (T1 χ= .468, p= .428). 
 
5.5.3 Neuroimaging scan procedure and analysis 
Section 2.9.1 includes a full description of the neuroimaging scans and analysis procedures 
used. In summary, two complimentary neuroimaging techniques were employed, MRI and 
PET.  
Participants with DS were scanned for 45 minutes using a three Tesla Siemens Verio MRI 
scanner with 12 channel head coil (Siemens AG, Erlangen, Germany). For all acquisitions 
the field of view was aligned in stereotactic space with the axial plane aligned to the anterior 
commissure – posterior commissure line and the sagittal plane to the interhemispheric 
fissure. For the T1-weighted structural MRI a magnetisation-prepared, rapid gradient-echo 
(MPRAGE) sequence was used. This allowed for good contrast between the grey and white 
matter, and the cerebrospinal fluid (CSF; Mugler & Brookeman, 1990). The following 
parameters were used: repetition time/ echo time/ inversion time/ flip angle = 2300ms/ 
2.29ms/ 900ms/ 9°, 176 slices and a voxel size of 1.0 x 1.0 x 1.0mm3.  
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For the purposes of the collaboration with this study, cortical thickness measures were 
analysed. Analysis was performed in FreeSurfer (version 5.3) and calculated using an 
estimated width of the cortical grey matter (the procedure used can be seen in; Dale, Fischl, 
& Sereno, 1999 and Fischl & Dale, 2000). Cortical regions were analysed in the temporal, 
parietal, frontal and occipital lobes for each hemisphere. Paired comparison tests were 
conducted to identify significant differences between the hemispheres (see appendix S), and 
data were combined across hemispheres, resulting in a single cortical thickness value for 
each cortical region. This methodological approach is in keeping with the analysis process 
of the retinal data. 
PET imaging was undertaken on a General Electrical Medical Systems advanced PET 
scanner with [11C]-PIB and took approximately 90 minutes. Acquired MRI data were used 
for the co-registration to the PET data. Statistical parametric mapping (version 8) was used 
to co-register the images and locate the regions of interest. Load and distribution of Aβ was 
investigated and participants were assigned to either PIB binding positive, or PIB binding 
negative groups. PIB positive groups indicated binding potential over two standards 
deviations of the PIB negative group and more than 0.2 binding level in the striatum. Details 
of the PIB classification are given in Annus et al., (2016).  
 
5.6 Results 
5.6.1 Retinal thickness in the presence and absence of brain Aβ binding 
 Retinal thickness comparisons between PIB groups 
The first aim for this exploratory chapter was to identify the differences between the retinal 
thicknesses of the PIB negative and PIB positive groups. It was predicted that the PIB 
positive group would show thinner retina than the PIB negative group. One-way ANOVAs 
were conducted between the two groups.  
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 N Mean ± SD  
Retinal region PIB negative, 
PIB positive 
PIB negative 
group 
PIB positive group p 
Global RNFL 12, 5 120.08 ± 13.25 117.6 ± 6.79 .700 
Fovea 10, 5 312.6 ± 21.59 325.9 ± 21.82 .283 
Macular inner ring 10, 5 362.59 ± 14.97 360.80 ± 18.19 .842 
Macular outer ring 10, 5 325.97 ± 12.56 316.83 ± 11.25 .193 
Inner retinal layers 10, 6 242.13 ± 12.31 232.64 ± 12.31 .155 
Outer retinal 
layers 
10, 6 78.04 ± 1.26 77.66 ± 2.15 .657 
Table 5.2 Results of one-way ANOVA assessment of retinal thickness between PIB 
negative and PIB positive groups. 
 
Results of the retinal thickness comparisons showed that between the PIB positive and PIB 
negative groups there were no significant differences, however in most regions the PIB 
positive group had lower average values than the PIB negative group. Only the fovea region 
in the PIB positive group had a thicker average mean than the PIB negative group. This trend 
implies that thinner retina in people with DS is associated with presence of Aβ in the brain; 
with larger groups a significant result between the retinal thicknesses may be seen.  In order 
to assess this, a sample size calculation was computed using G*Power (version 3.1.9.2; Faul 
et al., 2009) to determine the sample size required to show significant differences between 
the two groups. Assuming a large effect size of D=.08, α= .05 and power = .08 for a one-
tailed hypothesis it is recommended that a sample size of 21 participants per group is 
necessary to attain significant differences between the groups. The present study sample size 
falls well beneath this target in both groups. 
 
 Comparison between PIB groups in DS and age-matched controls 
The second part of this analysis will consider the differences between PIB groups and control 
participants age-matched to each of the groups since there was a significant difference 
between the ages of the PIB groups. To complete this analysis, groups formed of 10 control 
participants each were age-matched to the PIB negative and PIB positive group separately. 
There were no significant differences in age for the PIB positive group and their age-
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matched control group (t(14) = -.595, p = .561) or between the PIB negative group and their 
age-matched control group (t(20) = -.486, p = .633). Global average, macular regions and 
inner and outer layers of the retina were assessed for differences between groups; results of 
the independent t-tests are shown in Table 5.3.  
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 Mean ± SD Mean ± SD 
 
PIB negative DS 
group (n=12) 
Age-matched 
control group 
(n=10) p 
PIB positive DS 
group (n=6) 
Age-matched 
control group 
(n=10) p 
Global RNFL 120.08 ± 13.25 94.90 ± 6.09 < .001* 117.60 ± 6.79 97.7 ± 10.54* .002* 
Fovea 312.60 ± 21.59 275.20 ± 18.41 .001* 325.9 ± 21.82 268.70 ± 17.86* < .001* 
Macular inner ring 362.59 ± 14.97 343.90 ± 11.20 .005* 360.80 ± 18.19 339.34 ± 14.11 .025 
Macular outer ring 325.97 ± 12.56 304.44 ± 10.75 .001* 316.82 ± 11.25 298.10 ± 15.86 .036 
Average layers 316.6 ± 11.98 298.90 ± 11.33 .001* 310.33 ± 13.23 293.6 ± 14.05 .034 
Inner layers 242.13 ± 12.31 223.35 ± 11.33 .002* 232.64 ± 12.03 215.31 ± 12.97 .019 
Outer layers 78.04 ± 2.34 78.25 ± 2.38 .811 77.66 ± 2.15 78.24 ± 1.69 .554 
Table 5.3 Descriptive statistics of PIB negative and PIB positive DS groups’ retinal thickness compared to age-matched typically developing 
control groups. *indicates significant results to Bonferroni adjusted p-value in retinal thickness between PIB group and their age-
matched control group.  
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Figure 5.1 Scatterplot showing the outer macular thickness differences between PIB 
groups and age-matched control groups. 
 
Significantly thicker retina was identified in the PIB negative DS group compared to their age-
matched control group. This was significant in all regions apart from the outer layers of the 
retina. Conversely, the PIB positive DS group did not show significantly thicker retina than 
their age-matched control group in the majority of retinal areas, significantly thicker retinal 
measures were only seen in the global RNFL and fovea regions. All other regions were 
considered to be statistically similar in thickness to the control group. The scatterplot in Figure 
5.1 shows the outer macular thickness between the groups.  
* 
ns 
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Figure 5.2 Heyex produced colour map showing average retinal layer thickness differences 
between a PIB positive (a) and PIB negative DS (b) participant of similar age. 
Colour map represents thicker areas in warmer colours.  
 
Figure 5.2 demonstrates the thickness differences in the average of the total retinal layers 
between a PIB positive individual (male, 49 years (a)) and a PIB negative individual (male 45 
years (b)). The colour map indicates thicker areas in warmer colours. Specifically the macular 
region of the PIB negative individual appears to be thicker, with warmer colours (red and white) 
showing in the macular areas. Towards the optic nerve head (ONH) the colour map is much 
warmer in the PIB negative participant whilst the PIB positive shows a more uniform thickness 
surrounding the fovea. In the PIB negative participant the fovea region is clearly identifiable 
in green in the centre, indicating it is thinner than the surrounding macular, however for the 
PIB positive participant the fovea region is not easily distinguishable from the rest of the 
macular. This is an example between two participants of how the retina is different between 
PIB classifications in two individuals and is not generalizable to the whole group. 
 
5.6.2 Relationships between cortical and retinal thickness measures 
Bi-variate Pearson’s correlations tests between the retinal regions and the cortical thickness 
regions were conducted. Retinal regions including the RNFL, macular and retinal layers were 
correlated with the cortical areas, which include the average measures of each of the lobes, 
frontal, temporal, parietal, occipital and global cortical thickness. The average of both 
(a) (b) 
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hemisphere cortices are presented in data analysis in this section, paired comparison t-tests 
between the two hemispheres were conducted which found very strong associations between 
the paired lobes, although some significant differences between the hemispheres were 
identified (see appendix S).  
 
 Cortical thickness comparisons with RNFL thickness  
Results were completed in a top-down method, first correlating each of the cortical regions 
with only the global RNFL. There was a significant correlation found only between the 
temporal cortical thickness and the global RNFL thickness therefore quadrant analysis was 
only conducted for this region. Results are shown in Tables 5.4 and 5.5. 
 
 Global RNFL average thickness (n=18) 
Cortical region r p 
Global average thickness .319 .213 
Frontal lobe average thickness .294 .252 
Parietal lobe average thickness  -.021 .937 
Temporal lobe average thickness .610 .009* 
Occipital lobe average thickness .097 .710 
Table 5.4 Correlations between the global RNFL thickness and the average thickness 
measure of brain cortical regions.  
 
 Temporal cortical thickness 
r p 
Global RNFL .610 .009* 
Superior quadrant .606 .010* 
Inferior quadrant .376 .137 
Nasal quadrant .138 .598 
Temporal quadrant .365 .149 
Table 5.5 Correlations between the temporal cortex thickness and RNFL thickness 
measures. *Results significant to the Bonferroni adjusted p-value. 
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Quadrant analyses showed that the superior quadrant thickness was significantly correlated 
with the temporal cortical thickness. Figure 5.3 shows a large positive (r= .606) correlation 
indicating that thicker retina correlated with thicker cortical measures as was predicted.  
 
 
Figure 5.3 Scatterplot showing a significant positive relationship between global RNFL 
thickness and temporal cortical thickness. 
 
 Cortical thickness relationship with the macular  
There were no significant correlations between the thickness of the fovea, inner or outer 
macular rings and the thickness of any of the cortical regions. A trend towards significance was 
seen in the temporal cortical region with the macular outer ring (r= .591, p=. 020).  
 
 Cortical thickness relationship with the retinal layers  
The average thickness of all retinal layers significantly correlated with the thickness of the 
temporal cortical region (r= .620, p= .010) and no other cortical regions. The retinal layers were 
then segmented into the inner and outer layer compositions, the thickness of the inner layers 
was found to have a significant association with the temporal cortical thickness, (r= .611, p= 
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.012) whilst the outer layers showed no correlation (r=. 216, p= .421). The individual layers 
within the inner layers average were then analysed, results are shown in Table 5.6 
 
 Temporal cortical thickness 
 r p 
RNFL .556 .025 
GCL .703 .002* 
IPL .622 .010* 
INL .527 .036 
Table 5.6 Correlation statistics of the temporal cortical thickness measure with retinal 
inner layer thicknesses. *Results significant to the Bonferroni adjusted p-value. 
 
Within the inner retinal layers, the thickness of the GCL and IPL showed significant positive 
correlations with the temporal cortical thickness. Results from this section support our 
hypothesis that cortical thickness is positively correlated with retinal thickness. Interestingly 
the only region of the cortex to show significant associations with retinal thickness across all 
participants with DS was the temporal cortex.  
 
 PIB binding dependent relationships between cortical and retinal thickness 
Correlations between the temporal cortex thickness and several retinal regions have been 
identified in the previous section. This section will consider whether this correlation is 
impacted by PIB binding status. Global RNFL, macular regions and inner and outer retinal 
layer averages were computed against all four brain cortical thickness regions within each 
group.  
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 PIB negative group retinal thickness area  
Cortical thickness 
area 
Global 
RNFL 
(n=12) 
Fovea 
(n=10) 
Inner 
macular 
(n=10) 
Outer 
macular 
(n=10) 
Inner 
layers 
(n=10) 
Outer 
layers 
(n=10) 
Global cortex .501 -.041 .617 .622 .381 .218 
Frontal lobe cortex .531 -.078 .255 .399 .233 .152 
Temporal lobe 
cortex 
.689 .472 .775* .747 .801* -.033 
Parietal lobe cortex .108 -.241 .585 .365 .033 .260 
Occipital lobe 
cortex 
.095 -.199 .239 .295 .031 .373 
Table 5.7  PIB negative group correlations between retinal thickness and cortical 
thickness. *Results significant to the Bonferroni adjusted p-value. 
 
 PIB positive group retinal thickness area  
Cortical thickness 
area 
Global 
RNFL 
(n=5) 
Fovea 
(n=5) 
Inner 
macular 
(n=5) 
Outer 
macular 
(n=5) 
Inner 
layers 
(n=6) 
Outer 
layers 
(n=6) 
Global cortex -.691 -.917* -.819* -.433* -.226 .464 
Frontal lobe cortex -.695 -.899* -.878 -.529 -.320 .317 
Temporal lobe 
cortex 
-.615* -.802* -.577 -.194* -.057 .728 
Parietal lobe cortex -.730 -.942* -.833* -.459 -.166 .296 
Occipital lobe 
cortex 
-.256 -.563 -.372 .084 -.018 .647 
Table 5.8 PIB positive group correlations between retinal thickness and cortical thickness. 
*Results significant to the Bonferroni adjusted p-value. 
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For the PIB negative group the majority of the correlations between retinal and cortical 
thickness are positive. Again, the temporal cortex is most highly associated with retinal 
thickness, reporting significant positive correlations in the inner macular, and the inner and 
outer retinal layers. The outer macular was borderline significant at p= .013. Within the retinal 
layers, the temporal cortical thickness significantly correlated with the GCL thickness (r= .816, 
p= .004).  
In the PIB positive group the differences in correlations are very striking. In this group, there 
are very large negative correlations between retinal thickness and cortical thickness, which 
dominate through all retinal regions apart from the outer retinal layers. Although none of the 
correlations are significant this is most likely due to the small numbers in this group.  
Fisher’s r-to-z transformations were conducted to test for differences in the correlations 
between the groups in the correlation coefficients. Results identified that there were several 
correlations that were significantly different between the two groups. This was particularly 
prominent in the fovea region which showed no relationships in the PIB negative group and 
large negative relationships with cortical thickness for the PIB positive group. Inner and outer 
macular thickness measures showed differences between the relationships between groups, and 
the temporal lobe cortical thickness with global RNFL thickness also differed depending on 
PIB binding status.   
Data from this analysis suggests that thicker retina is associated with thinner cortex in people 
with DS who have positive PIB binding in the brain. In the PIB positive group, neuroimaging 
and retina analysis have both indicated thinner measures in comparison to the PIB negative 
group. Longitudinal studies assessing both retinal and cortical thickness would be required to 
understand how this relationship changed with time and the onset of dementia.  
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Figure 5.4 Disparity between inner macular thickness correlation with global cortical 
thickness between PIB negative and PIB positive groups.  
 
5.7 Summary of findings  
The aim of this exploratory study was to investigate the relationship between retinal and 
cortical thickness in adults with DS and to examine whether this was affected by the presence 
of Aβ binding in the brain. Results showed that there were positive correlations between retinal 
and cortical thickness, these were predominantly found in the temporal cortex. It was found 
that the PIB negative group showed significant positive correlations, whilst the PIB positive 
group displayed a shift towards negative non-significant correlations. These were significantly 
different from the correlations of the PIB positive group. Similar to findings of the 
neuroimaging study, PIB negative DS participants were found to have significantly thicker 
retina than age-matched controls, whereas PIB positive participants had statistically similar 
retinal thickness to their age-matched controls. Results imply that individuals who are PIB 
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positive may have thinner retina, although the PIB negative and PIB positive groups themselves 
were not significantly different in retinal thickness. In addition to this, cortical and retinal 
thickness correlations were found to be dramatically different between the PIB positive and 
PIB negative groups. Despite a trend towards retinal thinning in the PIB positive group, thinner 
cortex was associated with thicker retina in the PIB positive group, implying that there is 
increased thinning in the cortex compared to the retina. Interpretations of these results and 
limitations of the study are discussed below.  
 
5.8 Discussion 
The results of this study indicated that there is retinal thinning in people with DS when Aβ is 
detectable in the brain using PET neuroimaging. The retinal component of this study was 
conducted two years after the neuroimaging; therefore Aβ had been present in the brain for at 
least two years. As this is a cross-sectional study it is difficult to attribute a causal relationship 
as to whether there might be parallel and related processes that lead to both retinal and cortical 
change. However, these results do suggest that AD-related changes in the brain are in some 
way reflected in the retina in people with DS and future studies should consider this association. 
Results of this thesis have been unable to identify a link between retinal thickness and ageing 
in people with DS, which was surprising due to the natural age-related thinning seen in the 
typically developing population (Bundez et al., 2007; Guedes et al., 2003; Parikh et al., 2007; 
Poinoosawmy et al., 1997), and accelerated ageing seen in people with DS (Cossarizza et al., 
1990). As ageing is intertwined with AD in the DS population it was interesting to find that 
retinal thinning was identified in the PIB positive group, but not in older DS, which gives 
support to the idea that retinal changes are linked with the presence of Aβ, rather than a 
reflection of increasing age. Despite that there were no significant differences between retinal 
thickness of the PIB negative and positive groups, it was found that only the PIB negative 
group showed significantly thicker retina when compared to the age-matched control group. 
This result is similar to findings in the cortex which showed significantly thicker cortex only 
in the PIB negative group compared to controls.  
The PIB positive group showed statistically similar retinal and cortical thickness to their age-
matched control groups. It was not found that people with DS had accelerated age-related retina 
thinning, or even typical rates of retinal thinning, however, it is unlikely that people with DS 
are resistant to age-related changes and more likely that the retina is showing the effects of 
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ageing in a different way. Research in sporadic AD has found that cortical measures in patients 
with AD are thinner compared to healthy controls (Lerch et al., 2005) and patients with MCI 
(Bakkour et al., 2009; Desikan et al., 2009; Li et al., 2012). This indicates that cortical thinning 
could be a subtle measure of AD-related change. Becker et al., (2011) found that clinically 
normal elderly patients identified as PIB positive showed reduced cortical thickness, 
particularly in the parietal and cingulate regions. Unpublished data from the DiDS brain 
imaging study showed similar cortical thickness measures between the PIB positive and age-
matched control groups, whereas cortical thickness was significantly thicker in the PIB 
negative group compared to controls.  
Surprisingly, this study showed that specifically the temporal lobe was involved in correlations 
between retinal and cortical thickness. Given the direct links between the occipital lobe and 
vision, and that visual areas in the occipital cortex, such as Brodmann area 19 have been found 
to be reduced in people with glaucoma (Bogorodzki et al., 2014), it may have been more 
expected to find strong relationships in the occipital cortex, however no significant associations 
were found between the occipital cortex thickness and retinal thickness. The temporal lobes 
are involved in memory, and orientation (Dutton, 2003) and damage to this area can result in 
difficulties recalling visual stimuli, visual agnosia and prosopagnosia. In sporadic AD the 
temporal lobe is implicated, and also in frontotemporal dementia (Chan et al., 2001; Galton et 
al., 2001). The temporal lobe shows early signs of volume loss, which has been suggested as 
marking the beginning of the disease process (Kaye et al., 1997). Excessive atrophy in the 
temporal cortex may be influenced by the hippocampal region, which is located in the temporal 
medial lobe and is the first to have atrophy and test positive for Aβ plaques in late onset AD in 
the typically developing population.  
The brain in people with DS has been shown to be different in both volume and structure to the 
general population. Reduced volume is typically seen in total brain, frontal lobe and cerebellum 
(Lee et al., 2016; Mann, 1988; Pearlson et al., 1998), whilst larger percentage volumes have 
been seen in the parietal and occipital lobes (Beacher et al., 2010; Jernigan, Bellugi, Sowell, 
Doherty, & Hesselink, 1993).With ageing, greater reduction in brain volume is seen in people 
with DS than in typically developing controls (Beacher et al., 2010), however some have 
reported that the temporal lobes are spared from loss (Kesslak, Nagata, Lott, & Nalcioglu, 
1994; Strydom, Hassiotis, King, & Livingston, 2009). The temporal lobe, specifically the 
medial temporal lobe is often a particular focus in AD research as it is a well-known site of 
atrophy (Burton et al., 2009). The medial temporal lobe includes the hippocampal region, 
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which is heavily implicated in memory, particularly long term memory (Mormino et al., 2009), 
which is often more preserved in people with DS. In DS the hippocampus has been shown to 
be reduced in volume in comparison to the typically developing population (Aylward et al., 
1999; Kesslak et al., 1994; Strydom et al., 2009; Teipel et al., 2003). Reduced hippocampal 
volume has been associated both with increasing age in people with DS, and with dementia in 
people with DS compared to those without (Kesslak et al., 1994), which may lead to thinning 
of the temporal lobe.  
From the PET imaging results we know that the PIB positive group have Aβ burden in the 
brain, however we do not have any data on the Aβ burden in the retina. Previous studies in this 
area have found evidence of Aβ in the retinas of non-demented adults with DS (Rafii et al., 
2015) and Koronyo-Hamaoui et al., (2011) have reported Aβ deposition in the retina prior to 
its appearance in the brain in typically developing AD. As there is known overproduction of 
Aβ in people with DS it is more likely that Aβ is present in the retina of DS adults than controls, 
and particularly in those with DS who also show positive Aβ in the brain. This study has 
identified that the presence of Aβ in the brain appears to be associated with changes in the 
retina, although, due to the time lag between the two studies, it is impossible to say whether 
retinal changes preceded, coincided with, or occurred after positive Aβ burden in the brain. 
Longitudinal studies in people with DS may be able to provide information on the link between 
retinal thinning and Aβ in the brain, its association with the progression of dementia. Imaging 
people with DS is advantageous over retinal imaging in the typically developing population, 
where thinning of the retina could be caused either by AD pathology or typical ageing, in the 
DS group retinal thinning does not correlate with ageing. This difference in the mechanisms 
and course of AD pathology could help to screen for AD in people with DS both earlier and 
through more cost-effective methods if routine OCT examinations were in place in adults with 
DS.  
 
5.8.1 Limitations  
Time lag between studies 
One of the chief limitations of this study is that the neuroimaging and retinal imaging 
examinations were not completed in parallel. Neuroimaging studies were completed up to two 
years prior to the collection of the retinal data. Parallel data is vital if we hope to speculate on 
the trajectory of AD-related changes in the retina and whether any changes here can be seen 
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before changes in the brain, as has been suggested by some research in sporadic AD patients 
(Koronyo et al., 2012).  
In addition to the time lag, longitudinal studies measuring retinal changes over time are 
essential to monitor thickness changes. This study has reported that retinal thickness does not 
decrease with age in the DS population, however, this is based on cross-sectional data of a wide 
age range and not individuals and therefore these findings cannot truly measure age-related 
change. Combining retinal scans with longitudinal MRI and PET imaging will be necessary to 
show the true nature of the relationship between cortical and retinal thickness and how this 
changes during the onset of AD.  
 
Sample size 
Combining the useable data from both studies resulted in a much smaller number of 
participants than in the previous two chapters. This has the consequence of reducing effect 
sizes, diminishing significant results and the affecting the generalisability of the data. 
Particularly problematic was the stratification of participants into the PIB groups, as this 
resulted in only six participants in the PIB positive group. Many of the results in this group are 
seen as trends, which is possibly due to the fact that there were so few participants. Further 
studies with increased participant numbers would be required to validate these findings.   
 
5.9 Conclusion 
The results of this chapter have indicated that retinal thickness may be reflective of AD-related 
pathology in the brain. Results showed that temporal cortex thickness was positively correlated 
only with the retinal thickness of people with DS who had absence of Aβ binding in the brain. 
In those with positive Aβ binding it was shown that relationships with the temporal cortex were 
mostly inverted, although these were not significant. In comparing retinal thickness of the PIB 
negative and PIB positive groups, we were able to identify a trend towards thinner retinal areas 
in people with positive Aβ binding, although this appeared to be occurring later than cortical 
thinning. Although the two groups’ retinal thicknesses were not significantly different from 
one another, only the PIB negative group had significantly thicker retina than age-matched 
typically developing controls. Previous chapters have shown that the thickness of the retinal 
areas is not correlated with age; therefore this result is not simply showing age differences in 
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the DS retina, but appears to be related to the presence of amyloid in the brain. Due to the time 
lag between the two studies it is not possible to speculate on whether retinal thinning may 
precede brain Aβ, future studies and longitudinal assessment would be required to achieve this. 
However, a shift towards retinal thinning in people with DS may provide a marker of the 
progression of Aβ deposition in the brain, which would be an easier, more accessible way to 
screen those who should be recommended for neuroimaging evaluation.  
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Chapter Six: 
General Discussion 
6.1 Overall aims of the project 
The purpose of this study was to investigate retinal thickness in adults with Down’s syndrome 
(DS) as a marker of age-related change and Alzheimer’s disease (AD) pathology. To achieve 
this, optical coherence tomography (OCT) examinations of several retinal regions were 
undertaken in; adults over the age of 18 with DS, an age-matched typically developing group, 
and, an older comparison group. In order to assess the onset of dementia, cognitive ability and 
IQ were assessed using a range of neuropsychological tests and an informant interview. Finally, 
in a subset of participants with DS, relationships between retinal thickness and cortical 
thickness and presence of amyloid-beta (Aβ) binding were explored. Cortical thickness was 
measured using magnetic resonance imaging (MRI) and presence of Aβ was assessed in the 
brain using positron emission tomography (PET) as part of a collaborative project within our 
research group.  
The outcome of this study has the potential to recommend the retina as a marker of AD related 
change in people with DS. Using OCT, this could be more easily, effectively and economically 
imaged than current brain imaging technologies. This would provide a highly anticipated tool 
for screening for AD and for monitoring the efficacy of treatment trials.  
The aims of the study were:  
 To investigate retinal thickness in adults with DS in comparison to age-matched 
controls and an older age comparison group. 
 To assess the relationship between advancing age and retinal thickness in people with 
DS compared to the relationship seen in typically developing adults. 
 To evaluate the correlation between cognitive performance and retinal thickness in 
people with DS.  
 To correlate retinal thickness measures with cortical thickness measures in a subset of 
people with DS.  
 To identify differences in retinal thickness between individuals with DS with (a) a 
diagnosis of dementia and those without and, (b) a presence of Aβ binding in the brain 
and those without. 
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Primary hypotheses: 
 People with DS will have thinner retina than age-matched controls and will show more 
similar thickness to older age typically developing (non-demented) controls.  
 Retinal thinning will begin at a younger age in the DS group and will progress at a 
steeper rate. 
 Assessments of cognition will positively correlate with retinal thickness. 
 Cortical thickness will positively correlate with retinal thickness.  
 Individuals with DS with a diagnosis of dementia, and those with positive binding to 
Aβ in the brain will show thinner retinal measures than those without.  
 
6.2 Abstract of main findings 
Contrary to our initial hypotheses, this study found that the retina is significantly thicker in 
people with DS when compared to an age-matched control group,  in addition, the retina in 
people with DS does not show the expected age-related thinning seen in the typically 
developing population. Investigations with cognitive performance found that retinal thickness 
was not related to IQ or cognitive performance in people with DS, the latter being measured 
using tests sensitive to dementia related cognitive change. There were correlations found 
between retinal and cortical thickness, primarily the temporal cortical region was positively 
associated with RNFL and macular thickness. Individuals with DS who were identified as 
having dementia using the CAMDEX informant interview and as showing AD pathology in 
the brain displayed differences in retinal thickness compared to those who did not show 
evidence of AD. Those with dementia had thicker fovea and thinner outer nuclear layer (ONL) 
compared to individuals without evidence of dementia, whilst those with Aβ binding in the 
brain showed a shift towards thinner retina compared to those without Aβ binding.  
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Key findings 
Thicker retina in people with DS in comparison to age-matched typically developing controls 
and older comparison controls.  
Absence of a correlation between advancing age and retinal thinning in the DS group, with 
one exception of increased retinal thickening in the outer nuclear layer (ONL). 
No correlation between cognitive test performance and IQ with retinal thickness. 
PIB negative groups showed significantly thicker retinal measures than age-matched 
controls, whilst PIB positive groups did not show statistically thicker retinal than age-
matched controls.  
Temporal cortical thickness showed strong positive relationships with the PIB negative 
group retinal thickness, and no correlations or trends towards a negative relationship with 
the PIB positive group retinal thickness. 
Table 6.1  Summary of the key results of the thesis  
 
6.3 Exploration of findings 
6.3.1 Retinal thickness and ageing in adults with Down’s syndrome 
Studies in the typically developing population have found that patients with AD have 
significantly thinner retina when compared to age-matched non-AD populations (Bambo et al., 
2015; Garcia-Martin et al., 2016; Gunes et al., 2015; Iseri et al., 2006; Kang & Kim, 2013; 
Salobrar-Garcia, Hoyas, et al., 2015). People with DS have a very high prevalence for the early-
onset of dementia due to AD (Coppus et al., 2006; Holland, Hon, Huppert, Stevens, & Watson, 
1998; Visser, Aldenkamp, Van Huffelen, & Kuilman, 1997) and have signs of early ageing in 
many aspects of their lives (Oliver & Holland, 1986; Zigman, 2013). Based on this knowledge, 
it was predicted that adults with DS would have thinner retina when compared to age-matched 
typically developing controls, and that age-related thinning would start earlier in life and be 
more pronounced. Contrary to this hypothesis, the results of this study found that adults with 
DS had significantly thicker retina than both age-matched control participants and the older 
age comparison group. This finding was homogeneous across almost all areas of the retina. In 
addition to presenting with thicker retina, the DS group was also found not to show evidence 
of age-related thinning in the retina. In typically developing adults age-related thinning has 
been shown throughout life and to accelerate after the age of 50 years (Parikh et al., 2007). The 
control group data supported this research, showing a tendency towards thinning retina and 
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some areas of significant thinning when the groups were combined resulting in an age-range 
of 21-93. The absence of any age-related thinning in the DS group was particularly surprising 
as it is very unlikely that they would be resistant to ageing in the retina, people with DS 
typically experience accelerated ageing in most aspects of their physiology. It is therefore 
suggested that people with DS are experiencing ageing in the retina, but that it manifests in a 
different way to that which has been seen in the typically developing population.  
The majority of retinal thickness research conducted in AD patients has focussed on the 
peripapillary RNFL, and the four quadrants that this area is divided into. AD-related thinning 
has most consistently been attributed to the superior, and secondly the inferior quadrants in 
sporadic AD (Kesler et al., 2011; Lu et al., 2010; Polo et al., 2017). The expectations in this 
study were that these quadrants would be the first to show thinning in the DS group with 
increasing age and would show the most difference to the control groups. However, the 
findings were that the superior and inferior quadrants, as well as the temporal quadrant were 
significantly thicker in the DS group. Only the nasal quadrant did not show increased thickness 
in the DS group compared to controls. In sporadic, or late-onset, AD, the nasal quadrant has 
shown less thinning than other quadrants, it has been found that the nasal quadrant only ever 
showed significant change in AD alongside thinning in at least the superior quadrant and never 
independently (Kang & Kim, 2013; Kromer et al., 2014; Larrosa et al., 2014). As we showed 
that the nasal quadrant was statistically similar in the DS group to the control group it was 
predicted that this may be a reflection of thinning in this area in the DS group.  
This prediction was incorrect, this study found that no retinal areas showed thinning associated 
with age in the DS group. Control participants showed trends towards thinning retina and 
significant thinning in some retinal areas across the whole age sample, which serves as a 
verification that the methodology and analysis was not in some way responsible for these 
unexpected findings in the DS population. The ONL presented a positive correlational trend 
towards thicker values with increasing age, this correlation was significantly different to the 
negative correlation seen in the control group. A significant difference between the associations 
of the two groups implies that there is an opposite ageing effect occurring in the ONL in people 
with DS. The ONL is one of the outer retinal layers and is composed mainly of the 
photoreceptor cells; damage to this area is generally associated with apoptosis. Studies into 
apoptosis in the ONL have shown changes in Müller cell proliferation and gliosis as a result of 
the toxicity changes from apoptosis (Whiteley & Peiffer, 2002). Increased numbers of Müller 
cells and inflammation may be responsible for the increased thickening of this area of the retina, 
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although this would not explain why retinal thickening seemingly only occurs in this region. 
The ONL has not typically been analysed in research investigating sporadic AD. In one of the 
DS cross-sectional studies in children, significantly thicker outer retinal layers were seen in the 
DS children when compared to age-matched controls (O’Brien et al., 2015). Further delineation 
into individual layers was not undertaken and this was a cross-sectional study in a fairly limited 
age range (6-16 years) that could not provide data on changes with time or increasing age. 
However, this result is, in principle, supportive of our findings.  
 
6.3.2 Retinal thickness associations with cognition 
IQ and tests of cognition were conducted in this study and scores were correlated with retinal 
thickness measures in people with DS. IQ was assessed as a measure of cognitive development 
and neuropsychological tests as a measure of cognitive performance associated with the onset 
of dementia. Lower cognitive scores are indicative of cognitive decline, which may be 
attributable to dementia. As this was a cross-sectional study, cognitive scores across the sample 
are measured against retinal thickness, rather than cognitive change seen in individuals over 
time. Due to the extent of learning disability in people with DS it is difficult to disentangle 
lower cognitive scores associated with onset of dementia and those which are developmental 
in origin. IQ measures were included in this study to correlate cognitive development with 
retinal thickness. One of the suggestions for the thicker retina seen in people with DS was that 
this could be a developmental feature of the disorder. If this were the case, it may be possible 
to see an association between IQ and retinal thickness; furthermore, relationships between IQ 
and retinal thickness would suggest that IQ should be included as a confounding variable in 
people with DS during analysis of the retina. Results of these correlations found that no retinal 
areas were correlated with IQ suggesting that extent of learning disability is not a factor in the 
thicker retina seen in DS, this does not however rule out the possibility that a thicker retina 
could be a developmental characteristic of DS.  
It was predicted that cognitive performance would be associated with retinal thickness in DS 
as a measure of declining abilities linked to dementia. This hypothesis was formed on the basis 
of previous literature in patients with sporadic AD which has shown that poorer cognitive 
performance on the Mini Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 
1975) is associated with a thinner retina (Ascaso et al., 2014; Cunha et al., 2017; Garcia-Martin 
et al., 2014; Moreno-Ramos et al., 2013; Oktem et al., 2015; Trebbastoni et al., 2016). 
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However, the link between cognition and retinal thickness is debated, and some studies have 
shown no relationship between cognitive score and retinal thickness in AD (Eraslan et al., 
2015; Ferrari et al., 2017; Gao et al., 2015; Gharbiya et al., 2014; Gunes et al., 2015; Iseri et 
al., 2006; Kesler et al., 2011; Kirbas et al., 2013; Kromer et al., 2014; La Morgia et al., 2015; 
Paquet et al., 2007; Polo et al., 2017). Cognitive performance in the DS group was tested using 
two separate cognitive batteries, the CAMCOG and an executive test battery. No correlations 
were found between the IQ and cognitive measures and age. The majority of the retinal 
thickness measure also did not show any correlation with cognitive performance. The outer 
retinal layers thickness showed a significant association with the CAMCOG score, indicating 
that poorer cognition was correlated with thinner retina. This is supportive of the findings in 
sporadic AD and also particularly interesting as the ONL, which is one of the outer retinal 
layers, was found to show increased thickness with age. Although the expectation was that 
thinner retina would be associated with both increasing age and declining cognitive function, 
this was not found in people with DS. Finding no correlations between cognition and retinal 
thickness is not overly surprising as the results in sporadic AD have been very varied. In 
addition, research conducted in AD patients has typically focussed on identifying an 
association between the RNFL and cognition; therefore it is not altogether possible to relate 
the findings of this study to previous research. The results of this study suggest that other areas 
of the retina may also be associated with cognitive change in AD. It was predicted that people 
with DS would show a stronger relationship between cognitive scores and retinal thickness, 
based on our initial hypothesis that people with DS would have thinner retina. The unexpected 
result that people with DS have thicker retina which is unaffected by advancing age reduces 
the likelihood that a positive relationship with cognitive scores would be seen.  
 
6.3.3 Retinal thickness in the presence of brain Aβ  
Comparisons between DS with dementia and DS without dementia 
CAMDEX informant interviews were conducted with the parents or carers of participants with 
DS. The purpose of these interviews was to make a diagnosis of dementia. In this study, the 
retinal thicknesses of those identified as having dementia would be compared against those 
without any indication of dementia. Interviews were completed for all participants in this study; 
one CAMDEX result was inconclusive and removed from this analysis. Of the remaining 
participants, five were identified as having dementia. Further comparisons between the groups 
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were challenging as there were large differences between the dementia and no dementia groups. 
Results showed that there were differences between the two groups, and that the DS with 
dementia group displayed a thicker fovea than the DS without dementia group. Due to the 
disparity between the numbers of the two groups, a group of DS participants without dementia 
were age and IQ matched to the DS with dementia group, results of the matched groups showed 
that a trend towards thicker fovea in the dementia group was retained, although no longer 
significant. 
Exploratory analysis was conducted on the outer retinal layers, which had shown a significant 
increase in thickness with lower cognitive scores. The results of this analysis found that the DS 
with dementia had thinner ONL thickness than the DS without dementia group. The finding 
that the ONL was trending towards being thinner in the DS with dementia group was curious, 
particularly as the outer nuclear layer had previously been shown to increase in thickness both 
with older age, and lower cognitive scores, factors that increase the likelihood of dementia in 
people with DS and yet the ONL was not seen to be thicker in the DS with dementia group. As 
these were very small groups, it was not possible to generalise this result, however the 
trajectory of the ONL appears to be thus; thinner in people with DS showing gradual thickening 
with age, thicker in those with lower cognitive scores and thinner in those with clinical 
dementia (see Figure 6.1). An increase in retinal thickness prior to thinning may be an 
indication of inflammatory processes, which are seen in many neurodegenerative disorders. 
 
Figure 6.1 Exaggerated predicted trajectory of ONL thickness in relation to age and onset 
of dementia. 
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 Comparisons between DS with presence of brain Aβ and those without and further 
comparisons between retinal thickness and age-matched controls 
Presence of Aβ in the brain was measured using PET imaging. Stratification of the DS 
participants involved in this study resulted in 12 participants forming the PIB negative group 
(indicating binding potential below the threshold of that deemed necessary for positive amyloid 
binding), and six participants in the PIB positive group. Differences in retinal thickness 
between the two groups were investigated; the results showed that were no significant 
differences in retinal thickness, however, the retina appeared to trend towards being thinner in 
the PIB positive group. Further assessments against control retinal thicknesses were completed; 
these analyses found that only PIB negative participants showed significantly thicker cortical 
regions than age-matched controls. The PIB positive group showed statistically similar retina 
to the control group in almost every region examined, exempting the fovea and the global 
RNFL. Although the difference between PIB groups was not significant, there was a clear trend 
towards thinner retina in the PIB positive group. Significantly thicker fovea in the PIB positive 
group compared to controls is in agreement with the findings that the fovea was thicker in those 
diagnosed with clinical dementia.  
The results of both this and the neuroimaging study have suggested that there are thinner 
cortical and retinal measures in people with DS who have positive Aβ binding in the brain 
when compared to those without Aβ binding through comparisons to age-matched control 
groups. Whilst there was not a statistically significant result between PIB positive and PIB 
negative groups there is a suggestion that there is a loss of thickness in PIB positive 
participants. Future studies involving larger groups and specifically more people with DS with 
positive Aβ binding and clinical dementia would be needed to corroborate this theory.  
 
6.3.4 Cortical and retinal thickness associations 
Cortical thickness was assessed using PET neuroimaging as part of a collaborative study using 
a subset of the same participants as this study and was correlated with retinal thickness. The 
results of this previous neuroimaging study found that typically the cortex was thicker in people 
with DS compared to age-matched controls. The aim of this analysis was to identify whether 
the retina and the cortex were associated to the extent that thicker values in one correlated with 
thicker values in another. As previous results in this study had shown that people with DS 
presented thicker retina it was predicted that there would be a positive relationship between the 
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cortex and the retina. The thickness measures of the cortex were divided into each of the brain 
lobes for each hemisphere; the average thickness for both hemispheres was correlated with the 
average retinal thickness of both eyes. Results showed that there were significant positive 
correlations between the eye and the brain. Interestingly the temporal cortex was the most 
implicated in showing significant results with several different areas of the retina.  
Correlations between temporal cortical thickness and retinal measures were further 
investigated between PIB positive and PIB negative groups. The results of this analysis showed 
that the PIB negative group had strong positive correlations between the cortical and retinal 
thickness measures in almost every region. However, in the PIB positive group these 
correlations were different. It was seen that many of the correlations in the PIB positive group 
had shifted to negative correlations, suggesting that thinner temporal cortex was associated 
with thicker retina, particularly in the inner and outer macular. Whilst in the PIB negative 
group, thicker temporal cortex was always associated with thicker retina. None of the 
correlations in the PIB positive group were significant, although this may partly be due to the 
small numbers in this group. Analysis of the difference between the correlations of the groups 
found that there was a significant difference between the PIB negative and PIB positive group 
correlations suggesting significant change based on Aβ binding.  
 
6.4 Interpretation of results 
The results of this thesis have culminated into two main findings; (a) people with DS have 
thicker retina than typically developing controls without evidence of age-related thinning, and 
(b) that a shift towards retinal thinning is seen around the time that an individual presents with 
Aβ binding in the brain and presents with cortical thinning. Possible interpretations of these 
results are discussed below.   
 
6.4.1 Inflammation and Aβ in the retina 
Amyloid plaques 
The fact that people with DS have evidence of Aβ plaques in the brain by the age of 40 years 
is well established. It has been suggested that people with DS may also have early accumulation 
of Aβ in the retina, given the connection between the brain and the retina and the extent of 
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amyloidosis in people with DS. Rafii et al., (2015) has shown Aβ in the retinas of people with 
DS over the age of 30 years using in-vivo imaging technology. It is suggested that retinal 
amyloid may precede brain amyloid (Koronyo et al., 2012), and could be used as an early 
marker of AD pathology. In this thesis, retinal Aβ was not studied, however, it is proposed that 
the findings seen in retinal thickness may be a consequence of Aβ pathology both directly and 
indirectly, and therefore this methodology could provide a proxy measure of Aβ in the retina. 
As previously discussed, one explanation of the thicker retina seen in people with DS is that 
this is a developmental characteristic of people with DS. Cortical thickness has been shown to 
be thicker in people with DS compared to age-matched controls (Annus et al., 2017), which is 
supportive of this theory and the results of this study. However, previous OCT studies in people 
with DS to date have mainly been conducted in DS children, and these studies are inconclusive 
as to whether there are retinal differences compared to typically developing controls (O’Brien 
et al., 2015; Weiss et al., 2016). Even if it were the case that people with DS have a thicker 
retina as part of their phenotype, this would not explain how this study found that there were 
no age-related retinal thinning observations in the DS group. This latter finding was contrary 
to the retinal findings of the age-matched control group, and to the findings seen in age-related 
cortical thinning shown in many of the same DS participants (Annus et al., 2017). 
Morphometric studies in humans have shown that changes in early stages of AD are 
characterised by hypertrophy of the nuclear and cell bodies in the cortex (Fortea et al., 2010; 
Oh et al., 2009; West, Bach, Søderman, & Jensen, 2009), which has been linked to an early 
reaction as a result of Aβ deposition (Iacono et al., 2008, 2009; Riudavets et al., 2009). In the 
retina, very few studies have found an increase in RNFL and macular thickness with the onset 
of AD (Ascaso et al., 2014; Salobrar-Garcia, Hoyas, et al., 2015). Those that have both 
attributed increased thickness to very early changes in AD pathology. Ascaso et al., (2014) 
reports the finding of thicker macular only in patients with mild cognitive impairment (MCI), 
and that those with AD had significantly thinner retina than both controls and MCI patients. 
Findings in people with DS saw that the majority of retinal thinning was seen after the presence 
of Aβ identified in the brain supports this theory. In people with DS, there is increased 
likelihood that AD neuropathology has been evident for much longer and starts at a much 
younger age than in the typically developing population, therefore, seeing changes normally 
associated with the initial stages of AD for a prolonged period in people with DS may be 
reflective of the life-long overproduction of Aβ and subsequent effects. This is also supported 
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by findings that have suggested that people with DS can tolerate Aβ deposition without 
significant effects on their cognitive functioning (Hartley et al., 2014; Rafii et al., 2015). 
Research has shown that young children and adolescents with DS have evidence of Aβ in 
plasma (Mehta et al., 2007; Teller et al., 1996), and we know overproduction of Aβ continues 
through to adulthood as numerous studies have reported the presence of fibrillar Aβ and Aβ 
plaques in the brains of people with DS well before, and in the absence of, a clinical diagnosis 
of AD. Animals studies using transgenic mouse models of AD have shown that increased 
deposits of Aβ in the AD mouse brain (Gupta et al., 2016; Koronyo et al., 2012; Liu et al., 
2009; Ning et al., 2008; Perez et al., 2009a), which have not been correlated with retinal 
neuronal degeneration (Perez et al., 2009). Perez et al., (2009) considered the impact of retinal 
Aβ on retinal structure and found that presence of Aβ was not linked to degeneration of the 
retinal cells in the AD mouse. However, not all studies have shown evidence of positive Aβ in 
the mouse retina (Chidlow et al., 2017; Ho, Troncoso, Knox, Stark, & Eberhart, 2014). In 
human studies, retinal amyloid has been identified as a result of both post-mortem evaluation 
(Blanks, Schmidt, et al., 1996; Blanks, Torigoe, et al., 1996; Koronyo-Hamaoui et al., 2011), 
and more recently in in-vivo imaging (Koronyo et al., 2017). This in-vivo technology has the 
ability to image retinal amyloid deposits with curcumin and a scanning laser ophthalmoscope, 
a quantitative measure of increased curcumin fluorescence was constructed to form a 
calculation of retinal amyloid index. Koronyo et al. (2017) showed in a proof of principle study 
that the retinal amyloid imaging was increased 2.1-fold in patients with AD versus age-matched 
controls (p= .0031). To date, one study has investigated retinal amyloid in vivo in people with 
DS, this study identified numerous deposits of Aβ in the retinas of 12 non-demented adults 
with DS in comparison to age-matched controls (Rafii et al., 2015). This study identified the 
presence of retinal amyloid in all 12 DS adults, aged between 32 and 60 years. Retinal Aβ was 
detected even in the absence of positive Aβ in the brain. They were unable to correlate retinal 
Aβ with MRI, PET or cognitive data. Retinal thickness analysis was not completed; however, 
the results of this study might hypothesise that topography of the retina would be thicker in 
areas with Aβ deposits. The majority of research has found that AD pathology including Aβ is 
present in the retina of both animal and human models, which is supportive that the brain is not 
the only organ of the body AD in which AD pathology manifests.  
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Responses to amyloid  
A life-long overproduction of Aβ in the retina may directly lead to the increase in retinal 
thickness seen in this study; however, amyloid presence may also indirectly cause thickening 
of the retina. Aβ is toxic and its presence provokes an neuroprotective response, as Aβ is 
deposited in the brain, signals are sent which activate an immunoprotective response including 
inflammation and increased microglial activity (Dutescu et al., 2009; Gupta et al., 2016; 
Koronyo-Hamaoui et al., 2011; Tsai et al., 2014). Throughout development microglia play a 
fundamental role in remodelling the brain by removing redundant apoptotic neurons (Bessis, 
Bechade, Bernard, & Roumier, 2007; Calderó, Brunet, Ciutat, Hereu, & Esquerda, 2009). 
Microglia are able to recognize and respond to Aβ peptides, these cells exert a neuroprotective 
role through phagocytosis and clearing of soluble forms of Aβ (Mandrekar-Colucci & 
Landreth, 2010), however, in the case of Aβ plaques it has been reported that after increased 
migration towards the plaques, microglia are unable to degrade the amyloid (Majumdar et al., 
2008; Paresce, Chung, & Maxfield, 1997; Walker & Lue, 2005), possibly due to an 
inflammatory environment which hinders the microglial ability to engage in phagocytosis. This 
can pose further problems as microglia enters a state of frustrated phagocytosis, causing 
functional and phenotypic change in the microglia. The interaction of Aβ and microglia leads 
to a production of chemokines, and neurotoxic cytokines which are destructive to the CNS 
(Mandrekar-Colucci & Landreth, 2010) and may serve to increase later degeneration. 
In patients with AD, the appearance of Aβ in the brain coincides with activation of surrounding 
microglia. Microglia responds to Aβ deposition and accumulates within and around plaques 
(Luber-Narod & Rogers, 1988; Rogers, Luber-Narod, Styren, & Civin, 1988), potentially 
attempting phagocytosis. Physically, microglia increase in number and size in direct proportion 
to the plaque dimensions (Li, Bushnell, Lee, Perlmutter, & Wong, 1996; Liu et al., 2009; Perez 
et al., 2009) and are significantly more activated in AD patients (Cagnin et al., 2001; Edison et 
al., 2008). There is further support that microglia increase degeneration, despite the intent to 
remove Aβ, failure to do so results in inflammation. AD brains show increased levels of the 
inflammatory cytokines and chemokines produced during the interaction of Aβ and microglia. 
These have toxic effects on neurons and also insulin degrading enzyme levels, a key Aβ 
degrading protease (Mandrekar-Colucci & Landreth, 2010).  
Research in diseases such as optic neuritis and Leber hereditary optic neuropathy have found 
that swelling is followed by a reduction in cell count (Maresca, La Morgia, Caporali, Valentino, 
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& Carelli, 2012; Serbecic et al., 2011). In the retina, it has been suggested that swelling may 
represent a pre-apoptotic stage indicating imminent atrophy (Schmitz-Valckenberg et al., 
2009). Monocyte-chemotactic protein (MCP-1) attracts macrophages and microglia in retinal 
disorders, and inflammation from the over-expression of (MCP-1) has been shown in mouse 
models of AD as a direct response to retinal Aβ (Ambati et al., 2003; Davies, Eubanks, & 
Powers, 2006; Yoshida, Yoshida, Ishibashi, Elner, & Elner, 2003). Ning, Cui, To, Hsiao Ashe, 
& Matsubara, (2008) found that the accumulation of Aβ was not associated with a reduction in 
retinal thickness, which supports retinal stability with age in the DS population if Aβ is 
responsible for masking age-related thinning. In human patients, Ascaso et al., (2014) found 
evidence of thicker retina exclusively in patients with MCI, considered to be early stage AD. 
Retinal thickness in MCI patients was thicker than both controls and AD patients, implying 
that increased thickness is linked with early pathology. In this study, retinal changes in MCI 
were accredited to Müller cell swelling, another early response to inflammation. Müller cells 
support the survival of photoreceptors and neurons, and are responsible for the structural 
stabilisation of the retina and for modulating immune and inflammatory responses (Bringmann, 
Pannicke, et al., 2009). Müller cells have swelling properties and become activated by virtually 
all pathogenic stimuli (Bringmann, Iandiev, et al., 2009; Bringmann & Wiedemann, 2011). 
Reactive Müller cells are neuroprotective, but they may also stop supporting the neurons and 
begin contributing to neuronal degeneration. Reactive Müller cell gliosis is thought to represent 
a cellular attempt to protect the retinal tissue from damage and to promote retinal tissue repair 
(Bringmann, Pannicke, et al., 2009). The involvement of Müller cells in immune and 
inflammatory responses may have detrimental effects, after retinal injury the Müller cells 
upregulate inflammatory factors, which recruit phagocytic monocytes and macrophages and 
microglial cells to the injured area (Hollborn et al., 2008; Nakazawa et al., 2006). Müller cells 
draw water from fluid filled spaces outside of the neuroretina and therefore contribute to water 
influx and cell swelling (Pannicke et al., 2004; Reichenbach et al., 2007).  
Further support of swelling and inflammation in human patients with early AD is provided by 
Salobrar-Garcia et al., (2015) who found that sections of the RNFL showed increased 
thickening which was limited to those with mild-AD and projected to be an early phase of 
inflammation neural tissue prior to the degenerative process. This study assessed the RNFL by 
determining 12 sectors, rather than the more typically used quadrant system, and Ascaso et al., 
(2014) found MCI inflammation in the macular and not in the RNFL. Although the majority 
of studies have only reported an increase of thinning, in both patients with MCI and AD, it is 
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possible that subtleties in increased thickness may have been overlooked due to an 
overwhelming focus on the RNFL and quadrants. In this study, retinal thickness was increased 
across the entire DS age sample, unlike the seemingly short increased thickness seen in the 
MCI and mild AD patients. This would fit with the lifelong overproduction of Aβ in DS that 
promotes that gradual thickening is caused by Aβ and by inflammatory responses. It could be 
the case that the DS retina does in fact demonstrate thinning with age, with the natural loss of 
healthy cells, but that the overall increase in amyloid and Aβ responses are concealing the loss 
of healthy cells, resulting in a retina that seemingly does not change with age.  
 
6.4.2 Apoptosis of retinal cells 
Cell death is profoundly associated with neurodegenerative diseases and occurs via multiple 
pathways, one being apoptosis, which is a form of programmed cell death and is linked with 
neurodegenerative diseases such as AD. Apoptosis is a naturally occurring process vital to 
development, cell turnover and immune system functioning. The toxicity of Aβ causes stress 
to surrounding cells which results in induced apoptosis (Estus et al., 1997; Hitomi et al., 2004; 
Li et al., 1996; Tillement, Lecanu, & Papadopoulos, 2011). When the balance of apoptosis is 
upset, this can contribute to neurodegenerative disease, autoimmune disorders and cancers 
(Elmore, 2007). During apoptosis the cell undergoes morphological and biochemical changes, 
including cell shrinkage, chromatin condensation, membrane blebbing and degradation 
(Cordeiro, Migdal, Bloom, Fitzke, & Moss, 2011). After the process is completed the apoptotic 
bodies are immediately phagocytosed by neighbouring cells and macrophages, which avoids 
an inflammatory response in the apoptotic tissue (Williams & Smith, 1993; Wyllie, Kerr, & 
Currie, 1980). 
Increased apoptosis is seen in the retina during neurodegenerative disease (Elmore, 2007) and 
the onset of excessive apoptosis has been attributed to the toxic effects of Aβ accumulation, in 
addition to normal ageing factors (Li, Chan, Lai, & Yew, 1997). Excessive apoptosis eventually 
leads to cell shrinkage and cell loss, and is considered at least partly responsible for the high 
neuronal cell death in AD, and other retinal diseases such as glaucoma (Barinaga, 1998; 
Shimohama, 2000). Apoptosis has been confirmed in post-mortem AD brain tissue, in mouse 
models (Ning et al., 2008) and in human brains. Smale, Nichols, Brady, Finch, & Horton, 
(1995) found evidence of apoptosis in seven of eight AD patients’ brains tested, and only 
minimal evidence in one of four control brains. More recently, a novel in vivo method, 
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Detection of Apoptosing Retinal Cells (DARC), has been used in a triple transgenic mouse 
model of AD (Cordeiro et al., 2010). This  model, developed by Cordeiro et al. (2010) is the 
only model with both Aβ and tau neuropathology (Sensi, Rapposelli, Frazzini, & Mascetra, 
2008). In this model there is an early accumulation of intra-neuronal Aβ, which is most similar 
to the development of disease in patients with DS (La Ferla, Green, & Oddo, 2007). Data 
showed that there was a low level of apoptotic cell death occurring in normal healthy ageing 
mice, whilst in the AD mice there were significant increases in the relative numbers of retinal 
ganglion cells in early-phase apoptosis.  
Apoptosis assists in the removal of the dead cells by providing membrane coated vesicles, 
which are easily phagocytized. The removal of the apoptotic cells is crucial to preventing the 
spread of their contents into the environment (Paus, Rosenbach, Haas, & Czarnetzki, 1993). In 
people with DS the phagocytosis function has been suggested to be less efficient than in the 
typically developing population. Barkin, Weston, Humbert, & Sunada, (1980) determined in a 
study of 14 DS children that there was a diminished response in phagocytosis, a finding which 
was later supported in further studies in children (Licastro et al., 1990 and Wysocki, Wysocki, 
& Wierusz-Wysocka, 1987). The gene Dryk1a, which is located on chromosome 21 and 
triplicated in people with DS, has been suggested as prohibiting the natural process of apoptosis 
(Laguna et al., 2013). This study showed that removal of the additional copy of Dryk1a reduced 
the thickness of the retinal layers in a DS mouse model and therefore it is suggested that 
inhibition of apoptosis in the retina leads to increased retinal thickness. Conversely, Novo, 
Garcia, & Lavergne, (1993) did not find a difference in the phagocytosis functioning levels of 
12 children with DS compared to matched controls. Novo et al. (1993) indicated that the reason 
for differences between these studies could be attributed to the diverse range of methods used 
to assay the phagocytic process. In this study we saw increased thickness in the retinal layers 
of people with DS, which may be attributable to depositions of Aβ, and through this, increased 
levels of apoptosis. Apoptosis is linked with increased inflammation and, if apoptotic cells are 
not effectively cleared due to reduced phagocytosis functionality, there could be an increased 
build-up of apoptotic cell bodies in the DS retina disguising the cell loss.  
In people with DS, it is more likely than in any other population that AD is driven by Aβ and 
therefore resulting in pathology triggered by Aβ toxicity. Retinal Aβ seen in DS retinas (Rafii 
et al., 2015) further support this case. Increased rates of apoptosis are initially accompanied by 
an inflammatory response, and eventually results in cell loss and subsequently thinner retinal 
layers (Thomson, Yeo, Waddell, Cameron, & Pal, 2015). This sequence of events could explain 
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how the retina in people with DS showed stability of thickness until a certain point in the AD 
pathology, from which time a shift towards thinner retina was seen.  
 
6.5 Limitations 
6.5.1 Potential confounds 
Confounds of this thesis primarily stem from the common comorbidities with AD in people 
with DS, including age and developmental cognitive ability (IQ). Age is particularly 
problematic in the study of AD in DS, there is debate as to whether AD is an inevitable feature 
of ageing in DS (Ritchie & Kildea, 1995). It is impossible to ignore that there is a strong link 
between DS and AD and a certainty that people with DS will develop AD pathology (Ball et 
al., 2006;  Holland et al., 1998; Mann & Marcyniuk, 1987). Many changes in people with DS 
leading to clinical onset of dementia can also be viewed as an exacerbated ageing phenomenon. 
Therefore it is often difficult to control for age in DS research without subsequently controlling 
for dementia. Whilst this is certainly a challenge, this study did not find a relationship between 
ageing and retinal thickness in people with DS. However, there may be other age-related factors 
effects and processes resulting in a maintained retinal thickness with increasing age.  
Retinal thickness was not found to correlate with cognitive performance in this study, it was 
also established that developmental cognitive ability was not related to retinal thickness. It is 
possible that people with DS may have characteristically thicker retina. The findings of this 
study are not conclusive that retinal thickness is not in some way linked to the extent of ID in 
people with DS, the majority of participants recruited for this study were considered to have a 
mild-moderate ID. Had the study captured a wider range of ID, including those with severe and 
profound ID, we may have seen different results. 
Co-morbidity of retinal diseases is one of the most challenging factors to research completed 
in those with sporadic or late-onset AD. Ageing is a risk factor not only for AD but also retinal 
diseases such as glaucoma and age-related macular degeneration (AMD), both of which have 
similar presentation to the symptoms identified as AD-related. One of the principal benefits of 
the DS population is that they have almost 100% assurance of the development of AD-related 
pathology, unlike the typically developing population, therefore there is a higher assurance that 
changes seen in the eye are related to AD rather than a retinal disease. Presence of glaucoma, 
AMD and other retinal diseases were excluded in this study. 
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6.5.2 Sample size and completion of OCT examinations 
The sample size target for this study was originally 30 participants with DS and 30 healthy 
controls. This is well within the sample ranges seen for OCT studies investigating AD in 
typically developing patients and larger than those which have used OCT in children with DS. 
The study had a low dropout rate; however, due to some difficulties in the completion of retinal 
examinations, the sample size was increased to 50 participants. This increase negated the loss 
of data due to movement and fixation issues. Due to this data loss, not all participants have a 
full set of retinal scans, this proved to be increasingly problematic as participants were 
subdivided into smaller groups, such as those with a confirmation of dementia or those with 
positive Aβ binding in the brain.  
One of the difficulties for future research will be participant selection, although it was not 
investigated in depth, failure to fixate, excessive eye movements etc. did not appear to directly 
correlate with either age or IQ, thereby it will be challenging to predict which participants will 
struggle with imaging prior to assessment.  
 
6.5.3 Recruitment challenges 
There are numerous issues surrounding the recruitment of people with DS for research, which 
often leads to preferential sampling and recruitment of a particular “type” of individual who 
volunteers for research studies. Individuals with more severe learning difficulties are less likely 
to declare an interest in taking part in research, these individuals are also unlikely to be able to 
cooperate with the demands of research studies, which leads to over-recruitment of individuals 
with DS with mild-moderate ID, and an under-representation of those with severe/profound 
ID. In addition to this, there is the possibility that this study has seen a “cohort effect” in the 
older adults that were recruited to the study. Those with DS who survive into their 50s may be 
protected against age-related changes and dementia onset.  
This study found difficulties in the recruitment of older adults with DS; this was due to several 
factors. Firstly, our recruitment procedure was greatly assisted by the Down’s syndrome 
association (DSA), which was formed in 1970. From this date, DS births were automatically 
registered with the DSA. Due to this, there would have been many individuals over the age of 
45 who were not approached through this avenue (as of 2015, when this study began 
recruitment). Secondly, those over the age of 50 years are substantially more likely to have 
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clinical dementia, which impacts on the individual’s health, personality and mobility. 
Participants were required to make a trip to either Cambridge or London to undergo testing, 
which may have been difficult in those with poor health or reduced mobility. Furthermore, 
people with DS are typically supported by their parents or carers, older individuals with DS 
will have quite elderly parents, who may be unable to support them with travel. Those who are 
supported by carers also present difficulties, as often care homes are not equipped to provide 
one-to-one support and off-site assistance.  
Authorities often feel the need to restrict access to individuals with ID in order to protect them, 
as a vulnerable group, from exploitation and/or harm. These restrictions, whilst they can be 
necessary, can also result in ID groups being under-represented and understudied in research. 
The counter-argument to the view that vulnerable groups should be shielded from research, 
particularly when capacity to consent is uncertain, is that people with ID have the right to 
choose whether they would like to participate, and should therefore be given the option to 
refuse (Lai, Elliott, & Ouellette-Kuntz, 2006). By not including individuals with ID, we are 
potentially denying a group of people from the benefits that might arise from the research 
(Oliver et al., 2002). This is particularly relevant in AD related research, as people with DS 
have higher rates of AD diagnosis than any other population group and arguably more to gain 
from research and treatment trials in AD. Researchers in CIDDRG have undertaken studies 
investigating the effects of taking part in research on people with ID and their opinions of 
research (D’Abrera, Holland, Landt, Stocks-Gee, & Zaman, 2013). This study reported that 
generally people with ID enjoy taking part in research; they find it interesting and like the idea 
of helping other people in the future, even when there is no direct benefit to them.  
 
6.5.4 Multiple-comparison corrections 
As the areas of the retina were highly correlated with each other there was a strong possibility 
that significant results could have been seen by chance. To account for this the Bonferroni 
correction was applied to all data throughout all analyses that reduced the p value in order to 
increase certainty of a statistically significant result. Applying the Bonferroni correction 
reduced the acceptable significance value from the uncorrected p< .05 to p< .012, p< .007 and 
p< .005 dependent on the retinal region and the number of comparable areas within each one. 
The Bonferroni correction controls for alpha error and is considered to be the gold standard for 
169 
 
multiple comparison corrections (Reuter & Montag, 2016). Having applied the Bonferroni 
correction and only reported significant results as those which met the revised criteria it is 
presumed that multiple correction concerns are resolved.   
 
6.5.5 Generalisability 
As with all research, there are limits as to how far the findings of the study can be extended. In 
the case of this study a population of adults with DS and typically developing adults were 
approached to take part in a study that had no benefits to the individual for taking part, including 
no payment. The participants involved in the study are self-selecting and it must be noted that 
there could be particular traits of people who take part in research without any benefits to 
themselves. There is a limited age range in this research, adolescents and children were not 
studied. Based on the findings of potentially developmentally thicker retina in people with DS 
it would be beneficial to study these groups in the future. Upper age range is fairly well 
represented in this study as participants were recruited close in age to the average life 
expectancy in DS (60 years; Bittles & Glasson, 2004), however fewer participants in the 50s 
age bracket were recruited than any other decade. In the control group an older age comparison 
group was recruited to compare DS to older age as well as matched age in order to further 
assess the accelerated ageing effects in the retina.  
 
6.6 Developing the research 
6.6.1 Key improvements for future studies 
Based on the limitations discussed in both this chapter and the limitation sections of the results 
chapters there are several key areas where improvements could be made to benefit future 
studies in this area.  
 Changes to the imaging protocol;  
▪ For the DS cohort it would be recommended that two OCT examinations were 
conducted, with a break in between. This is because some participants may 
benefit from a “practice” and the best quality scans from both sets would be 
analysed.  
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▪ In an attempt to improve the percentages of usable scans it would be 
recommended to standardise the order of the retinal imaging, particularly 
starting with the same eye in each participant so that more usable data from the 
same areas could be gathered.  
▪ More controlled environment of the examination, such as reducing the number 
of people in the room and more guidance on not distracting the participant 
during the scan.  
  Increased focus on the recruitment of older adults with DS and particularly those with 
clinical dementia in order to increase the numbers in these groups, and the statistical 
reliability of analysis.  
 Longitudinal retinal imaging to assess age-related change more accurately. 
 Brain and retinal imaging to run within a more succinct time frame. 
 
6.7 Future directions 
6.7.1 Detection of apoptosing retinal cells 
As part of a phase II clinical trial, a study investigating rates of retinal apoptosis in vivo in 
people with DS was conducted in June 2017. The data for this study was gathered as part of 
this PhD but due to delays in the project start date it was not possible to analyse and incorporate 
the findings into this thesis. The purpose of the DARC study was to investigate the natural rates 
of apoptosis in people with DS compared to several other populations; healthy controls, 
patients with optic neuritis, patients with glaucoma and patients with age-related macular 
degeneration (AMD). Rates of apoptosis observed in people with DS were quantified and 
would be assessed with relation to age, AD diagnosis and cognitive decline. Analysis between 
the OCT and DARC data investigating a link between retinal thickness and rates of apoptosis 
will also be investigated. Sixteen people with DS were included in this study, 14 of whom had 
previous OCT scans and therefore longitudinal OCT data was collected for these participants, 
cross-sectional OCT data was collected from the other two participants.  
Apoptosis is a natural process of cell death and renewal, which increases gradually with age. 
Increased levels of apoptosis have been studied alongside the onset of neurodegenerative 
disease and can be induced by the presence of Aβ, excessive apoptosis eventually leads to 
irreparable cell loss. As a proxy measure for amyloid in the retina this study predicted that (a) 
there would be more apoptosis in the retinas of the DS group when compared to the control 
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group, and, (b) rates of apoptosis would increase with age and with a clinical diagnosis of 
dementia. This study has the potential outcome of being able to provide a marker for AD related 
change, and a technology which has the ability to be utilised in the monitoring of future 
treatment trials targeting both Aβ and cell degeneration which could then be seen with greater 
ease than current brain scanning technology. 
 
6.7.2 Investigating Aβ and further retinal features in Down’s syndrome and 
Alzheimer’s disease 
As part of the Deep and Frequent Phenotyping study in patients with AD, a retinal imaging 
component has been approved that will also be conducted in people with DS. I have received 
funding to begin this project in people with DS commencing in March 2018. The imaging 
protocol of this study includes many components that are of particular interest in the DS 
population. Firstly, OCT examinations will be conducted which will both increase the cross-
sectional sample of this study and provide longitudinal assessments of those who volunteer for 
this study, at this time some participants could have a total of three longitudinal OCT 
assessments over a period of five years. This will allow us to examine the peripheral retina 
using ultra-wide field imaging. Crucially, Aβ imaging in the retina will be investigated using 
NeuroVision imaging technology.  
Direct comparison with both a typically developing control group and an AD patient group will 
be conducted as part of this study. As part of another ongoing study in the CIDDRG, 
Neuropsychological Assessment of Dementia in Individuals with Intellectual Disabilities, 
participants with DS will undertake longitudinal MRI and PET assessments over a five-year 
period. The intentions of this study will be to correlate retinal data where possible for those 
participants who volunteer for both studies.  
 
6.8 Final conclusions 
In conclusion, this thesis aimed to assess retinal thickness in adults with DS and relate this to 
AD through further investigations of the effects of retinal thickness with age, 
neuropsychological test performance, and onset of AD as measured by clinical assessments 
and Aβ-beta binding data. To achieve these aims, the study measured the RNFL, macular and 
posterior pole retinal thicknesses, including individual layers for the posterior pole using OCT. 
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The thesis then correlated these results with age, performance on neuropsychological tests and 
cortical thickness. Comparisons of retinal thickness between groups were assessed including; 
comparisons between DS and age-matched typically developing adults and older age adults 
and between DS groups identified as having positive Aβ binding in the brain and negative Aβ 
binding. 
The findings of this thesis have revealed surprising results about the thickness of the retina in 
DS and its resistance to normal age-related thinning. In addition, areas of retinal thinning have 
been associated with those with positive Aβ binding in the brain indicating that presence of Aβ 
in at least the brain is reflected in a change in retinal thickness. The findings of this study have 
opened many other possible avenues of study, and have laid the groundwork for at least two 
studies, one recently completed and another due to start in 2018. The presence of soluble Aβ 
in the eye may not be directly indicative of AD, but would provide a useful marker in a 
treatment trial. Measures of apoptotic cell death in the retina are a more direct measure of an 
endpoint in the AD process. The results of these proposed studies will provide further insight 
into the effects of AD pathology on the retina in people with DS and will further evaluate the 
use of multiple retinal imaging methodologies tools for the investigation of early AD-related 
changes in people with DS and for monitoring the results efficacy of treatment trials.  
This study has attempted to answer the question of whether retinal thickness may be used as a 
biomarker in establishing early AD-related change in people with DS. Results of the analyses 
with the PET data have suggested increased retinal thinning after Aβ binding is established in 
the brain, this indicates that retinal changes occur after brain pathology has manifested. 
However, in this study, people with DS were found to show thicker retina throughout life, the 
cause of which is not yet understood. There is a possibility that there is a point at which the 
retina begins to increase in thickness in people with DS that could be representative of other 
AD-related pathology. Further studies are required to determine the nature of the thicker retina 
in people with DS in order to understand the potential of the retina as a marker in AD.  
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Appendices 
 Ethics committee approval 
  
NRES Committee East of England - Cambridge Central  
Royal 
Standard 
Place  
Nottingham  
NG1 6FS  
 Telephone: 
0115 
8839309  
:  
03 November 2014  
  
Miss Madeleine J. Walpert  
Cambridge Intellectual and Developmental Disabilities Research Group  
Department of Psychiatry, University of Cambridge  
Douglas House, 18b Trumpington Road, Cambridge  
CB2 8AH  
  
Dear Miss Walpert   
  
Study title:  Retinal cell degeneration as biomarkers in the eyes: a proof 
of concept study in people with Down's syndrome, a high 
risk population for Alzheimer's disease  
REC reference:  14/EE/1118  
Protocol number:  1  
IRAS project ID:  135131  
  
Thank you for your letter of 07 October 2014, responding to the Committee’s request for 
further information on the above research and submitting revised documentation.  
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The further information has been considered on behalf of the Committee by the Chair.   
  
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three 
months from the date of this opinion letter.  Should you wish to provide a substitute 
contact point, require further information, or wish to make a request to postpone 
publication, please contact the  
REC Manager, Miss Jessica Parfrement,  
NRESCommitte.EastofEngland-CambridgeCentral@nhs.net.  
  
Confirmation of ethical opinion  
  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below.  
  
Mental Capacity Act 2005  
  
I confirm that the committee has approved this research project for the purposes of the 
Mental Capacity Act 2005. The committee is satisfied that the requirements of section 
31 of the Act will be met in relation to research carried out  as part of this project on, or 
in relation to, a person who lacks capacity to consent to taking part in the project.   
  
  
  
Conditions of the favourable opinion  
  
The favourable opinion is subject to the following conditions being met prior to the start 
of the study.  
  
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned.  
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Management permission ("R&D approval") should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements.  
  
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance 
should be sought from the R&D office on the information it requires to give permission 
for this activity.  
  
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation.   
  
Sponsors are not required to notify the Committee of approvals from host organisations  
  
Registration of Clinical Trials  
  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees).    
  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details 
as part of the annual progress reporting process.  
  
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory.  
  
If a sponsor wishes to contest the need for registration they should contact Catherine 
Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions to 
be made. Guidance on where to register is provided within IRAS.   
  
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable).  
  
Ethical review of research sites  
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NHS sites  
  
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see "Conditions of the favourable opinion" below).  
  
Approved documents  
  
The final list of documents reviewed and approved by the Committee is as follows:  
  
Document    Version    Date    
Copies of advertisement materials for research participants 
[Healthy control recruitment poster]   
1   15 August 2014   
Covering letter on headed paper [Cover letter]      15 August 2014   
Evidence of Sponsor insurance or indemnity (non NHS 
Sponsors only) [Provisional insurance letter]   
1   13 August 2014   
GP/consultant information sheets or letters [GP letter for DS ]   1   15 August 2014   
GP/consultant information sheets or letters [GP letter for pilot]   1   15 August 2014   
GP/consultant information sheets or letters [GP letter for 
healthy controls]   
1   15 August 2014   
IRAS Checklist XML [Checklist_20102014]      20 October 2014   
Letter from funder [Funding confirmation letter]   1   10 March 2014   
Letters of invitation to participant [Letter of invitation to pilot 
study]   
1   15 August 2014   
Letters of invitation to participant [Invitation letter for 
participants new participants]   
1   15 August 2014   
Letters of invitation to participant [Invitation letter for 
participants involved in previous studies]   
1   15 August 2014   
Other [Certificate for DS participants]   1   15 August 2014   
Other [End of study letter]   1   15 August 2014   
Other [Nominated consultee information sheet]   2   14 October 2014   
Other [Personal Consultee Declaration form]   3   20 October 2014  
Other [Nominated consultee declaration form]   3   20 October 2014   
Participant consent form [Consent form for pilot study]   3   20 October 2014   
Participant consent form [Consent form for DS participants for 
main study]   
1   30 September 
2014  
Participant consent form [Consent form for previous DS 
participants for main study]   
2   20 October 2014   
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Participant information sheet (PIS) [Participant information 
sheet for those involved in previous studies, non easy-read 
version]   
3   20 October 2014   
Participant information sheet (PIS) [Participant info booklet - 
previous participants ]   
1  30 July 2014   
Participant information sheet (PIS) [PIS for pilot study non-
easy read version]   
2   20 October 2014   
Participant information sheet (PIS) [Participant information 
sheet for new participants, non easy-read version]   
3   20 October 2014   
REC Application Form [REC_Form_18082014]      18 August 2014   
REC Application Form [REC_Form_14102014]      14 October 2014   
Research protocol or project proposal [Protocol]   1   15 August 2014   
Response to Request for Further Information [Response to 
Response Not Complete]   
   14 October 2014   
Response to Request for Further Information      07 October 2014   
Summary CV for Chief Investigator (CI) [Miss Madeleine 
Walpert CV]   
1   15 August 2014   
Summary CV for student [Miss Madeleine Walpert CV]   1   15 August 2014   
Summary CV for supervisor (student research) [Prof Holland 
CV]   
1   15 August 2014   
Validated questionnaire [Paper for the validation of the Arizona 
cognitive test battery. Questionnaire cannot be provided for 
copyright reasons]   
      
Validated questionnaire [SIB]         
Validated questionnaire [CAMDEX]         
Validated questionnaire [Addenbrooke's cognitive examination 
revised]   
      
Validated questionnaire [CAMCOG ]         
Validated questionnaire [Paper for the validation of the Oliver 
memory test. Questionnaire cannot be provided for copyright 
reasons]   
      
Other [Participant Information Sheet easy-read for pilot study]  2  30 September 
2014  
Other [Participant Information Sheet easy-read for new 
participants]  
2  30 September 
2014  
Other [Participant Information Sheet easy-read for previous 
participants]  
2  30 September 
2014  
Other [Participant Information Booklet for new participants]  1  15 August 2014  
Other [Participant Information Booklet for pilot study]  1  15 August 2014  
Participant Consent Form [Healthy control]  1  15 August 2014  
Participant information sheet (PIS) [Personal consultee]  2  14 October 14  
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Statement of compliance  
  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
  
After ethical review  
  
Reporting requirements  
  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
  
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The HRA website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures.  
  
User Feedback  
  
The Health Research Authority is continually striving to provide a high quality service 
to all applicants and sponsors. You are invited to give your view of the service you have 
received and the application procedure. If you wish to make your views known please 
use the feedback form available on the HRA website:  
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/     
  
HRA Training  
  
We are pleased to welcome researchers and R&D staff at our training days – see details 
at http://www.hra.nhs.uk/hra-training/    
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14/EE/1118                          Please quote this number on all correspondence  
  
With the Committee’s best wishes for the success of this project.  
  
Yours sincerely  
  
Chair Mrs Carolyn Read  
  
Email:NRESCommitte.EastofEngland-CambridgeCentral@nhs.net   
  
Enclosures:    “After ethical review – guidance for  
      researchers” SL-AR2  
  
Copy to:  Sponsor/R&D Contact - Mr Stephen Kelleher  
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 Participant information sheet for people with Down’s syndrome (full version) 
Cambridge Intellectual and Developmental Disabilities Research Group  
PARTICIPANT INFORMATION SHEET       
Eye investigations in Down’s syndrome 
We would like to ask you if you are interested in taking part in a research study. This study 
aims to investigate the link between Down’s syndrome and Alzheimer’s disease by looking at 
images of the eyes. In this study we will be using optical coherence tomography (OCT) 
scanning technology, which is used in everyday eye tests at opticians. We are interested in 
seeing whether this technique can be used to show changes in the eyes which might be able to 
indicate signs of memory problems. We would like to ask you to read this information 
explaining what the research study involves and why it is being undertaken.  
If you are interested in taking part we will arrange to meet you to discuss the study in more 
detail and you can ask any questions you have about the study. 
This study is being undertaken by Maddie Walpert as part of a doctoral training programme, 
which is supervised by Prof Tony Holland and Dr Shahid Zaman.  
 
 
What is the purpose of this study? 
People with Down’s syndrome have a high risk of developing Alzheimer’s disease early in life. 
Brain scan studies have shown that there may be a link between the changes we find in the 
brain and changes shown in the retina at the back of the eye. The retina is an extension of the 
brain and we believe it likely that Alzheimer’s disease related changes could be seen here early 
in the disease development, and by using less invasive methods. It is very important to try and 
identify signs of Alzheimer’s disease as early as possible so that new therapies can be 
introduced which would have the most effect on slowing the disease. The goal of this study is 
to develop new ways of identifying markers of Alzheimer’s disease at an early stage in 
development, which will help the development of treatment strategies. 
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What will happen if I take part in this study?  
If you would like to take part in this study, you will be asked to sign a consent form to say that 
you understand what will happen during the study and that you agree to take part. You can still 
withdraw from the study at a later stage. 
You will be asked to complete some memory puzzles and games and we will also ask your 
main carer, or the person who knows you best, to answer some questions about you. You and 
your carer will be asked to come to the hospital for an eye examination using an optical 
coherence tomography (OCT) scan; which will take around 10 minutes and will require us to 
dilate your pupils using an eye drop which will increase visibility during the scan. OCT scans 
are used in everyday eye tests at the opticians. You will be asked to stay as still as possible and 
look at a flashing blue light while we take pictures of the eyes. We may also need to take a 
small sample of blood to test for genetic risk factors associated with memory problems in 
Down’s syndrome.   
We would like to notify your GP that you are taking part in the study. We will also ask your 
GP for any confirmation of Down’s syndrome tests results they may have and for a copy of 
your latest thyroid test. If anything unusual if found during any aspect of our investigations we 
would inform your GP of this.  
 
Will my involvement be confidential? 
Any information about you that we collect from this study will be fully anonymised and kept 
in secure locked filing cabinets. Your name will not be used on any of the data and only 
members of the research team will be able to see this data. All research information is 
confidentially stored for 15 years after which it will be disposed of securely.  
Blood samples and data collected during this study will be stored securely and may be re-
visited in future studies. Your name will not be attached to these samples or data and will 
remain anonymised.  
 
Will you cover the costs of taking part in this study? 
Yes, we will reimburse all travel costs to and from the hospital; we will also cover any food 
and drink costs while you are visiting the hospital.   
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What are the risks and benefits of taking part?  
There are few risks involved in taking part in this study. The eye examinations will be 
conducted by a trained ophthalmologist and will feel very similar to when you go to the optician 
for a normal eye test.  These scans may take a little longer as we will be taking high-resolution 
images of the back of the eyes but they are not at all invasive. The eye drop we will use to 
dilate your pupils contains tropicamide which is safe although it may cause slight blurred 
vision, which would wear off shortly after. The blood sample will be taken by a medical 
professional and as with any blood sample there may be some discomfort involved, this should 
not last more than a few seconds and we will do everything possible to make this as comfortable 
as possible.  The benefits to taking part are that you will help us learn more about the 
progression of Alzheimer’s disease in people with Down’s syndrome and we hope that this will 
lead to the development of new drugs which can treat Alzheimer’s disease at an early stage.  If 
we find anything irregular in your eyes we would be able to inform you and your GP 
immediately.   
 
Do I have to take part?  
No, it is entirely your decision whether you would like to take part in this study. You can 
withdraw at any time the study at any time and this will not affect your current or future 
treatment.   
 
What if something goes wrong? 
If you wish to complain about any aspect of the way you have been treated during this study 
you can contact the Patient Advice and Liaison Service (PALS), Addenbrooke’s: 01223 
216756, Western Eye Hospital: 020 3312 7777.  This study has been approved by the 
Cambridgeshire Research Ethics Committee, and it will then be possible for this research to 
have insurance cover for negligent and non-negligent harm under the University’s Clinical 
Trials policy.   
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Contact for further information 
If you have any questions before, during or after the research please contact Maddie Walpert, 
who is leading the research, or Professor Tony Holland and Dr Shahid Zaman, who are 
supervising the research.  
Madeleine Walpert   01223 746172   mjw208@medschl.cam.ac.uk 
Dr Shahid Zaman   01223 746100   shz10@medschl.cam.ac.uk 
Prof Tony Holland   01223 746112   ajh1008@medschl.cam.ac.uk 
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 Participant information sheet for people with Down’s syndrome (easier-read version) 
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 Picture booklet for people with Down’s syndrome  
What is this study about? 
We want to investigate why some people with Down’s syndrome get memory 
problems as they get older.   
 
 
 
 
 
 
 
 
 
 
We think we might be able to see changes in the eyes that will tell us what is 
happening in the brain.  
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What will happen? 
We will do some tests with you first which will be like those you have when you get new glasses 
We will ask you to read some letters 
 
We will look in your eyes to check for cataracts 
 
We will ask you to stare at an object and then follow an object with your eyes 
After this we will put a special eye drop in your eyes which will make the scan easier 
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Optical coherence tomography (OCT) scanner 
We will use this special scanner to take photographs of the back of your 
eye  
This will take about 5 minutes and you will need to try and stay still and 
look straight ahead 
We will ask you to focus on a flashing blue light  
 
 
 
The pictures we take of your eye will look like this one here.  These 
pictures will show us things that are happening at the back of your eyes  
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Memory puzzles 
We will also do some memory puzzles with you and ask you questions about 
things you like to do.  
We would also like to ask your parent or carer questions about the things 
that you do. 
 
 
We may also wish to take a blood sample to test for risks associated with 
dementia, if we do, this would be taken by a trained healthcare professional 
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Who is involved in the study? 
This project is being led by Maddie and is supervised by Prof. Tony Holland 
and Dr. Shahid Zaman 
You will also meet Dr. Eddie Normando who will be taking the pictures of 
your eyes  
Contact information 
This booklet is designed to give you some more information about the study. 
The decision to take part is entirely up to you. If you would like to speak to 
somebody about the study you can contact Maddie 
 
 
 
 
You can also check out our website for details of all our studies www.defeatdementiainds.com 
  
01223746172 
 
mjw208@cam.ac.uk 
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 Consent form for participants with Down’s syndrome 
Cambridge Intellectual and Developmental Disabilities Research Group 
CONSENT FORM 
Study title: Optical coherence tomography assessments in people with Down’s syndrome, the 
link between the eyes and dementia 
Please read through the following statements carefully and initial in the corresponding 
box if you agree 
 
I confirm that I have read and understand the information sheet  
 
date........................................., version number............... 
 
 
I have been able to ask questions and discuss the study  
 
I understand that my participation is voluntary and that I can leave the study at any time, 
without giving any reason and that my care and legal rights will not be affected.  
 
I consent to take part in this study  
 
I understand that parts of my medical notes may be looked at by individuals on the research 
team. I give permission for these individuals to have access to my records.  All the data 
collected in this study will be anonymised and stored securely for up to 10 years.  
 
I consent to the research team contacting my GP to inform him/her of my participation in 
this study  
 
 
 
I consent to have a blood sample taken 
 
 
I am happy for my anonymised data to be used in other studies  
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I consent to the research team contacting me about future studies that I may be interested 
in taking part in. 
                                   
 
Full name:  
  ........................................................................................................... 
   
Date: 
  ...........................................................................................................  
Signature: 
  ........................................................................................................... 
 
To be completed by the researcher 
Full name:   .......................................................................................................... 
 
Date:   .......................................................................................................... 
 
Signature: .......................................................................................................... 
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 Personal consultee information sheet   
Cambridge Intellectual and Developmental Disabilities Research Group  
PERSONAL CONSULTEE INFORMATION SHEET        
We have written to ask N if s/he would be interested in taking part in a research study.  This 
study aims to investigate the link between Down’s syndrome and Alzheimer’s disease by 
looking at images of the eyes. We feel that N may be unable to decide for him/herself about 
whether to take part in the study. As N’s main carer, or person who knows them best, we would 
like to ask you to read this information explaining what the research study involves and why it 
is being undertaken.   
If you decide that N would like to take part in this research you will be asked to sign the personal 
consultee declaration form, N can still withdraw from the study at any time and this will not 
affect his or her care in any way. If you have any concerns or think that N should be withdrawn 
from the study, please let us know. If you are unsure about taking on the role of consultee you 
may seek independent advice. We will understand if you do not want to take on this 
responsibility.   
  
Eye investigations in Down’s syndrome  
This study is investigating age changes in the eyes using an optical coherence tomography 
(OCT) scan, which are used in everyday eye tests at opticians. We are interested in seeing 
whether this technique can be used to show changes in the eyes which might be able to indicate 
signs of memory problems.  
This study is being undertaken by Maddie Walpert as part of a doctoral training programme, 
which is supervised by Prof Tony Holland and Dr Shahid Zaman.   
  
What is the purpose of this study?  
People with Down’s syndrome have a high risk of developing Alzheimer’s disease early in life. 
Brain scan studies have shown that there may be a link between the changes we find in the 
brain and changes shown in the retina at the back of the eye. The retina is an extension of the 
brain and we believe it likely that Alzheimer’s disease related changes could be seen here early 
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in the disease development, and by using less invasive methods. It is very important to try and 
identify signs of Alzheimer’s disease as early as possible so that new therapies can be 
introduced which would have the most effect on slowing the disease. The goal of this study is 
to develop new ways of identifying markers of Alzheimer’s disease at an early stage in 
development, which will help the development of treatment strategies.  
  
What will happen if N takes part in this study?   
If N does take part in the study s/he will be asked to complete some memory tasks to assess 
his/her memory function, we will also ask N’s main carer, or person who knows them best, to 
answer some questions about N’s behaviour and personality. N will be asked to come to the 
hospital for an eye examination using an OCT scan; which will take around 10 minutes.  OCT 
scans are used in everyday eye tests at the opticians, and it will be very likely that N has seen 
this machine before. You would be welcome to stay in the room with N during the eye 
examination. N will be seated front of the machine which will have a chin and forehead rest, 
s/he will be asked to stay as still as possible and fixate their gaze on a flashing blue light while 
we take pictures of his/her eyes. We would also take a small sample of blood to test for genetic 
risk factors associated with memory problems in Down’s syndrome.    
We would like to notify N’s GP that s/he is taking part in the study and we would ask for 
consent to do this. We will also ask N’s GP for any confirmation of Down’s syndrome tests 
results they may have and for a copy of N’s latest thyroid test. If there are any complications 
during the eye examination we would write to the GP to inform them. Any information about 
N that we collect from this study will be fully anonymised and kept in secure locked filing 
cabinets. N’s name will not be used on any of the data and only members of the research team 
will be able to see this data. All research information is confidentially stored for 15 years after 
which it will be disposed of securely.   
  
Will you cover the costs of taking part in this study?  
Yes, we will reimburse all travel costs to and from the hospital; we will also cover any food 
and drink costs while you are visiting the hospital.    
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 What are the risks and benefits of taking part?   
There are few risks involved in taking part in this study. The eye examinations will be 
conducted by a trained ophthalmologist and will feel very similar to when N goes to the optician 
for a normal eye test. These scans may take a little longer as we will be taking highresolution 
images of the back of N’s eyes but they are not at all invasive. The blood sample will be taken 
by a medical professional and as with any blood sample there may be some discomfort 
involved, this should not last more than a few seconds and we will do everything possible to 
make this as comfortable as possible.    
The benefits to taking part are that N will help us learn more about the progression of 
Alzheimer’s disease in people with Down’s syndrome and we hope that this will lead to the 
development of new drugs which can treat Alzheimer’s disease at an early stage. If we find 
anything irregular in N’s eye we would be able to inform you and your GP immediately.    
  
What if something goes wrong?  
If N or yourself wishes to complain about any aspect of the way you have been treated during 
this study you can contact the Patient Advice and Liaison Service (PALS) 01223 216756.  This 
study has been approved by the Cambridgeshire Research Ethics Committee, and it will then 
be possible for this research to have insurance cover for negligent and non-negligent harm 
under the University’s Clinical Trials policy.    
  
Contact for further information  
If you have any questions before, during or after the research please contact Maddie Walpert 
who is leading the research, or Professor Tony Holland and Dr Shahid Zaman, who are 
supervising the research.  
Madeleine Walpert     01223 746172     mjw208@medschl.cam.ac.uk  
Dr Shahid Zaman     01223 746100     shz10@medschl.cam.ac.uk  
Prof Tony Holland     01223 746112     ajh1008@medschl.cam.ac.uk  
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  Personal consultee declaration form 
Cambridge Intellectual and Developmental Disabilities Research Group  
PERSONAL CONSULTEE DECLARATION FORM   
Eye investigations in Down’s syndrome  
1. I (name of consultee……………………………………………………….…………) 
have been consulted about (name of potential participant 
……………………………………………………………………) taking part in this 
research study. I have had the opportunity to ask questions about the study and I 
understand what is involved.  
  
2. In my opinion (name of potential participant 
………………………………………………………………) would have no objection 
to taking part in the above study. 
  
3. I understand that I can request that s/he is withdrawn from the study at any time, without 
giving any reason and without his/her legal rights being affected.   
  
4. I understand the relevant sections of his/her medical notes and data collected during the 
study may be looked at by responsible individuals from the Cambridge Intellectual and 
Developmental Disabilities Research Group or by collaborative researchers or 
regulatory authorities where it is relevant to my taking part in research.  
  
5. I agree to the GP of the person named being informed of their participation in this study.  
  
6. I consent to the research team keeping samples taken during the study for additional 
testing and future studies.  
  
7. I consent to the research team looking at data from previous studies the named person 
may have been involved in with this research group  
  
8. I agree to the Down’s syndrome research group contacting the person named above 
about future studies.  
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________________________    ________________    ________________________  
Name of Consultee      
  
 
 
Relationship to participant:   
  
  
  
Date        Signature  
________________________    ________________    ________________________  
Name of Researcher      Date        Signature  
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 Nominated consultee information sheet 
Cambridge Intellectual and Developmental Disabilities Research Group  
NOMINATED CONSULTEE INFORMATION SHEET        
We have written to ask N if s/he would be interested in taking part in a research study.  This 
study aims to investigate the link between Down’s syndrome and Alzheimer’s disease by 
looking at images of the eyes. We feel that N may be unable to decide for him/herself about 
whether to take part in the study. As a person or professional who knows N well, we would 
like to ask you to read this information explaining what the research study involves and why it 
is being undertaken.   
If you decide that N would like to take part in this research you will be asked to sign the 
nominated consultee declaration form, N can still withdraw from the study at any time and this 
will not affect his or her care in any way. If you have any concerns or think that N should be 
withdrawn from the study, please let us know. If you are unsure about taking on the role of 
consultee you may seek independent advice. We will understand if you do not want to take on 
this responsibility.   
  
Eye investigations in Down’s syndrome  
This study is investigating age changes in the eyes using an optical coherence tomography 
(OCT) scan, which are used in everyday eye tests at opticians. We are interested in seeing 
whether this technique can be used to show changes in the eyes which might be able to indicate 
signs of memory problems.  
This study is being undertaken by Maddie Walpert as part of a doctoral training programme, 
which is supervised by Prof Tony Holland and Dr Shahid Zaman.   
  
What is the purpose of this study?  
People with Down’s syndrome have a high risk of developing Alzheimer’s disease early in life. 
Brain scan studies have shown that there may be a link between the changes we find in the 
brain and changes shown in the retina at the back of the eye. The retina is an extension of the 
brain and we believe it likely that Alzheimer’s disease related changes could be seen here early 
  
233 
 
in the disease development, and by using less invasive methods. It is very important to try and 
identify signs of Alzheimer’s disease as early as possible so that new therapies can be 
introduced which would have the most effect on slowing the disease. The goal of this study is 
to develop new ways of identifying markers of Alzheimer’s disease at an early stage in 
development, which will help the development of treatment strategies.  
  
What will happen if N takes part in this study?   
If N does take part in the study s/he will be asked to complete some memory tasks to assess 
his/her memory function, we will also ask N’s main carer, or person who knows them best, to 
answer some questions about N’s behaviour and personality. N will be asked to come to the 
hospital for an eye examination using an OCT scan; which will take around 10 minutes.  OCT 
scans are used in everyday eye tests at the opticians, and it will be very likely that N has seen 
this machine before. You would be welcome to stay in the room with N during the eye 
examination. N will be seated front of the machine which will have a chin and forehead rest, 
s/he will be asked to stay as still as possible and fixate their gaze on a flashing blue light while 
we take pictures of his/her eyes. We would also take a small sample of blood to test for genetic 
risk factors associated with memory problems in Down’s syndrome.    
We would like to notify N’s GP that s/he is taking part in the study and we would ask for 
consent to do this. We will also ask N’s GP for any confirmation of Down’s syndrome tests 
results they may have and for a copy of N’s latest thyroid test. If there are any complications 
during the eye examination we would write to the GP to inform them. Any information about 
N that we collect from this study will be fully anonymised and kept in secure locked filing 
cabinets. N’s name will not be used on any of the data and only members of the research team 
will be able to see this data. All research information is confidentially stored for 15 years after 
which it will be disposed of securely.   
  
Will you cover the costs of taking part in this study?  
Yes, we will reimburse all travel costs to and from the hospital; we will also cover any food 
and drink costs while you are visiting the hospital.    
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 What are the risks and benefits of taking part?   
There are few risks involved in taking part in this study. The eye examinations will be 
conducted by a trained ophthalmologist and will feel very similar to when N goes to the optician 
for a normal eye test. These scans may take a little longer as we will be taking highresolution 
images of the back of N’s eyes but they are not at all invasive. The blood sample will be taken 
by a medical professional and as with any blood sample there may be some discomfort 
involved, this should not last more than a few seconds and we will do everything possible to 
make this as comfortable as possible.    
The benefits to taking part are that N will help us learn more about the progression of 
Alzheimer’s disease in people with Down’s syndrome and we hope that this will lead to the 
development of new drugs which can treat Alzheimer’s disease at an early stage. If we find 
anything irregular in N’s eye we would be able to inform you and your GP immediately.    
  
What if something goes wrong?  
If N or yourself wishes to complain about any aspect of the way you have been treated during 
this study you can contact the Patient Advice and Liaison Service (PALS) 01223 216756.  This 
study has been approved by the Cambridgeshire Research Ethics Committee, and it will then 
be possible for this research to have insurance cover for negligent and non-negligent harm 
under the University’s Clinical Trials policy.    
  
Contact for further information  
If you have any questions before, during or after the research please contact Maddie Walpert 
who is leading the research, or Professor Tony Holland and Dr Shahid Zaman, who are 
supervising the research.  
  
Madeleine Walpert     01223 746172     mjw208@medschl.cam.ac.uk  
Dr Shahid Zaman     01223 746100     shz10@medschl.cam.ac.uk  
Prof Tony Holland     01223 746112     ajh1008@medschl.cam.ac.uk 
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 Nominated consultee declaration form  
Cambridge Intellectual and Developmental Disabilities Research Group 
NOMINATED CONSULTEE DECLARATION FORM  
Eye investigations in Down’s syndrome 
1. I (name of consultee……………………………………………………….…………) 
have been consulted about (name of potential 
participant……………………………………………………………………) taking 
part in this research study. I have had the opportunity to ask questions about the study 
and I understand what is involved. 
 
2. In my opinion (name of potential 
participant………………………………………………………………) would have no 
objection to taking part in the above study. 
 
3. I understand that I can request that s/he is withdrawn from the study at any time, without 
giving any reason and without his/her legal rights being affected.  
 
4. I understand the relevant sections of his/her medical notes and data collected during the 
study may be looked at by responsible individuals from the Cambridge Intellectual and 
Developmental Disabilities Research Group or by collaborative researchers or 
regulatory authorities where it is relevant to my taking part in research. 
 
5. I agree to the GP of the person named being informed of their participation in this study. 
 
6. I consent to the research team keeping samples taken during the study for additional 
testing and future studies. 
 
7. I consent to the research team looking at data from previous studies the named person 
may have been involved in with this research group 
 
8. I agree to the Down’s syndrome research group contacting the person named above 
about future studies. 
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____________________   _______________       ______________________ 
Name of Consultee    Date    Signature 
 
 
 
 
Relationship to participant:  
 
 
 
 
___________________   ________________  ______________________ 
Name of Researcher    Date    Signature 
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 Participant information sheet for control and comparison participants 
Cambridge Intellectual and Developmental Disabilities Research Group   
CONTROL PARTICIPANT INFORMATION SHEET              
Eye investigations in Down’s syndrome  
Thank you for your interest in this study. This sheet is designed to give you more information 
about the study and what will be involved if you do decide to take part.  Please feel free to ask 
any questions you have about the study.  
This study is being undertaken by Maddie Walpert as part of a doctoral training programme, 
which is supervised by Prof Tony Holland and Dr Shahid Zaman.   
  
What is the purpose of this study?  
People with Down’s syndrome have a high risk of developing Alzheimer’s disease early in life. 
Brain scan studies have shown that there may be a link between the changes we find in the 
brain and changes shown in the retina at the back of the eye. The retina is an extension of the 
brain and we believe it likely that Alzheimer’s disease related changes could be seen here early 
in the disease development, and by using less invasive methods. It is very important to try and 
identify signs of Alzheimer’s disease as early as possible so that new therapies can be 
introduced which would have the most effect on slowing the disease. The goal of this study is 
to develop new ways of identifying markers of Alzheimer’s disease at an early stage in 
development, which will help the development of treatment strategies.  
We would like to ask you, as a person without Down’s syndrome, to help make up our control 
sample.  It is important to compare any suspected AD changes seen in a high risk population 
such as Down’s syndrome to a non-high risk population to ensure that any changes seen in the 
eyes are not part of the typical aging process.  
  
What will happen if I decide to take part in this study?   
If you would like to take part in this study you will be invited to the hospital for a visit which 
may last up to 1 hour.  You will be asked to sign a consent form to say that you have read this 
information sheet and been given the opportunity to ask questions about what will happen 
during the study.    
  
238 
 
At the hospital we will ask you to have an optical coherence tomography (OCT) scan of both 
your eyes. This scan is used in everyday eye tests and is not invasive but we may need to dilate 
your pupils with an eye drop to allow for better visibility during the examination.  It will take 
around 5-10 minutes to complete these scans and will require you to fixate on a flashing light 
for around 30 seconds at a time whilst the images are taken. We will also ask to take blood 
sample from you which will be taken by a trained nurse at the facility. Finally we will do a 
quick memory test with you to rule out any possibility of dementia.    
Within the consent form we will ask your permission to notify your GP that you are involved 
in the study. We would most likely only notify your GP if the ophthalmologist found something 
unusual in your eyes during the examination.    
  
Will my involvement by confidential?  
Any information we collect from you for this study will be fully anonymised and stored 
securely in a locked filing cabinet. Your name will not be used on any of the data and only 
members of the research team will be able to see this data. All research information is stored 
confidentially for 15 years after which it is disposed of securely.   
Blood samples and data collected during this study will be stored and may be re-visited in 
future studies. Your name will not be attached to these samples or data and will remain 
anonymised.   
  
Will you cover the costs of me taking part in this study?  
Yes, we will reimburse all travel costs to and from the hospital; we will also cover any food 
and drink costs while you are visiting the hospital.    
  
 What are the risks and benefits of taking part?   
There are few risks involved in taking part in this study. The eye examinations will be 
conducted by a trained ophthalmologist and will feel very similar to an eye examination at the 
optician for a normal eye test. These scans may take a little longer as we will be taking high-
resolution images of the back of your eyes but they are not at all invasive. The eye drop we 
will use to dilate your pupils contains tropicamide which is safe although it may cause slight 
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blurred vision, which would wear off shortly after. The blood sample will be taken by a medical 
professional and as with any blood sample there may be some discomfort involved, this should 
not last more than a few seconds and we will do everything possible to make this as comfortable 
as possible.    
The benefits to taking part are that your involvement will help us learn more about the 
progression of Alzheimer’s disease in people with Down’s syndrome and in the general 
population, we hope that this will lead to the development of new drugs which can treat 
Alzheimer’s disease at an early stage. If we were to find anything irregular in your eyes we 
would be able to inform you and your GP immediately.    
  
Do I have to take part?   
No, it is entirely your decision whether you would like to take part in this study.  You can 
withdraw from the study at any time, and this will not affect your current or future treatment.    
  
What if something goes wrong?  
If you wish to complain about any aspect of the way you have been treated during this study 
you can contact the Patient Advice and Liaison Service (PALS) Addenbrooke’s: 01223 
216756, Western Eye Hospital: 020 3312 7777.  This study has been approved by the 
Cambridgeshire Research Ethics Committee, and it will then be possible for this research to 
have insurance cover for negligent and non-negligent harm under the University’s Clinical 
Trials policy.    
  
Contact for further information  
If you have any questions before, during or after the research please contact Maddie Walpert 
who is leading the research, or Professor Tony Holland and Dr Shahid Zaman, who are 
supervising the research.   
  
Madeleine Walpert     01223 746172     mjw208@medschl.cam.ac.uk  
Dr Shahid Zaman     01223 746100     shz10@medschl.cam.ac.uk  
Prof Tony Holland     01223 746112     ajh1008@medschl.cam.ac.uk  
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 Consent form for control and comparison participants 
Cambridge Intellectual and Developmental Disabilities Research Group 
CONSENT FORM 
Study title: Optical coherence tomography assessments in people with Down’s syndrome, the 
link between the eyes and dementia 
 
Please read through the following statements carefully and initial in the corresponding box 
if you agree 
1. I confirm that I have read and understand the information sheet  
 
date........................................., version number............... 
 
 
2. I have been given the opportunity to ask questions and discuss the study  
 
 
3. I understand that my participation is voluntary and that I have the right to withdraw at any 
time, without reason and that my medical care and legal rights will not be affected.  
 
 
4. I consent to take part in this study  
 
 
5. I understand that sections of my medical notes may be looked at by responsible individuals 
from the Cambridge Intellectual and Developmental Disabilities Research Group or by 
collaborative researchers or regulatory authorities where it is relevant to my taking part in 
research.  I give permission for these individuals to have access to my records.  All the 
data collected in this study will be anonymised and stored securely for up to 10 years.  
 
 
6. I consent to the research team contacting my GP to inform him/her of my participation in 
this study  
 
 
7. I consent to have a blood sample taken 
 
8. I am happy for my anonymised data to be used in other studies  
 
 
9. I consent to the research team contacting me about future studies that  
I may be interested in taking part in.        
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Full name:  
  ........................................................................................................... 
   
Date: 
  ...........................................................................................................  
Signature: 
  ........................................................................................................... 
 
To be completed by the researcher 
Full name:   .......................................................................................................... 
Date:   .......................................................................................................... 
Signature: .......................................................................................................... 
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 Sample size calculation and justification 
At the time of the study proposal we were aware of one meta-analysis of studies comparing 
RNFL thickness in those with AD compared to controls without AD – He et al., (2012). 
However, in this paper, only seven studies were finally considered, further, the authors find 
that there is significant heterogeneity among the results of the studies considered (χ²=62.96, 
p<0.0001), suggesting important differences between studies. For the purpose of this sample 
size calculation we have considered the studies listed in He et al., (2012) and several others 
(see Table L.1), and selected the study that most closely resembled the planned study.  
Moschos, Chatziralli and Moschos (2012) was selected, as this study matched control 
participants to the patient group on age and sex (as is intended in this study), and importantly, 
had the largest range of ages. The proposed study will recruit participants with DS from 18 
years, with no upper limit (expected is 60s), therefore powering from a study with a similarly 
wide age range (42-84, the widest comparable range) is reasonable.  
Basing a sample size calculation on Moschos et al., (2012) is non-trivial as they use a Mann-
Whitney U test to compare RNFL between groups, rather than the more ubiquitous two sample 
t-test. First, we determined the effect size of the difference observed between those with AD 
and controls. The proposed study will look at average RNFL thickness and the four 
measurement sites in the RNFL (superior, inferior, temporal and nasal) whilst in Moschos et 
al., (2012) these four sites were compared separately on left and right eyes. From these eight 
comparisons, Z-statistics values are produced for each (all indicating a significant thickness 
reduction in those with AD); we take the median Z-value (-4.21) as an indication of effect size. 
This can be converted to a correlation measure of effect size r, using the formula given by 
Rosenthal (1991): r=Z/√(N), where N is the total sample size being compared in the Mann-
Whitney U test. Thus r=4.21/√(60)=0.54. In turn, this correlation can be converted to Cohen’s 
D, giving D=1.28, using a formula given in Rosenthal (1994), as implemented in Decoster’s 
spreadsheet for converting between effect sizes (Decoster, 2012).  
We now calculate a sample size for a (two tailed) two-sample t-test comparison. Given the 
above comparison we conservatively assume an effect size of D=1, along with α=0.05 and 
power=0.9 and calculate (using G*Power version 3.1.9.2, as described in Faul et al., (2007)) a 
sample size of 23 per group. Given the use of the non-parametric Mann-Whitney U test in 
Moschos et al., (2012), we inflate this sample size to 24 per group (based on the asymptotic 
relative efficiency of 3/π of the Mann-Whitney compared to the t-test, as reported in Lehmann 
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(1975): 23/(3/π)≈24). Finally we assume a drop-out/loss of information of 20% indicating a 
need to recruit a minimum of 30 people per group (30/0. 8≈30), giving a total recruitment of 
90 people.  
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 Control group AD patient group 
MCI Patient 
group Matching 
Author 
N Mean age in 
years (s.d) 
N Mean age 
in years 
(s.d) 
N  Mean age 
in years 
(s.d) 
Age 
matched  
Sex 
matched 
Ascaso et al., (2014) 41 72.9 (7.9) 18 72.1 (8.7) 21 72.1 (8.7) Yes Yes 
Berisha et al., (2007) 9 74.3 (5.8) 8 74.3 (3.3) 
N/A 
Yes Not clear 
Garcia-Martin et al., (2014) 28 72.1 (5.1) 20 79.3 (4.1) Yes Yes 
Gharbiya, Trebbastoni, Parisi, & Manganiello, 
(2014) 
21 70.3 (7.3) 21 73.1 (6.9) 
Yes Yes 
Iseri, Altinaş, Tokay, & Yüksel, (2006) 15 65.1 (9.8) 14 70.1 (9.7) Yes Yes 
Kesler, Vakhapova, Korczyn, Naftaliev, & 
Neudorfer, (2011) 
24 70.9 (9.2) 30 73.7 (9.9) 34 71.1 (10) 
Yes Not clear 
Kirbas, Turkyilmaz, Anlar, Tufekci, & Durmus, 
(2013) 
40 68.9 (5.1) 40 69.3 (4.9) 
N/A 
Yes Yes 
Larrosa et al., (2014) 61 55 – 91 (age 
range) 
22 66 – 88 
(age range) 
Yes Yes 
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Moreno-Ramos, Benito-León, Villarejo, & 
Bermejo-Pareja, (2013) 
10 70.2 (5.5) 10 73 (6.5) 
Yes Yes 
Moschos et al., (2012) 30 Age matched 
to AD group 
30 42 – 84 
(age range) 
Yes Yes 
Paquet et al., (2007) 15 75.5 (5.1) 12  
14* 
78.8 (4.9) 
78.3 (5.1) 
23 78.7 (6.2) 
Yes Not clear 
Parisi et al., (2001)  14 Not given 17 70.37 (6.1) 
N/A 
Yes Not clear 
Polo et al., (2014) 75 73.98 (9.05) 60 74.15 (9.5) Yes Not clear 
Table L.1  Literature reviewed for the sample size calculation * For Paquet et al., (2003) the AD group was divided into mild AD (n=12) and 
severe AD (n=14). 
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 Paired comparison tests between eyes within participants 
 
Paired area Mean SD t p 
Global RNFL (right eye – left eye) 2.311 8.325 1.862 .069 
Temporal RNFL (right eye – left eye) 2.933 14.618 1.346 .185 
Superior RNFL (right eye – left eye) -2.900 14.360 -1.355 .182 
Nasal RNFL (right eye – left eye) 1.800 14.490 .833 .409 
Inferior RNFL (right eye – left eye) 7.011 20.295 2.317 .025 
Fovea macular (right eye – left eye) .129 7.535 .095 .925 
Inner macular (right eye – left eye) 2.830 8.747 1.802 .082 
Outer macular (right eye – left eye) 2.306 7.272 1.766 .088 
Table M.1 Table showing no significant differences between retinal thickness scores 
dependent on eye  
 
 
  
247 
 
 Quality selection process for highest scan quality eye 
The signal strength (0-40) of each scan was reviewed, and scans with signal strength of less 
than 15 (as suggested by the manufacturer) were excluded from the analysis. Nine eyes from 
the DS group had a rating of <15 and were therefore excluded, none of the control eye data fell 
below this threshold. For the macular scans the eye with the best quality scan from each 
participant was selected for analysis. In cases where only one eye had a full scan, this eye was 
chosen.  
Macular scan quality index for the macular/posterior pole scan is assessed per each of the 61 
individual line scans, therefore, in order to assess the average quality of the scan an average 
score was produced. As there was a large quantity of data to assess, approximately 176 scans 
each with 61 data entry points it was decided that a best call judgement would be made from 
scanning the data.  
In the first instance 10 randomly selected participants were scanned and a best call judgement 
made, each quality index rating for each scan was then rated and average to provide the true 
result. Results were compared between the judgement call and the true result. The decision of 
the judgement call was also rated on difficulty, scored as “easy”, “medium” or “difficult” to 
determine. The same eye scans were independently inter-rated by a moderator Tables N.1 and 
N.2 show the results of the rating.  
Correct decisions were made on 8/10 scans by the first examiner and 7/10 correct scans by the 
independent inter-rater, one decision was incorrectly made by both examiners. In all cases 
where an incorrect decision was made the difference between the quality indexes of the two 
scans was < 1.5. After all the best judgement decisions had been made a random nine 
participants were selected for re-analysis, of these three were incorrectly judged, however there 
was a negligible differences of < .37 between the quality index rating for each eye.  
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Group (ID number) Actual best 
eye 
Best eye 
decision 
(student) 
Best eye decision 
(moderator) 
Ease of 
decision 
(student) 
Ease of decision 
(moderator) 
Difference 
between eye 
quality average 
Control (IDSC063) Left Left Left Easy Easy 1.16 
Control (IDSC003) Right Right Right Easy Easy 4.97 
Control (IDSC020) Left Left Right Medium Difficult 1.18 
Control (IDSC029) Right Left Left Difficult Medium .38 
Control (IDSC030) Left Left Left Easy Easy 1.57 
DS (IDS036) Right Right Right Difficult Easy .56 
DS (IDS407) Left Left Left Easy Medium 4.49 
DS (IDS021) Right Right Right Easy Difficult 3.56 
DS (IDS203) Right Left Right Difficult Difficult .92 
DS (IDS039) Left Left Right Medium Medium 1.49 
Table N.1  Shows the best eye decision making process. The “actual best eye” column refers to the manual extraction of scan quality numbers 
and averaging to determine the highest value, the student and moderators ‘skimming decisions’ are highlighted as green for correct and blue for 
incorrect.  
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Group (code) Actual best eye Best eye 
decision 
(student) 
Ease of 
decision 
Difference 
between eye 
quality average 
Control (IDSC041) Left Left Difficult .84 
Control (IDSC021) Right  Left  Difficult .14 
Control (IDSC072) Left  Right Medium .36 
Control (IDSC022) Left Right  Medium .13 
Control (IDSC046) Left  Left  Easy 4.75 
Control (IDSC013) Left  Left  Easy 3.95 
DS (IDS212) Left  Left Medium .09 
DS (IDS514)  Right  Right Easy .7 
DS (IDS505) Left  Left Difficult 1.16 
Table N.2 Showing retrospective checking of best eye decision made. 7/10 of decisions 
made were correct. In the cases of an incorrect decision being made the difference between the 
scan qualities of each eye was less than .36. 
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 Retinal layer age and thickness correlations for Down’s syndrome and age-matched 
control groups 
 
Retinal layer DS group  p Control group p 
RNFL -.087 .596 -.305 .066 
GCL -.220 .178 -.408 .012 
IPL -.118 .475 -.351 .033 
INL -.058 .727 -.217 .197 
OPL -.254 .118 .120 .480 
ONL .338 .035 -.236 .159 
RPE .160 .329 .311 .061 
Table O.1  Table showing the non-significant correlations for the DS and age-matched 
control group retinal thicknesses and age 
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 CAMCOG neuropsychological assessment 
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 Executive function battery 
 
Imaging Brain Aβ in Adults with Down’s Syndrome 
 
Neuropsychological Test Battery - REVISED 
 
 
 
 
 
 
 
 
 
Participant Number:............................................................ 
Date of Assesment:.............................................................. 
Researcher’s name: .............................................................. 
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Cats and Dogs 
This test was adapted by Sarah Ball (2006) from Willner et al.’s Day and Night test. Ball’s 
version of the test involves participants pointing to a series of animals and naming them.  
A sequence of 16 pictures, 8 cats (c) and 8 dogs (d) was presented on a single strip in the 
following order: c,d,d,c,d,c,c,d,d,c,d,c,c,d,c,d 
 
 
 
Say, “Now I am going to ask you to name some pictures of animals. I want you to point to 
each picture, and tell me the name of the animal that you see. I want you to do this as 
quickly as you can. I’ll have a go first to show you.” 
Demonstrate what is required of the participant by pointing to each animal in turn and naming 
it.  
After you have demonstrated this, the participant should have a practice go. Say, “Now you 
have a go, have a practice.” If they get the first FOUR animals correct, stop them and say. 
“That’s it, you’ve got the hang of it.” 
Then say, “Ok let’s have a proper go now. Remember, I want you to name each animal as 
quickly as you can. Are you ready? Ok, go!” 
When the participant has finished, say, “Well done, that was very good.” 
In the next part of the task, participants must again point to each picture in turn, but this time 
if they point to a cat they must say ‘dog’, and if they point to a dog they must say, ‘cat’. 
Say to the participant, “Ok, now we’re going to change the rule. This time, if you point at 
a cat you must say ‘Dog’, and if you point to a dog you must say ‘Cat’. Ok? Can you 
remember that? I’ll have a go first to show you”  
Demonstrate what is required of the participant by pointing to each animal in turn and naming 
it according to the new rule.   
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After you have demonstrated this, the participant should have a practice go. Say, “Now you 
have a go, have a practice.” If they get the first FOUR animals correct, stop them and say. 
“That’s it, you’ve got the hang of it.” 
Then say, “Ok let’s have a proper go now. Remember, I want you to name each animal as 
quickly as you can, but try and remember the new rule. Are you ready? Ok, go!” 
When the participant has finished, say, “Well done, that was very good.” 
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Score: 16 -            errors at reversal stage =        points 
 
Tower of London Task 
SCORE REVERSAL 
STAGE! 
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Procedure adapted from Kirkorian, Bartok & Gay, 1994, J Clin Exptl Neuropsychology, 16, 6, 
840-850. 
 
Sit opposit the participant and place the two boards with the longest peg on the participant’s 
left and the numbers 1, 2, 3 pointing towards you; one in front of them, with the beads in the 
start position, and one in front of you, with the beads in the practice trial position (Practice 1). 
 
Say “I want you to move the beads on your pegs to make them the same as the beads on 
my pegs.” 
When they have done it say, “that’s good. That’s the idea. Each time we’ll start with your 
beads like this (arrange the beads into the start position). I’ll change mine and you have to 
make yours the same as mine. I also want you to do it in a certain number of moves. A 
move means taking a bead from a peg and putting it on another peg. There are two rules. 
You can only pick up one bead at a time so you can’t do this (pick up two beads in one 
hand) or this (pick up on bead in each hand). You can’t put the beads down on the table. If 
you get stuck we can go back to the beginning. Shall we have a practice?” 
Arrange your board to the first practice problem again. Say, “Now, try and make yours look 
like this in two moves.” 
Provide feedback if the participant tries to make an illegal move and about the number of moves 
allowed. Say, “Remember the rule. You can’t....... . Let’s start again. Have another go. 
Remember that you have to do it in (X) moves.” 
Provide one more practice trial with feedback as above. 
After practice, go through the problems in the order presented on the sheet and continue to 
provide feedback if the participant tries to make an illegal move and about the number of moves 
allowed for the problem. Say, “Remember the rule. You can’t....... . Let’s start again. Have 
another go. Try again. Remember that you have to do it in (X) moves.” 
 
Discontinue after three consecutive failed problems (i.e. 9 consecutive failed trials).  
Scoring 
The pegs are labelled 1, 2, 3 (small to large) and the beads are called R, G, B. Write down the 
moves the participant makes on the score sheet. The problem is solved if the end position is 
achieved in the required number of legal moves.  
 
A trial ends if the participant realises that the trial will not succeed or if an illegal move is 
made. The beads are then reset to the start position for the next trial. Do not provide feedback 
after each incorrect move, wait until the end of the trial.  
A participant is allowed to modify a move if they are still holding a bead. 
Three trials will are allowed for each problem. Three points are scored if the problem is solved 
on the first trial, two if on the second trial, and on point if on the third. 
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Tower of London Task – Record Sheet 
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The Weigl Sorting Test 
 
This is a version of Weigl’s test (aka Weigl-Goldstein-Scheerer Colour Form Sorting Test; 
Goldstein & Scheerer, 1941, 1953; Weigl, 1941) administered and scored in a similar way to 
Strauss &Lewin, 1982.  
It consists of 12 blocks of four colours (red, green, blue, yellow) and three shapes (circle, 
square, triangle).  
 
Name................................................................  Subj. Number.........................  
Assessor................ 
 
Spread out the block in front of the participant. 
Say, “Here are some blocks. I want you to sort them so that the ones which belong together 
will be in a pile together.” 
If the participant is finding the initial sort difficult, repeat the instructions or prompt, “Put the 
ones which are similar in a pile together.” 
 
Initial Sort achieved?  No  OR  Yes  According to Colour/Shape (circle 
appropriate). 
Say, “Why have you grouped them in this way? (In case of difficulty, prompt with) How do 
these ones belong together? So why have you put them in these piles?” 
 
Response.......................................................................................................................................
.......... 
 
Say, “Now I want you to sort the blocks so that they belong together in a different way.” 
Shift achieved now?  No   OR    Yes  Level 1 
 
If shift is not achieved, say, “Here you have grouped them according to Colour/Shape. This 
time you must group the differently.”  
Shift achieved now?  No   OR    Yes  Level 2 
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If shift is not achieved, say, “Here you have put them in piles of Red, Green, Blue & 
Yellow/Triangular, Square and Round. This time try to make the piles differently.” 
Shift achieved now?  No   OR    Yes  Level 3 
Allow up to a total of four trials, for the fifth trial sort three blocks according to the new rule. 
Then say, “I’ve started it off. See if you can put the rest of the blocks in piles like this.” 
Shift achieved now?  No   OR    Yes  Level 4 
 
If shift is not achieved give the new rule explicitly. Say, “can you put them in piles of 
different shapes/colours?” 
Shift achieved now?  No   OR    Yes  Level 5 
 
After a shift is achieved at any level 1-4, ask “Why have you grouped them in this way? (In 
case of difficulty, prompt with) How do these ones belong together? So why have you put 
them in these piles?” 
Response.......................................................................................................................................
........ 
 
Scoring 
 
 
Failed to sort initially  
Failed to shift at level 5   0 Points  
 
Shifted    Please encircle: 
 
 
 
 
 
 
 
 
 
 
At level 1 2 3 4 5 
Points awarded 5 4 3 2 1 
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Spatial Reversal 
This test is a modified version of that by McEvoy et al. (1993), adapted by Sarah Ball for use 
with participants with intellectual disabilities.  
 
The Set-Attainment Stage 
In this stage of the task, the participant is instructed to find a coin hidden underneath one of 
two identical boxes, placed either side of the participant’s midline. While the coin was being 
hidden, the boxes should be out of the participant’s view behind a cardboard screen.  
Put up the cardboard screen and hide a coin underneath BOTH boxes to ensure that the 
participant’s search is successful. When the coins are hidden, remove the screen.  
Say to the participant, “Ok, there is a coin hidden underneath one of the boxes. See if you 
can find it.”  
Once the participant has a selected a box and revealed the coin, congratulate them on doing 
well. Then replace the screen, removing the coin that was not found. Then place the coin that 
was found back underneath the box they first searched in.  
Say, “There is a rule about which side the coin will be hidden. See if you can work out 
where it will be this time.”  
If the participant selects the correct box say, “Well done! You’ve got the hang of this. Let’s 
have another go.”  
If the participant picks the empty box say, “Never mine! Let’s have another go. See if you 
can work out what the rule is.” Continue to hide the coin underneath the box on the same 
side until the participant has made four consecutive correct responses, at which point, go to 
‘The Reversal Stag.’ 
If four consecutive correct responses are NOT made, continue until the coin has been hidden 
on the same side for ten trials (at which point, the session should end).  
 
The Reversal Stage 
In this stage the rule is reversed WITHOUT TELLING THE PARTICIPANT. The procedure 
is repeated with the coin hidden on the opposite side. The aim of this stage is to measure how 
many trials it takes before the participants adjusts their responding patter according to the new 
rule. The session should be stopped after four consecutive correct responses, or after ten trials.  
Remember: Put up the cardboard screen when hiding the coin on each trial. Congratulate 
participants on correct responses, and encourage them to try again when they make mistakes.  
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Spatial Reversal Score Sheet 
 
 
Spatial reversal training 
Set attainment Reversal 
Site of hiding   L / R Site of hiding   L / R 
Trial Correct (tick) Score Trial 
Correct 
(tick) 
Score 
1   1   
2   2   
3   3   
4   4  7 
5   5  6 
6   6  5 
7   7  4 
8   8  3 
9   9  2 
10   10  1 
4 consecutive correct?        Yes    4 consecutive correct? Yes     
 No     0  No     0 
  Score  
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Scrambled Boxes 
Equipment: Small boxes with shapes on. Three coins.  
Stationary condition 
Say to the participant, "I am going to put a coin under each of these boxes". Then hide 
the coins. After a short delay, say, "I would like you to choose one of the boxes and look 
under it to see if you can find a coin." 
  
After the participant has found a coin, remove it and say, "Now lets put that box back and 
try to find another coin."   After replacing the empty box in its original position, say, "This 
time I would like you to choose a box you haven’t looked in before. Try not to choose an 
empty one."   
If participant successfully chooses a full box then say “Well done!  Now try again and see if 
you can find another coin. Try to choose a box you haven’t looked under before”   
If participant chooses the empty box then say “Oh dear it’s empty.  Never mind, let’s have 
another go. Try to choose a box you haven’t looked in before”     
Repeat as above until participant has found all the coins or has made FOUR of errors. 
If participant successfully finds all coins then say “Well done, you’ve found all the coins 
now.  Let’s try the same thing again but this time, to make it a bit more difficult, I’m 
going to move the boxes around.” 
 
Scrambled condition 
 Say, "I am going to put a coin under each of the boxes again".  Then hide the coins .  
After a short delay, say, "Now I'm going to mix them up. I would like you to choose one of 
the boxes and look under it to see if you can find a coin. While giving this instruction mix 
up the location of the boxes while the participant watches.  
When the participant finds a coin, say "Now let’s put that box back and try to find 
another coin."    
Replace empty box and after a short delay, say to them, "I'm going to mix the boxes up again 
and I would like you to choose a box you haven’t looked in before. Try not to choose an 
empty one." While giving this instruction mix up the location of the boxes again while the 
participant watches.  
If participant successfully chooses a full box then say, “Well done!  Now try again and see if 
you can find another coin. Try to choose a box you haven’t looked under before.” Again, 
while giving this instruction mix up the location of the boxes while the participant watches. 
If participant chooses the empty box then say “Oh dear it’s empty.  Never mind, let’s have 
another go. Try to choose a box you haven’t looked in before” Again, while giving this 
instruction mix up the location of the boxes while the participant watches.  
Continue until participant has found all the coins or made FOUR of errors. 
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If the participant completes both the stationary and scrambled stages with three boxes, then 
repeat the process with SIX boxes. In this case, testing continues until all the coins have been 
retrieved or until SEVEN errors have been made. 
 
 
Oliver Object Memory Test 
 
 
SCORE THE SCRAMBLED STAGE
 
 
 
  
  
Score = 4 - errors 
 
 
 
  
  
Score = 7 - errors 
 
 
 
  
  
Total score:           /11
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This test was first developed by Oliver et al. (1998) and was designed to measure memory 
deficits in older people with Down’s syndrome.  
Equipment needed: Spoon, letter (addressed envelope with stamp), pencil, key, comb, 
toothbrush, watch, coin (10p), purse and a book.  
Training Stage 
First say to the participant, “I want you to name some objects for me now.”  
Show the participant one object at a time, asking “What is this?” each time you show them an 
object. Discard any objects they name incorrectly. 
Then, take two objects that they participant named correctly. Ask again, “What is this?” for 
each object. Then say, “Now I am going to cover of these,” and while the participant watches, 
cover one of the objects with a small box. Then say to the participant, “What’s under the 
box?”  
Testing Stage 
Randomly select two other correctly named objects and ask the participant to name them (to 
ensure they have looked at them). Then say, “Try to remember these. Now close your eyes.” 
While the participant’s eyes are closed, cover one of the objects with the box and record the 
hidden stimulus on the record sheet. Then say, “Open your eyes. What’s under the box?” 
Make a record of the answer.  
Repeat this process once more with 2 objects. Then do the same twice with 3 objects, twice 
with 4 objects, twice with 5 objects and twice with 6 objects. Testing should stop if the 
participant makes an error on both tasks with the same number of objects.  
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Scoring 
One point should be awarded for each object correctly recalled. The maximum score is 10. 
Number of Objects Stimulus Object Response Score 
2    
2    
3    
3    
4    
4    
5    
5    
6    
6    
Total Score    (max 10)  
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The Oliver Memory for Sentences Test 
This test was developed by Crayton and Oliver (1993) for use with older adults with DS. It was 
adapted from the Stanford-Binet test. 
Training Stage 
Say to the participant, “I am going to say something and I want you to say it after me. Say 
‘Watch’.” Then wait for a response. Then say, “Say ‘coin’.” After giving them each word, 
wait for their response. Repeat this process for all of the objects in the Oliver Object Memory 
Test until the participant repeats the word correctly. Immediately after the training stage, move 
into the testing stage. 
Testing Stage 
Say to the participant, “Say ‘He had a book’.” Then write down what the participant says on 
the score sheet below. Do this for each of the six sentences.  
Scoring 
Give one point for each word correctly recalled.  
Sentences Score     
/max 
Test He had a book  
Response 
 
               /4 
Test His father saw him leave  
Response 
 
            /5 
Test They took their water from the tap  
Response 
 
              /7 
Test She went to the table to eat her food  
Response 
 
             /9 
Test My brother does not like me to sleep in his room  
Response           /11 
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Test Each week they find a pretty flower and plant it in the garden  
Response 
 
         /13 
 
Total Score (max 49) 
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Scoring 
 
 
 
 
                                     GRAND TOTAL 
 
Executive Functioning 
Tower of London             /12 
Wiegl Sorting Task             /5 
Spatial Reversal             /7 
Scrambled Boxes             /11 
Cats and Dogs             /16 
TOTAL             /56 
Memory 
Oliver Memory for Object             /10 
Oliver Memory for Sentences             /49 
TOTAL             /100 
              /156 
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 CAMDEX 
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305 
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 Hemisphere comparisons for cortical thickness data 
 
 Brain hemisphere mean cortical thickness Correlation between 
hemisphere averages 
 Right Left p r p 
Frontal 2.548 2.615 .001 .896 .001 
Parietal 2.511 2.504 .001 .902 .001 
Temporal 2.958 2.914 .010 .876 .001 
Occipital 2.386 2.313 .730 .848 .001 
Table S.1  Paired comparison data on cortical thickness measures between hemispheres. 
